NCT Number,Study Title,Study URL,Acronym,Study Status,Study Results,Conditions,Interventions,Sponsor,Collaborators,Study Type,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted
NCT06511973,A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants,https://clinicaltrials.gov/study/NCT06511973,,COMPLETED,NO,Pain|Healthy Volunteers,DRUG: Naproxen (BAYH006689)|DRUG: Placebo Gel|DRUG: A solution of 0.9% Saline|DRUG: A solution of 0.2% SLS,Bayer,,INTERVENTIONAL,2024-07-23,2024-08-20,2024-08-20,2024-07-22,,2024-09-19
NCT06487845,A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants,https://clinicaltrials.gov/study/NCT06487845,,COMPLETED,NO,Chronic Kidney Disease|Non-proliferative Diabetic Retinopathy|Healthy Volunteers,DRUG: BAY3283142|DRUG: Placebo,Bayer,,INTERVENTIONAL,2024-07-04,2024-09-19,2024-09-19,2024-07-05,,2024-09-24
NCT06474208,A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years,https://clinicaltrials.gov/study/NCT06474208,,COMPLETED,NO,Heart Failure,DRUG: Formulation 1|DRUG: Formulation 2|DRUG: Formulation 3|DRUG: Formulation 4|DRUG: Formulation 5 (placebo),Bayer,,INTERVENTIONAL,2024-07-01,2024-09-30,2024-09-30,2024-06-25,,2024-10-08
NCT06415019,A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants,https://clinicaltrials.gov/study/NCT06415019,,COMPLETED,NO,Pain|Healthy Volunteers,DRUG: Naproxen (BAYH006689)|DRUG: Placebo Gel|DRUG: A solution of 0.9% Saline,Bayer,,INTERVENTIONAL,2024-06-05,2024-08-01,2024-08-01,2024-05-16,,2024-08-14
NCT06412926,A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants,https://clinicaltrials.gov/study/NCT06412926,,COMPLETED,NO,Soil-transmitted Helminth Infection|Onchocerciasis (River Blindness),DRUG: BAY 44-4400|DRUG: BAY 44-4400,Bayer,,INTERVENTIONAL,2024-05-07,2024-08-27,2024-08-27,2024-05-14,,2024-09-27
NCT06378658,A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants,https://clinicaltrials.gov/study/NCT06378658,,COMPLETED,NO,Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers,DRUG: BAY2927088|DRUG: Esomeprazole|OTHER: Food,Bayer,,INTERVENTIONAL,2024-03-29,2024-06-11,2024-06-11,2024-04-22,,2024-07-05
NCT06360211,A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants,https://clinicaltrials.gov/study/NCT06360211,,COMPLETED,NO,Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers,DRUG: BAY2927088|DRUG: Midazolam,Bayer,,INTERVENTIONAL,2024-04-17,2024-06-28,2024-06-28,2024-04-11,,2024-07-03
NCT06348888,A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants,https://clinicaltrials.gov/study/NCT06348888,,COMPLETED,NO,Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers,DRUG: BAY2927088|DRUG: Itraconazole|DRUG: Carbamazepine,Bayer,,INTERVENTIONAL,2024-04-10,2024-06-12,2024-06-12,2024-04-05,,2024-06-20
NCT06329895,A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants,https://clinicaltrials.gov/study/NCT06329895,,COMPLETED,NO,Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers,DRUG: BAY2927088|DRUG: Dabigatran etexilate|DRUG: Rosuvastatin,Bayer,,INTERVENTIONAL,2024-03-25,2024-06-10,2024-06-10,2024-03-26,,2024-07-05
NCT06293326,"A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants",https://clinicaltrials.gov/study/NCT06293326,,COMPLETED,NO,Heartburn|Indigestion|Stomach Acid Related Symptoms|Nocturnal Stomach Acid Related Symptoms|Healthy Volunteers,DRUG: bi-layer calcium carbonate tablet (BAY1180654)|DRUG: Immediate release calcium carbonate tablet (BAY1180654),Bayer,,INTERVENTIONAL,2024-03-06,2024-05-15,2024-05-15,2024-03-05,,2024-07-03
NCT06221475,A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants,https://clinicaltrials.gov/study/NCT06221475,,COMPLETED,NO,Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers,DRUG: BAY2927088 coated tablet 10 mg|DRUG: [14C]-BAY2927088 solution for infusion|DRUG: [14C]-BAY2927088 oral solution,Bayer,,INTERVENTIONAL,2024-01-25,2024-04-05,2024-05-08,2024-01-24,,2024-06-28
NCT06219902,A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women,https://clinicaltrials.gov/study/NCT06219902,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo to elinzanetant|DRUG: Zopiclone|DRUG: Placebo to zopiclone,Bayer,,INTERVENTIONAL,2024-01-08,2024-04-15,2024-04-15,2024-01-23,,2024-05-08
NCT06195930,A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction,https://clinicaltrials.gov/study/NCT06195930,,COMPLETED,NO,Chronic Heart Failure With Reduced Ejection Fraction,DRUG: Vericiguat (BAY1021189) 5 mg,Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2024-04-18,2024-07-29,2024-07-29,2024-01-08,,2024-08-16
NCT06135181,A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants,https://clinicaltrials.gov/study/NCT06135181,,COMPLETED,NO,Contrast Enhancement in Magnetic Resonance Imaging|Healthy Volunteers,DRUG: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|DRUG: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|DRUG: Matching placebo,Bayer,,INTERVENTIONAL,2020-08-26,2021-02-02,2021-04-30,2023-11-18,,2023-11-18
NCT06125366,A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants,https://clinicaltrials.gov/study/NCT06125366,,COMPLETED,NO,Contrast Enhancement in Magnetic Resonance Imaging|Healthy Volunteers,DRUG: BAY1747846|DRUG: Matching placebo,Bayer,,INTERVENTIONAL,2019-04-17,2019-06-19,2019-07-11,2023-11-09,,2023-11-09
NCT05915728,A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems),https://clinicaltrials.gov/study/NCT05915728,Quanti OBR,COMPLETED,NO,Contrast Enhancement in Magnetic Resonance Imaging|Non-central Nervous System Pathology,DRUG: Gadoquatrane (BAY1747846)|DRUG: Gadobutrol|DRUG: Gadoterate meglumine|DRUG: Gadoteridol,Bayer,,INTERVENTIONAL,2023-07-24,2024-05-31,2024-06-01,2023-06-23,,2024-06-13
NCT05915702,A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems,https://clinicaltrials.gov/study/NCT05915702,Quanti CNS,COMPLETED,NO,Contrast Enhancement in Magnetic Resonance Imaging|Central Nervous System Pathology,DRUG: Gadoquatrane (BAY1747846)|DRUG: Gadobutrol|DRUG: Gadoterate meglumine|DRUG: Gadoteridol,Bayer,,INTERVENTIONAL,2023-07-24,2024-05-30,2024-05-31,2023-06-23,,2024-06-13
NCT05915026,"A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)",https://clinicaltrials.gov/study/NCT05915026,,COMPLETED,NO,Contrast Enhancement in Magnetic Resonance Imaging|Children,DRUG: Gadoquatrane (BAY1747846),Bayer,,INTERVENTIONAL,2023-08-16,2024-09-18,2024-10-16,2023-06-22,,2024-10-29
NCT05800444,"A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants",https://clinicaltrials.gov/study/NCT05800444,,COMPLETED,NO,Chronic Kidney Disease|Healthy Volunteers,DRUG: BAY3283142|OTHER: Placebo,Bayer,,INTERVENTIONAL,2023-04-03,2023-07-19,2023-07-19,2023-04-05,,2023-08-21
NCT05656911,A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis,https://clinicaltrials.gov/study/NCT05656911,Damask,COMPLETED,NO,Atopic Dermatitis,DRUG: Zabedosertib (BAY1834845)|DRUG: Placebo to zabedosertib (BAY 1834845),Bayer,,INTERVENTIONAL,2022-12-21,2024-01-03,2024-01-31,2022-12-19,,2024-02-28
NCT05599997,"A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function",https://clinicaltrials.gov/study/NCT05599997,,COMPLETED,NO,Congestive Heart Failure|Renal Impairment,DRUG: Pecavaptan (BAY1753011)|DRUG: Pecavaptan (BAY1753011),Bayer,,INTERVENTIONAL,2019-11-25,2021-01-22,2021-05-18,2022-10-31,,2022-10-31
NCT05563454,"A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants",https://clinicaltrials.gov/study/NCT05563454,,COMPLETED,NO,Diabetic Neuropathic Pain|Healthy Volunteers,DRUG: BAY2395840,Bayer,,INTERVENTIONAL,2022-10-11,2023-02-28,2023-02-28,2022-10-03,,2023-03-15
NCT05517746,"Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants",https://clinicaltrials.gov/study/NCT05517746,,COMPLETED,NO,Endometriosis,DRUG: BAY2395840 tablet|DRUG: BAY2395840 oral solution|DRUG: Placebo oral solution|DRUG: Placebo tablet,Bayer,,INTERVENTIONAL,2019-12-18,2020-12-17,2021-03-11,2022-08-26,,2022-08-26
NCT05515432,"A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight",https://clinicaltrials.gov/study/NCT05515432,,COMPLETED,NO,Chronic Kidney Disease|Renal Impairment|Healthy Volunteers,DRUG: Single oral dose of BAY3283142 IR (immediate release) tablet,Bayer,,INTERVENTIONAL,2022-08-11,2023-03-07,2023-06-06,2022-08-25,,2023-08-21
NCT05491642,"A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses",https://clinicaltrials.gov/study/NCT05491642,,COMPLETED,NO,Chronic Kidney Disease|Hypertension,DRUG: BAY3283142|DRUG: Placebo to BAY3283142,Bayer,,INTERVENTIONAL,2022-09-08,2023-01-03,2023-04-28,2022-08-08,,2023-05-17
NCT05485805,A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo,https://clinicaltrials.gov/study/NCT05485805,,COMPLETED,NO,Postoperative Dental Pain,DRUG: Naproxen sodium and caffeine (BAY2880376)|DRUG: Naproxen sodium (Aleve)|DRUG: Caffeine|DRUG: Placebo,Bayer,,INTERVENTIONAL,2022-09-21,2024-01-25,2024-01-29,2022-08-03,,2024-02-08
NCT05481528,"A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants",https://clinicaltrials.gov/study/NCT05481528,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes|Healthy Volunteers,DRUG: Moxifloxacin|DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2022-08-19,2023-02-07,2023-04-28,2022-08-01,,2023-05-09
NCT05471817,"A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants",https://clinicaltrials.gov/study/NCT05471817,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes|Healthy Volunteers,DRUG: Elinzanetant (BAY3427080)|DRUG: Dabigatran etexilate,Bayer,,INTERVENTIONAL,2022-08-05,2022-09-20,2022-11-14,2022-07-25,,2022-11-22
NCT05419635,"A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function",https://clinicaltrials.gov/study/NCT05419635,,COMPLETED,NO,Prevention of Thromboembolic Events|Atrial Fibrillation|Acute Myocardial Infarction|Non-cardioembolic Ischemic Stroke|Hepatic Impairment,DRUG: Asundexian (BAY2433334),Bayer,,INTERVENTIONAL,2022-06-14,2023-05-24,2023-08-21,2022-06-15,,2023-08-29
NCT05381142,"A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years",https://clinicaltrials.gov/study/NCT05381142,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes|Healthy Volunteers,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2022-05-23,2022-07-11,2022-07-11,2022-05-19,,2022-07-27
NCT05351892,"A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants",https://clinicaltrials.gov/study/NCT05351892,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes|Healthy Volunteers,DRUG: Elinzanetant (BAY3427080),Bayer,,INTERVENTIONAL,2022-05-04,2022-06-09,2022-06-20,2022-04-28,,2022-07-19
NCT05219812,A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain,https://clinicaltrials.gov/study/NCT05219812,,COMPLETED,NO,Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Peripheral Neuropathic Pain|Diabetes Mellitus,DRUG: BAY2395840|DRUG: Placebo for BAY2395840,Bayer,,INTERVENTIONAL,2022-02-16,2022-11-07,2022-11-21,2022-02-02,,2023-11-13
NCT05099159,A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2),https://clinicaltrials.gov/study/NCT05099159,,COMPLETED,NO,Vasomotor Symptoms Associated With Menopause|Hot Flashes,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-10-29,2023-06-13,2023-10-10,2021-10-29,,2024-05-29
NCT05098938,A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally,https://clinicaltrials.gov/study/NCT05098938,,COMPLETED,NO,Recurrent Herpes Labialis,"DRUG: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|DRUG: Placebo",Bayer,,INTERVENTIONAL,2021-11-23,2023-07-19,2024-07-02,2021-10-28,,2024-07-24
NCT05086952,A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately,https://clinicaltrials.gov/study/NCT05086952,,COMPLETED,NO,Heart Failure|Children,"DRUG: Vericiguat (BAY1021189) - Intervention A|DRUG: Vericiguat (BAY1021189) - Intervention B|DRUG: Vericiguat (BAY1021189) - Intervention C|DRUG: Vericiguat (Verquvo, BAY1021189) - Intervention D",Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2021-10-12,2021-12-22,2022-02-15,2021-10-21,,2023-02-02
NCT05071729,"A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally",https://clinicaltrials.gov/study/NCT05071729,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,DRUG: Elinzanetant (BAY3427080),Bayer,,INTERVENTIONAL,2021-10-14,2022-10-19,2022-10-19,2021-10-08,,2022-10-27
NCT05061979,"A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function",https://clinicaltrials.gov/study/NCT05061979,,COMPLETED,NO,Contrast Enhancement in Magnetic Resonance Imaging,DRUG: BAY1747846,Bayer,,INTERVENTIONAL,2021-10-12,2022-03-16,2022-07-14,2021-09-30,,2022-11-21
NCT05061563,"A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults",https://clinicaltrials.gov/study/NCT05061563,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes,DRUG: Elinzanetant (BAY3427080)|DRUG: Esomeprazole,Bayer,,INTERVENTIONAL,2021-09-30,2021-12-09,2022-02-23,2021-09-29,,2022-03-17
NCT05042362,A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause,https://clinicaltrials.gov/study/NCT05042362,OASIS-1,COMPLETED,NO,Vasomotor Symptoms Associated With Menopause|Hot Flashes,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-08-27,2023-07-25,2023-11-27,2021-09-13,,2024-06-27
NCT05030584,A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause,https://clinicaltrials.gov/study/NCT05030584,OASIS-3,COMPLETED,NO,Vasomotor Symptoms Associated With Menopause|Hot Flashes,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-08-27,2023-03-29,2024-02-12,2021-09-01,,2024-03-15
NCT05028608,"A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.",https://clinicaltrials.gov/study/NCT05028608,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,DRUG: Elinzanetant (BAY3427080)|DRUG: Midazolam|DRUG: Carbamazepine,Bayer,,INTERVENTIONAL,2021-09-06,2021-10-31,2022-01-20,2021-08-31,,2022-02-25
NCT05026320,A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.,https://clinicaltrials.gov/study/NCT05026320,,COMPLETED,NO,Soft Tissue Injury,DRUG: Naproxen gel|DRUG: Diclofenac gel|DRUG: Placebo gel,Bayer,Deutsche Sporthochschule Köln,INTERVENTIONAL,2021-08-08,2021-12-20,2021-12-20,2021-08-30,,2022-12-15
NCT05013008,"An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants",https://clinicaltrials.gov/study/NCT05013008,FIGARO-BM,COMPLETED,YES,Chronic Kidney Disease|Type 2 Diabetes Mellitus,"DRUG: Finerenone (Kerendia, BAY94-8862)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2021-08-18,2021-12-31,2021-12-31,2021-08-19,2023-03-31,2023-09-15
NCT05003089,A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants,https://clinicaltrials.gov/study/NCT05003089,,COMPLETED,NO,Immune Mediated Inflammatory Diseases,DRUG: BAY1834845|DRUG: BAY1830839|DRUG: Prednisolone|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-06-28,2021-12-16,2022-01-20,2021-08-12,,2022-12-16
NCT04981431,"A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults",https://clinicaltrials.gov/study/NCT04981431,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-08-11,2022-03-13,2022-03-13,2021-07-29,,2022-03-29
NCT04908436,"A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution",https://clinicaltrials.gov/study/NCT04908436,,COMPLETED,NO,Worsening Chronic Heart Failure|Chronic Kidney Disease,DRUG: Finerenone (BAY94-8862),Bayer,,INTERVENTIONAL,2010-10-27,2011-05-05,2012-01-27,2021-06-01,,2022-01-28
NCT04903821,A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants,https://clinicaltrials.gov/study/NCT04903821,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,DRUG: BAY3427080,Bayer,,INTERVENTIONAL,2021-06-01,2022-03-15,2022-03-15,2021-05-27,,2022-03-24
NCT04889287,A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants,https://clinicaltrials.gov/study/NCT04889287,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,DRUG: Elinzanetant (BAY3427080)|DRUG: Rosuvastatin,Bayer,,INTERVENTIONAL,2021-05-26,2021-07-23,2021-09-29,2021-05-17,,2023-08-09
NCT04881994,"A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution",https://clinicaltrials.gov/study/NCT04881994,,COMPLETED,NO,Worsening Chronic Heart Failure|Diabetic Nephropathy,DRUG: Finerenone (BAY94-8862),Bayer,,INTERVENTIONAL,2014-03-25,2014-09-16,2014-12-08,2021-05-11,,2021-07-16
NCT04872387,"A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose",https://clinicaltrials.gov/study/NCT04872387,,COMPLETED,NO,Obstructive Sleep Apnea,DRUG: BAY2586116|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-05-11,2021-08-04,2021-08-26,2021-05-04,,2023-03-01
NCT04851483,A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants,https://clinicaltrials.gov/study/NCT04851483,,COMPLETED,NO,Endometriosis,DRUG: BAY2328065|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-04-28,2021-12-14,2022-02-14,2021-04-20,,2022-06-01
NCT04845841,Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body,https://clinicaltrials.gov/study/NCT04845841,,COMPLETED,NO,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,DRUG: Elinzanetant (BAY3427080) treatment A|DRUG: Elinzanetant (BAY3427080) treatment B,Bayer,,INTERVENTIONAL,2021-04-09,2021-06-01,2021-06-01,2021-04-15,,2023-08-09
NCT04802343,"A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men",https://clinicaltrials.gov/study/NCT04802343,,COMPLETED,NO,Healthy Volunteers,DRUG: BAY1817080|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-04-02,2021-07-19,2021-10-29,2021-03-17,,2022-10-19
NCT04771390,"Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants",https://clinicaltrials.gov/study/NCT04771390,,COMPLETED,NO,Solid Tumors Harboring NTRK Fusion,DRUG: Selitrectinib (BAY2731954) Adult tablet|DRUG: Selitrectinib (BAY2731954) Pediatric tablet|DRUG: Selitrectinib (BAY2731954) Oral solution|DRUG: Selitrectinib (BAY2731954) Oral suspension,Bayer,,INTERVENTIONAL,2021-02-16,2021-05-20,2021-07-06,2021-02-25,,2021-08-25
NCT04727021,A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men,https://clinicaltrials.gov/study/NCT04727021,,COMPLETED,NO,Healthy Volunteers,"DRUG: 20 mg tablet rivaroxaban|DRUG: 20 mg rivaroxaban, granules for oral suspension",Bayer,,INTERVENTIONAL,2017-07-04,2017-09-04,2017-10-27,2021-01-27,,2021-01-27
NCT04722991,Non-proliferative Diabetic Retinopathy Treated With Runcaciguat,https://clinicaltrials.gov/study/NCT04722991,NEON-NPDR,COMPLETED,NO,Diabetic Retinopathy,DRUG: Runcaciguat (BAY1101042)|OTHER: Placebo,Bayer,,INTERVENTIONAL,2021-03-17,2024-03-18,2024-04-22,2021-01-25,,2024-10-18
NCT04722562,"A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants",https://clinicaltrials.gov/study/NCT04722562,,COMPLETED,NO,Heart Failure,DRUG: Vericiguat (BAY1021189),Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2014-07-16,2015-01-21,2015-04-30,2021-01-25,,2021-01-25
NCT04722484,"A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants",https://clinicaltrials.gov/study/NCT04722484,,COMPLETED,NO,Heart Failure,DRUG: Vericiguat (BAY1021189),Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2014-06-12,2015-01-22,2015-01-22,2021-01-25,,2021-01-25
NCT04720092,A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants,https://clinicaltrials.gov/study/NCT04720092,,COMPLETED,NO,Thromboembolic Disorders,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2017-07-05,2017-08-28,2017-10-27,2021-01-22,,2021-01-22
NCT04713826,A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea,https://clinicaltrials.gov/study/NCT04713826,SPRAY-SMART,COMPLETED,NO,"Sleep Apnea, Obstructive",DRUG: BAY2586116|DRUG: Placebo,Bayer,,INTERVENTIONAL,2021-03-03,2021-08-17,2021-11-11,2021-01-19,,2022-10-26
NCT04704154,A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors,https://clinicaltrials.gov/study/NCT04704154,,COMPLETED,YES,Solid Tumors,"DRUG: Regorafenib, (Stivarga, BAY73-4506)|DRUG: Nivolumab (Opdivo)",Bayer,"Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd",INTERVENTIONAL,2021-02-03,2023-03-09,2024-03-29,2021-01-11,2024-07-23,2024-07-23
NCT04696055,Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors,https://clinicaltrials.gov/study/NCT04696055,,COMPLETED,YES,Hepatocellular Carcinoma,"DRUG: Pembrolizumab|DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2021-02-03,2022-05-05,2024-04-23,2021-01-06,2023-05-30,2024-05-01
NCT04654897,Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT04654897,,COMPLETED,NO,Healthy,DRUG: [14C]-NT-814,Bayer,Quotient Sciences,INTERVENTIONAL,2020-09-30,2020-10-29,2020-10-29,2020-12-04,,2021-10-28
NCT04562155,Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough,https://clinicaltrials.gov/study/NCT04562155,PAGANINI,COMPLETED,YES,Refractory and/or Unexplained Chronic Cough,DRUG: BAY1817080|DRUG: Placebo,Bayer,,INTERVENTIONAL,2020-10-02,2021-06-22,2021-07-23,2020-09-24,2022-08-18,2022-08-18
NCT04545580,Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB),https://clinicaltrials.gov/study/NCT04545580,OVADER,COMPLETED,NO,Overactive Bladder,DRUG: Placebo|DRUG: BAY1817080,Bayer,,INTERVENTIONAL,2020-09-16,2021-12-22,2022-01-21,2020-09-11,,2022-12-22
NCT04534491,Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.,https://clinicaltrials.gov/study/NCT04534491,,COMPLETED,YES,Overactive Bladder,"DRUG: Oxybutynin (Oxytrol, BAY839380)",Bayer,,INTERVENTIONAL,2010-05-25,2011-06-22,2011-06-22,2020-09-01,2020-10-20,2020-10-20
NCT04534452,Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study,https://clinicaltrials.gov/study/NCT04534452,,COMPLETED,NO,Nasal Congestion Due to Allergic Rhinitis,"DRUG: Phenylephrine HCl (Sinus Comfort, BAY112476)",Bayer,,INTERVENTIONAL,2012-05-12,2012-06-06,2012-06-06,2020-09-01,,2020-09-01
NCT04534114,"Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",https://clinicaltrials.gov/study/NCT04534114,RE-THINc ESRD,COMPLETED,YES,End Stage Renal Disease Requiring Hemodialysis,DRUG: Fesomersen sodium (BAY2976217)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2020-09-04,2022-01-24,2022-05-12,2020-09-01,2023-07-03,2023-07-03
NCT04532164,Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants,https://clinicaltrials.gov/study/NCT04532164,,COMPLETED,YES,"Dermatitis, Photoallergic",DRUG: Butenafine HCl 1% (BAY1896425) - Induction Phase|DRUG: Butenafine HCl 1% (BAY1896425) - Challenge Phase,Bayer,,INTERVENTIONAL,2013-06-10,2013-11-11,2013-11-11,2020-08-31,2020-11-16,2020-11-16
NCT04531813,Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test),https://clinicaltrials.gov/study/NCT04531813,,COMPLETED,YES,Hypersensitivity,DRUG: Butenafine HCl 1% (BAY1896425)|DRUG: Positive Control-Sodium lauryl sulfate (SLS)|OTHER: Negative Control,Bayer,,INTERVENTIONAL,2013-06-10,2013-07-01,2013-07-01,2020-08-31,2020-09-25,2020-09-25
NCT04531540,Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test),https://clinicaltrials.gov/study/NCT04531540,,COMPLETED,YES,Hypersensitivity,DRUG: Butenafine HCl 1% (BAY1896425),Bayer,,INTERVENTIONAL,2013-09-09,2013-10-18,2013-10-18,2020-08-28,2020-09-25,2020-11-17
NCT04531527,Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects,https://clinicaltrials.gov/study/NCT04531527,,COMPLETED,YES,"Dermatitis, Phototoxic",DRUG: Butenafine HCl 1% (BAY1896425),Bayer,,INTERVENTIONAL,2013-06-24,2013-06-28,2013-06-28,2020-08-28,2020-09-21,2020-11-13
NCT04523220,Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis,https://clinicaltrials.gov/study/NCT04523220,CONVERT,COMPLETED,YES,End-stage Renal Disease|Prevention of Thromboembolic Events|Hemodialysis|Hemodiafiltration,DRUG: BAY1213790 (Osocimab)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2020-08-28,2021-12-28,2022-05-30,2020-08-21,2023-07-21,2023-07-21
NCT04511637,Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects,https://clinicaltrials.gov/study/NCT04511637,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2019-01-21,2019-03-07,2019-04-12,2020-08-13,,2020-08-13
NCT04511611,Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects,https://clinicaltrials.gov/study/NCT04511611,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2019-01-24,2019-03-27,2019-05-13,2020-08-13,,2020-08-13
NCT04510987,"Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy (""Dialysis"")",https://clinicaltrials.gov/study/NCT04510987,,COMPLETED,NO,Prevention of Thromboembolic Events,DRUG: BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|OTHER: BAY2433334 on dialysis treatment day,Bayer,,INTERVENTIONAL,2020-08-12,2021-09-13,2021-12-15,2020-08-12,,2021-12-22
NCT04507061,Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.,https://clinicaltrials.gov/study/NCT04507061,CONCORD,COMPLETED,NO,Chronic Kidney Disease,DRUG: runcaciguat|OTHER: Placebo,Bayer,,INTERVENTIONAL,2020-09-01,2022-03-08,2022-04-05,2020-08-10,,2023-04-04
NCT04487431,A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B),https://clinicaltrials.gov/study/NCT04487431,,COMPLETED,NO,Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,DRUG: BAY1817080|DRUG: [14C]BAY1817080,Bayer,,INTERVENTIONAL,2020-08-05,2020-09-30,2021-02-11,2020-07-27,,2023-01-26
NCT04471337,"Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function",https://clinicaltrials.gov/study/NCT04471337,,COMPLETED,NO,Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,DRUG: BAY1817080,Bayer,,INTERVENTIONAL,2020-08-12,2021-02-15,2021-05-06,2020-07-15,,2024-03-26
NCT04454424,"Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function",https://clinicaltrials.gov/study/NCT04454424,,COMPLETED,NO,Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,DRUG: BAY1817080|DRUG: Midazolam,Bayer,,INTERVENTIONAL,2020-07-23,2021-06-24,2021-12-15,2020-07-01,,2023-01-20
NCT04435626,Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%,https://clinicaltrials.gov/study/NCT04435626,FINEARTS-HF,COMPLETED,NO,Heart Failure,DRUG: Finerenone (BAY94-8862)|OTHER: Placebo,Bayer,,INTERVENTIONAL,2020-09-14,2024-05-15,2024-06-14,2020-06-17,,2024-07-03
NCT04423744,Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants,https://clinicaltrials.gov/study/NCT04423744,,COMPLETED,NO,Cough|Endometriosis|Overactive Bladder,DRUG: BAY1817080|DRUG: Moxifloxacin|DRUG: Placebo,Bayer,,INTERVENTIONAL,2020-06-18,2020-11-09,2021-01-21,2020-06-09,,2022-01-24
NCT04423718,Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye,https://clinicaltrials.gov/study/NCT04423718,PULSAR,COMPLETED,YES,Neovascular Age-Related Macular Degeneration,"DRUG: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|DRUG: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2020-08-11,2022-07-27,2024-08-07,2020-06-09,2023-09-06,2024-09-19
NCT04366622,"Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight",https://clinicaltrials.gov/study/NCT04366622,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Riociguat (Adempas, BAY 63-2521)",Bayer,,INTERVENTIONAL,2010-04-14,2011-04-28,2011-09-15,2020-04-29,,2020-04-29
NCT04364464,"Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight",https://clinicaltrials.gov/study/NCT04364464,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Riociguat (Adempas, BAY 63-2521)",Bayer,,INTERVENTIONAL,2010-02-19,2011-03-17,2011-09-20,2020-04-28,,2020-04-28
NCT04315597,Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes,https://clinicaltrials.gov/study/NCT04315597,,COMPLETED,NO,Moderate Depressive Episodes (Major Depression),"DRUG: Laif® 900, BAY98-7108|DRUG: Placebo",Bayer,Steigerwald Arzneimittelwerk GmbH,INTERVENTIONAL,2009-03-03,2011-11-22,2011-11-22,2020-03-19,,2020-03-19
NCT04307186,Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions,https://clinicaltrials.gov/study/NCT04307186,,COMPLETED,YES,Central Nervous System Pathology,DRUG: Gadoquatrane (BAY1747846)|DRUG: Gadobutrol (Gadovist/Gadavist),Bayer,,INTERVENTIONAL,2020-11-18,2022-09-05,2022-09-06,2020-03-13,2023-11-15,2023-11-15
NCT04304534,Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack,https://clinicaltrials.gov/study/NCT04304534,PACIFIC-AMI,COMPLETED,YES,Acute Myocardial Infarction,DRUG: BAY2433334|OTHER: BAY2433334 matching placebo,Bayer,,INTERVENTIONAL,2020-06-17,2022-02-21,2022-02-21,2020-03-11,2023-04-05,2023-04-05
NCT04304508,Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.,https://clinicaltrials.gov/study/NCT04304508,PACIFIC-STROKE,COMPLETED,YES,Acute Non-cardioembolic Ischemic Stroke,DRUG: BAY2433334|OTHER: BAY2433334 matching placebo,Bayer,Population Health Research Institute,INTERVENTIONAL,2020-06-15,2022-02-18,2022-02-18,2020-03-11,2023-04-19,2023-04-19
NCT04275960,"Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body",https://clinicaltrials.gov/study/NCT04275960,,COMPLETED,NO,Solid Tumors Harboring NTRK Fusion,DRUG: Selitrectinib (BAY2731954),Bayer,,INTERVENTIONAL,2020-02-28,2020-10-01,2020-11-30,2020-02-19,,2020-12-29
NCT04265781,Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants,https://clinicaltrials.gov/study/NCT04265781,,COMPLETED,NO,Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,DRUG: BAY1817080|DRUG: Matching Placebo,Bayer,,INTERVENTIONAL,2020-02-15,2020-09-20,2020-09-20,2020-02-12,,2023-01-26
NCT04264637,Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis,https://clinicaltrials.gov/study/NCT04264637,,COMPLETED,NO,Allergic Rhinitis,DRUG: Azelastine hydrochloride (BAYR9258)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2020-02-03,2021-03-17,2021-03-17,2020-02-11,,2022-03-25
NCT04252300,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",https://clinicaltrials.gov/study/NCT04252300,,COMPLETED,NO,Drug Interactions,DRUG: Rosuvastatin|DRUG: Rosuvastatin + BAY1817080,Bayer,,INTERVENTIONAL,2020-03-02,2020-08-29,2020-12-07,2020-02-05,,2021-03-11
NCT04236440,Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration,https://clinicaltrials.gov/study/NCT04236440,KOALA,COMPLETED,NO,"Sleep Apnea, Obstructive",DRUG: BAY2586116 (A1)|DRUG: Placebo (A2)|DRUG: BAY2586116 (B1)|DRUG: BAY2586116 (B2)|DRUG: BAY2586116 (B3)|DRUG: BAY2586116 (C),Bayer,,INTERVENTIONAL,2020-02-04,2021-05-06,2021-06-24,2020-01-22,,2022-08-08
NCT04218266,"Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.",https://clinicaltrials.gov/study/NCT04218266,PACIFIC-AF,COMPLETED,YES,Atrial Fibrillation (AF),DRUG: BAY2433334|DRUG: Apixaban|OTHER: BAY2433334 matching placebo|OTHER: Apixaban matching placebo,Bayer,,INTERVENTIONAL,2020-01-30,2021-10-08,2021-10-08,2020-01-06,2022-10-27,2022-10-27
NCT04147819,"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",https://clinicaltrials.gov/study/NCT04147819,,COMPLETED,NO,Cancers With HER2 Expression,DRUG: BAY2701439|DRUG: BAY2701439,Bayer,,INTERVENTIONAL,2020-07-02,2023-08-21,2023-09-26,2019-11-01,,2024-09-27
NCT04132336,Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed,https://clinicaltrials.gov/study/NCT04132336,,COMPLETED,YES,"Pain, Postoperative",DRUG: Naproxen sodium/Caffeine (BAY2880376)|DRUG: Naproxen sodium (Aleve)|DRUG: Caffeine|DRUG: Placebo,Bayer,,INTERVENTIONAL,2019-11-12,2020-03-02,2020-03-03,2019-10-18,2021-06-16,2021-09-01
NCT04126733,Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable),https://clinicaltrials.gov/study/NCT04126733,,COMPLETED,YES,Colorectal Cancer,"DRUG: Regorafenib (Stivarga, BAY73-4506)|BIOLOGICAL: Nivolumab (Opdivo)",Bayer,Bristol-Myers Squibb,INTERVENTIONAL,2019-10-14,2020-11-11,2022-03-28,2019-10-15,2021-12-14,2023-07-18
NCT04125693,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,https://clinicaltrials.gov/study/NCT04125693,,COMPLETED,NO,Cancer,DRUG: Rogaratinib (BAY1163877)|DRUG: Combination drug,Bayer,,INTERVENTIONAL,2019-10-30,2021-02-16,2021-02-16,2019-10-14,,2022-04-01
NCT04095273,"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",https://clinicaltrials.gov/study/NCT04095273,,COMPLETED,NO,Advanced Solid Tumors,DRUG: Elimusertib (BAY1895344)|DRUG: Pembrolizumab (Keytruda®),Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2019-09-30,2022-11-24,2023-04-11,2019-09-19,,2024-04-02
NCT04069026,A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT04069026,,COMPLETED,NO,Advanced Solid Tumors,DRUG: BAY2416964|DRUG: BAY2416964,Bayer,,INTERVENTIONAL,2019-08-15,2024-01-17,2024-01-17,2019-08-28,,2024-03-06
NCT04065581,Bioequivalence Study for Acarbose/Metformin FDC,https://clinicaltrials.gov/study/NCT04065581,,COMPLETED,NO,"Diabetes Mellitus, Type 2",DRUG: Acarbose/Metformin FDC(BAY81-9783)|DRUG: Glucobay|DRUG: Glucophage,Bayer,,INTERVENTIONAL,2019-10-14,2019-11-25,2020-03-06,2019-08-22,,2020-04-13
NCT04059900,Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus,https://clinicaltrials.gov/study/NCT04059900,,COMPLETED,NO,Functional Gastrointestinal Disorders,"DRUG: STW5 (Iberogast®, BAY98-7411)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-06-18,2013-05-03,2013-05-03,2019-08-16,,2019-09-19
NCT04027192,"Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.",https://clinicaltrials.gov/study/NCT04027192,,COMPLETED,NO,Endometriosis,DRUG: BAY2328065 LSF|DRUG: BAY2328065 tablet|DRUG: Placebo LSF|DRUG: Placebo tablet|DRUG: Midazolam,Bayer,,INTERVENTIONAL,2019-07-31,2020-09-11,2020-11-16,2019-07-19,,2020-11-23
NCT04015492,Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII),https://clinicaltrials.gov/study/NCT04015492,,COMPLETED,NO,Hemophilia A,"BIOLOGICAL: Damoctocog-alfa-pegol (BAY94-9027, Jivi)|BIOLOGICAL: Rurioctocog alfa pegol (Adynovi)",Bayer,,INTERVENTIONAL,2019-08-08,2019-10-25,2020-01-29,2019-07-11,,2020-12-21
NCT04004208,Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy,https://clinicaltrials.gov/study/NCT04004208,FIREFLEYE,COMPLETED,YES,Retinopathy of Prematurity (ROP),"DRUG: Eylea (Aflibercept, BAY86-5321)|PROCEDURE: Laser photocoagulation",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2019-09-25,2021-02-12,2021-02-12,2019-07-01,2022-05-06,2022-05-06
NCT04004195,"Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status",https://clinicaltrials.gov/study/NCT04004195,,COMPLETED,NO,Pharmacokinetics,DRUG: BAY2327949,Bayer,,INTERVENTIONAL,2019-07-10,2020-02-07,2020-06-04,2019-07-01,,2020-06-11
NCT03965728,"Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants",https://clinicaltrials.gov/study/NCT03965728,,COMPLETED,NO,Healthy Volunteers,DRUG: BAY1830839|DRUG: Placebo|DRUG: Midazolam|DRUG: Methotrexate,Bayer,,INTERVENTIONAL,2019-06-05,2022-01-21,2022-05-11,2019-05-29,,2023-05-09
NCT03929861,Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations,https://clinicaltrials.gov/study/NCT03929861,Orca,COMPLETED,NO,"Pharmacology, Clinical",DRUG: Fluconazole (BAYT006267) 150 mg capsules|DRUG: Fluconazole 150 mg capsules (DiflucanTM),Bayer,,INTERVENTIONAL,2012-07-31,2012-09-10,2012-09-10,2019-04-29,,2019-04-29
NCT03901729,A Trial to Study BAY1753011 in Patients With Congestive Heart Failure,https://clinicaltrials.gov/study/NCT03901729,AVANTI,COMPLETED,NO,Heart Failure (HF),DRUG: BAY 1753011|OTHER: Placebo BAY 1753011|DRUG: Furosemide|OTHER: Placebo Furosemide,Bayer,,INTERVENTIONAL,2019-05-29,2021-04-16,2021-05-21,2019-04-03,,2022-04-18
NCT03890731,A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed,https://clinicaltrials.gov/study/NCT03890731,,COMPLETED,YES,Solid Cancer,"DRUG: BAY73-4506 (Regorafenib, Stivarga)",Bayer,,INTERVENTIONAL,2019-04-02,2023-02-28,2023-02-28,2019-03-26,2024-04-02,2024-04-02
NCT03789890,Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants,https://clinicaltrials.gov/study/NCT03789890,,COMPLETED,NO,Drug Interactions,DRUG: BAY1902607|DRUG: Itraconazole,Bayer,,INTERVENTIONAL,2019-01-08,2019-03-04,2019-05-23,2018-12-31,,2019-05-29
NCT03788603,Rogaratinib (BAY1163877) in Chinese Patients,https://clinicaltrials.gov/study/NCT03788603,,COMPLETED,NO,Neoplasms,DRUG: Rogaratinib (BAY1163877),Bayer,,INTERVENTIONAL,2019-01-07,2019-04-30,2020-04-14,2018-12-27,,2021-03-29
NCT03787368,End-stage Renal Disease (ESRD) Pilot Study,https://clinicaltrials.gov/study/NCT03787368,,COMPLETED,NO,Renal Dialysis,DRUG: BAY1213790|DRUG: 0.9% sodium chloride solution,Bayer,,INTERVENTIONAL,2019-01-31,2021-09-15,2021-09-15,2018-12-26,,2022-03-16
NCT03773068,"A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein",https://clinicaltrials.gov/study/NCT03773068,,COMPLETED,NO,Biological Availability,DRUG: BAY1817080 - Formulation A|DRUG: BAY1817080 - Formulation B|DRUG: [13C715N]-BAY 181708 stable isotope label (SIL),Bayer,,INTERVENTIONAL,2018-12-13,2019-06-21,2019-08-12,2018-12-12,,2019-08-19
NCT03754660,"This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",https://clinicaltrials.gov/study/NCT03754660,ATMOS,COMPLETED,NO,"Hypertension, Pulmonary",DRUG: BAY1237592,Bayer,,INTERVENTIONAL,2019-01-21,2022-04-24,2022-11-03,2018-11-27,,2023-09-28
NCT03735628,An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03735628,,COMPLETED,NO,Non-small Cell Lung Cancer (NSCLC)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Hepatocellular Carcinoma (HCC),DRUG: Copanlisib|DRUG: Nivolumab,Bayer,,INTERVENTIONAL,2018-10-17,2022-10-13,2022-10-13,2018-11-08,,2023-10-06
NCT03724747,"Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer",https://clinicaltrials.gov/study/NCT03724747,,COMPLETED,NO,Metastatic Castration Resistant Prostate Cancer (mCRPC),DRUG: BAY2315497 Injection|DRUG: Darolutamide(BAY1841788),Bayer,,INTERVENTIONAL,2018-12-18,2022-08-25,2024-10-31,2018-10-30,,2024-11-08
NCT03708133,Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation,https://clinicaltrials.gov/study/NCT03708133,,COMPLETED,NO,Bioequivalence,"DRUG: Nifurtimox (Lampit, BAYA2502)_Test|DRUG: Nifurtimox (Lampit, BAYA2502)_Reference",Bayer,,INTERVENTIONAL,2018-12-05,2019-04-17,2019-06-18,2018-10-17,,2020-06-11
NCT03704519,Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.,https://clinicaltrials.gov/study/NCT03704519,,COMPLETED,NO,Cerebrovascular Circulation,DRUG: Darolutamide (BAY1841788)|DRUG: Enzalutamide|OTHER: Placebo,Bayer,,INTERVENTIONAL,2018-10-23,2019-10-01,2019-11-05,2018-10-12,,2020-10-30
NCT03666273,Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.,https://clinicaltrials.gov/study/NCT03666273,,COMPLETED,NO,Advanced Solid Tumor|Head and Neck Squamous Cell Carcinoma,DRUG: Bapotulimab (BAY1905254)|DRUG: Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®),Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2018-09-12,2023-06-16,2024-05-15,2018-09-11,,2024-05-28
NCT03655301,Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics,https://clinicaltrials.gov/study/NCT03655301,,COMPLETED,YES,Healthy Volunteers,"DRUG: Copanlisib (Aliqopa, BAY80-6946)|DRUG: Metformin",Bayer,,INTERVENTIONAL,2018-09-11,2018-11-12,2019-02-12,2018-08-31,2019-12-23,2020-01-28
NCT03639675,Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied,https://clinicaltrials.gov/study/NCT03639675,VENERA,COMPLETED,YES,"Glaucoma, Neovascular","DRUG: Aflibercept (EYLEA, BAY86-5321)|DRUG: Topical IOP-lowering drugs",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2018-10-03,2019-02-14,2019-03-14,2018-08-21,2020-02-18,2020-03-03
NCT03603678,Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor,https://clinicaltrials.gov/study/NCT03603678,SANDMAN,COMPLETED,NO,"Sleep Apnea, Obstructive",DRUG: BAY2253651|DRUG: Placebo,Bayer,,INTERVENTIONAL,2018-08-13,2019-05-23,2019-09-02,2018-07-27,,2020-12-11
NCT03596762,A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT03596762,SWITCH-1,COMPLETED,YES,Menopause|Hot Flashes|Night Waking,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,Nerre Therapeutics Ltd.,INTERVENTIONAL,2018-11-20,2019-11-21,2019-11-21,2018-07-24,2023-03-10,2023-03-10
NCT03596372,Study of BAY1834942 in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT03596372,,COMPLETED,NO,Advanced CEACAM6-expressing Solid Tumors,DRUG: BAY1834942,Bayer,,INTERVENTIONAL,2018-06-19,2020-11-16,2021-02-22,2018-07-23,,2022-06-02
NCT03570554,A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale,https://clinicaltrials.gov/study/NCT03570554,,COMPLETED,YES,"Osteoarthritis, Knee","DRUG: Naproxen Sodium (Aleve, BAY117031)|DRUG: Acetaminophen ER|DRUG: Celecoxib|DRUG: Placebo",Bayer,,INTERVENTIONAL,2018-06-29,2019-06-14,2019-06-14,2018-06-27,2020-06-19,2020-06-19
NCT03562624,A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components,https://clinicaltrials.gov/study/NCT03562624,INDessa,COMPLETED,NO,Contraception,"DRUG: BAY98-7443|DRUG: Levonogestrel (Skyla, BAY86-5028)",Bayer,,INTERVENTIONAL,2018-06-22,2019-05-16,2019-08-01,2018-06-19,,2019-08-12
NCT03547583,Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF,https://clinicaltrials.gov/study/NCT03547583,VITALITY-HFpEF,COMPLETED,YES,Chronic Heart Failure With Preserved Ejection Fraction,"DRUG: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|DRUG: Placebo",Bayer,Merck Sharp & Dohme LLC|Canadian VIGOUR Centre|Duke Clinical Research Institute,INTERVENTIONAL,2018-06-15,2019-10-15,2019-11-04,2018-06-06,2020-12-03,2021-01-06
NCT03543657,Maintenance Treatment of Renal Anemia in Dialysis Subjects,https://clinicaltrials.gov/study/NCT03543657,MIYABI HD-M,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934)|DRUG: Darbepoetin alfa|DRUG: Placebo of Molidustat (BAY85-3934)|DRUG: Placebo of Darbepoetin alfa,Bayer,,INTERVENTIONAL,2018-06-23,2019-08-07,2019-12-24,2018-06-01,,2021-01-29
NCT03540615,"BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics",https://clinicaltrials.gov/study/NCT03540615,,COMPLETED,NO,"Arthritis, Rheumatoid",DRUG: BAY1830839|DRUG: Placebo,Bayer,,INTERVENTIONAL,2018-06-28,2019-02-05,2019-08-01,2018-05-30,,2020-08-05
NCT03535168,Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients,https://clinicaltrials.gov/study/NCT03535168,,COMPLETED,NO,Cough,DRUG: BAY1902607|DRUG: Matching placebo|DRUG: Midazolam,Bayer,,INTERVENTIONAL,2018-05-29,2019-09-25,2019-10-11,2018-05-24,,2021-02-10
NCT03517956,"Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT03517956,ROCOCO,COMPLETED,NO,Advanced or Metastatic Solid Tumor,DRUG: Rogaratinib (BAY1163877)|DRUG: Copanlisib (BAY80-6946),Bayer,,INTERVENTIONAL,2018-07-25,2021-02-01,2021-02-01,2018-05-08,,2022-07-14
NCT03517943,A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT03517943,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)",Bayer,,INTERVENTIONAL,2018-04-24,2018-08-30,2018-08-30,2018-05-08,,2018-09-13
NCT03517930,A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT03517930,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)",Bayer,,INTERVENTIONAL,2018-04-17,2018-07-20,2018-07-20,2018-05-08,,2018-09-19
NCT03507452,"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",https://clinicaltrials.gov/study/NCT03507452,,COMPLETED,NO,"Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma|Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma|Advanced Recurrent Serous Ovarian Cancer|Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)",DRUG: BAY2287411|DRUG: BAY2287411,Bayer,,INTERVENTIONAL,2018-06-13,2021-09-29,2022-03-29,2018-04-25,,2023-03-20
NCT03504982,Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat,https://clinicaltrials.gov/study/NCT03504982,,COMPLETED,NO,Coronary Artery Disease,DRUG: Vericiguat (BAY1021189)|DRUG: Moxifloxacin|DRUG: Placebo,Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2018-05-17,2018-11-29,2019-02-26,2018-04-20,,2020-04-17
NCT03498430,Copanlisib Chinese PK Study,https://clinicaltrials.gov/study/NCT03498430,,COMPLETED,NO,"Lymphoma, Non-Hodgkin","DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,INTERVENTIONAL,2018-04-27,2019-08-06,2020-06-02,2018-04-13,,2021-05-19
NCT03493269,A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis,https://clinicaltrials.gov/study/NCT03493269,,COMPLETED,NO,Healthy Volunteers|Psoriasis,DRUG: BAY1834845|OTHER: Matching Placebo|DRUG: Midazolam,Bayer,,INTERVENTIONAL,2018-04-16,2020-09-16,2021-02-05,2018-04-10,,2021-02-26
NCT03484585,Rogaratinib (BAY1163877) Human Mass Balance Study,https://clinicaltrials.gov/study/NCT03484585,,COMPLETED,NO,"Clinical Trial, Phase I|Pharmacokinetics",DRUG: Rogaratinib (BAY1163877),Bayer,,INTERVENTIONAL,2018-04-06,2018-05-25,2018-08-09,2018-04-02,,2018-08-14
NCT03481946,A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia,https://clinicaltrials.gov/study/NCT03481946,,COMPLETED,NO,Hemophilia A; Hemophilia B,DRUG: BAY1093884|DRUG: BAY1093884,Bayer,,INTERVENTIONAL,2018-05-10,2018-10-17,2019-02-20,2018-03-29,,2020-09-16
NCT03473756,Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma,https://clinicaltrials.gov/study/NCT03473756,FORT-2,COMPLETED,NO,Urothelial Carcinoma,DRUG: Rogaratinib (BAY1163877)|DRUG: Atezolizumab,Bayer,,INTERVENTIONAL,2018-05-15,2021-07-16,2024-07-10,2018-03-22,,2024-09-19
NCT03427788,"BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect",https://clinicaltrials.gov/study/NCT03427788,,COMPLETED,NO,Endometriosis,DRUG: BAY2328065|DRUG: Placebo,Bayer,,INTERVENTIONAL,2018-03-21,2018-10-29,2019-02-11,2018-02-09,,2024-02-29
NCT03424135,A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions,https://clinicaltrials.gov/study/NCT03424135,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Naproxen sodium and diphenhydramine hydrochloride soft capsules|DRUG: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)",Bayer,,INTERVENTIONAL,2018-03-02,2018-04-04,2018-04-04,2018-02-06,,2019-03-20
NCT03418168,A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects,https://clinicaltrials.gov/study/NCT03418168,MIYABI PD,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934),Bayer,,INTERVENTIONAL,2018-02-22,2019-07-25,2019-07-29,2018-02-01,,2021-01-29
NCT03412006,"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease",https://clinicaltrials.gov/study/NCT03412006,CADA DIA,COMPLETED,NO,Diabetic Kidney Disease,DRUG: Fulacimstat (BAY1142524)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2018-02-02,2019-10-02,2019-10-10,2018-01-26,,2022-03-03
NCT03411980,Pharmacokinetics and Safety of Vilaprisan in Renal Impairment,https://clinicaltrials.gov/study/NCT03411980,,COMPLETED,NO,Uterine Fibroids|Endometriosis,DRUG: Vilaprisan (BAY1002670),Bayer,,INTERVENTIONAL,2018-02-02,2018-10-10,2019-02-06,2018-01-26,,2019-12-03
NCT03410693,Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma,https://clinicaltrials.gov/study/NCT03410693,FORT-1,COMPLETED,YES,"Carcinoma, Transitional Cell",DRUG: Rogaratinib (BAY1163877)|DRUG: Chemotherapy,Bayer,,INTERVENTIONAL,2018-05-31,2020-10-27,2020-10-27,2018-01-25,2021-12-29,2022-09-28
NCT03402438,Renal Impairment Study,https://clinicaltrials.gov/study/NCT03402438,,COMPLETED,NO,"Clinical Trial, Phase I",DRUG: Fulacimstat (BAY1142524),Bayer,,INTERVENTIONAL,2018-02-12,2018-12-04,2019-03-19,2018-01-18,,2020-03-16
NCT03399526,1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat,https://clinicaltrials.gov/study/NCT03399526,,COMPLETED,NO,Psoriasis,"DRUG: Mapracorat (ZK 245186, BAY 86-5319)|DRUG: Prednicarbate 0.25% ointment|DRUG: Clobetasol 0.05% ointment|DRUG: Calcipotriene 0.005% ointment|DRUG: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment",Bayer,,INTERVENTIONAL,2013-02-11,2013-05-31,2013-05-31,2018-01-16,,2018-01-16
NCT03396250,A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT03396250,,COMPLETED,NO,Pain,"DRUG: Naproxen sodium and diphenhydramine hydrochloride soft capsules|DRUG: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)",Bayer,,INTERVENTIONAL,2018-02-12,2018-03-26,2018-03-29,2018-01-10,,2019-03-20
NCT03364998,BAY94-9027 PK Study Comparing to Another Long Acting Product,https://clinicaltrials.gov/study/NCT03364998,,COMPLETED,NO,Hemophilia A,"DRUG: Damoctocog (Jivi, BAY94-9027)|DRUG: Elocta",Bayer,,INTERVENTIONAL,2017-11-30,2018-01-25,2018-09-28,2017-12-07,,2019-09-09
NCT03353857,Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam,https://clinicaltrials.gov/study/NCT03353857,,COMPLETED,NO,Biological Availability,"DRUG: levonorgestrel/ Microlut|DRUG: Norethindrone/ Noriday|DRUG: Desogestrel/ Cerazette|DRUG: Dienogest/ Visanne|DRUG: Drospirenone, Ethinylestradiol/ Yasmin|DRUG: Midazolam/ Midazolam-ratiopharm|DRUG: Rifampicin",Bayer,,INTERVENTIONAL,2017-11-29,2018-07-04,2019-02-19,2017-11-27,,2020-04-15
NCT03351166,A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects,https://clinicaltrials.gov/study/NCT03351166,MIYABI HD-C,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934),Bayer,,INTERVENTIONAL,2018-01-22,2018-10-23,2018-11-20,2017-11-22,,2021-01-29
NCT03350347,A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects,https://clinicaltrials.gov/study/NCT03350347,MIYABI ND-M,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934)|DRUG: Darbepoetin alfa,Bayer,,INTERVENTIONAL,2017-12-13,2019-07-05,2019-11-28,2017-11-22,,2021-01-29
NCT03350321,A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects,https://clinicaltrials.gov/study/NCT03350321,MIYABI ND-C,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934)|DRUG: Darbepoetin alfa,Bayer,,INTERVENTIONAL,2017-12-12,2019-05-17,2019-10-11,2017-11-22,,2021-01-29
NCT03350295,"Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg",https://clinicaltrials.gov/study/NCT03350295,,COMPLETED,NO,Chagas Disease,"DRUG: Nifurtimox (Lampit, BAYA2502)",Bayer,,INTERVENTIONAL,2018-06-14,2018-09-18,2018-12-14,2017-11-22,,2019-12-12
NCT03349684,Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients,https://clinicaltrials.gov/study/NCT03349684,,COMPLETED,NO,"Diabetes Mellitus, Type 2",DRUG: Acarbose|DRUG: Metformin|DRUG: Placebo,Bayer,,INTERVENTIONAL,2018-03-05,2019-08-12,2019-08-21,2017-11-21,,2020-08-05
NCT03347292,Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC,https://clinicaltrials.gov/study/NCT03347292,,COMPLETED,NO,"Carcinoma, Hepatocellular","DRUG: Regorafenib(Stivarga, BAY73-4506)|DRUG: Pembrolizumab",Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2018-06-18,2020-12-17,2022-09-06,2017-11-20,,2023-07-25
NCT03334838,Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study,https://clinicaltrials.gov/study/NCT03334838,,COMPLETED,NO,Chagas' Disease,"DRUG: Nifurtimox (Lampit, BAYA2502)",Bayer,,INTERVENTIONAL,2019-06-10,2019-11-07,2020-01-29,2017-11-07,,2020-12-30
NCT03310645,Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients,https://clinicaltrials.gov/study/NCT03310645,,COMPLETED,NO,Cough,DRUG: BAY1817080|DRUG: Matching Placebo,Bayer,,INTERVENTIONAL,2017-12-07,2019-05-28,2019-06-19,2017-10-16,,2023-01-26
NCT03276143,FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty,https://clinicaltrials.gov/study/NCT03276143,FOXTROT,COMPLETED,NO,"Knee Arthroplasty, Total",DRUG: Enoxaparin|DRUG: Apixaban|DRUG: BAY1213790,Bayer,,INTERVENTIONAL,2017-09-21,2018-08-20,2019-01-02,2017-09-08,,2020-03-03
NCT03255512,Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients,https://clinicaltrials.gov/study/NCT03255512,VISOR,COMPLETED,NO,Coronary Artery Disease,DRUG: Vericiguat (BAY1021189)|DRUG: Placebo|DRUG: Isosorbide mononitrate (ISMN),Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2017-08-17,2018-02-07,2018-03-23,2017-08-21,,2021-12-29
NCT03252002,"Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects",https://clinicaltrials.gov/study/NCT03252002,,COMPLETED,NO,Healthy Volunteer,DRUG: BAY1101042|DRUG: Placebo,Bayer,,INTERVENTIONAL,2017-08-16,2019-04-30,2019-07-24,2017-08-16,,2019-08-19
NCT03244462,"Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate",https://clinicaltrials.gov/study/NCT03244462,,COMPLETED,NO,Inflammation,DRUG: BAY1834845|DRUG: BAY1834845|DRUG: Methotrexate,Bayer,,INTERVENTIONAL,2017-08-18,2018-01-22,2018-07-20,2017-08-09,,2019-07-15
NCT03237416,Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers,https://clinicaltrials.gov/study/NCT03237416,,COMPLETED,NO,Prostatic Neoplasms,DRUG: Dabigatran etexilate|DRUG: Midazolam|DRUG: BAY1841788 (darolutamide),Bayer,"Orion Corporation, Orion Pharma",INTERVENTIONAL,2017-08-02,2017-10-05,2017-12-18,2017-08-02,,2018-11-06
NCT03235076,"Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects",https://clinicaltrials.gov/study/NCT03235076,,COMPLETED,NO,Renal Impairment,DRUG: BAY1101042,Bayer,,INTERVENTIONAL,2017-08-15,2018-11-07,2019-03-13,2017-08-01,,2023-06-05
NCT03225352,A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets,https://clinicaltrials.gov/study/NCT03225352,,COMPLETED,NO,Moderate Pain,"DRUG: 500 mg acetylsalicylic acid (Aspirin, BAYE4465)|DRUG: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|DRUG: 400 mg ibuprofen(Nurofen)|DRUG: 400 mg ibuprofen (Dolormin Extra)",Bayer,,INTERVENTIONAL,2017-08-07,2017-10-07,2017-10-16,2017-07-21,,2018-06-06
NCT03215511,A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer,https://clinicaltrials.gov/study/NCT03215511,,COMPLETED,NO,Solid Tumors Harboring NTRK Fusion,DRUG: Selitrectinib (BAY2731954),Bayer,,INTERVENTIONAL,2017-07-03,2022-04-11,2023-01-30,2017-07-12,,2024-10-30
NCT03212586,"BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect",https://clinicaltrials.gov/study/NCT03212586,,COMPLETED,NO,"Clinical Trials, Phase I as Topic",DRUG: BAY1902607|DRUG: Placebo,Bayer,,INTERVENTIONAL,2017-07-18,2018-05-03,2018-07-27,2017-07-11,,2019-05-14
NCT03210246,Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC),https://clinicaltrials.gov/study/NCT03210246,,COMPLETED,NO,"Clinical Trial ,Phase I",DRUG: Vilaprisan (BAY 1002670)|DRUG: Vilaprisan Placebo|DRUG: Microgynon|DRUG: Microgynon Placebo,Bayer,,INTERVENTIONAL,2017-07-17,2018-06-21,2019-01-23,2017-07-06,,2019-02-28
NCT03188965,First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,https://clinicaltrials.gov/study/NCT03188965,,COMPLETED,NO,Advanced Solid Tumor|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,DRUG: Elimusertib (BAY1895344),Bayer,,INTERVENTIONAL,2017-07-06,2022-12-02,2023-09-13,2017-06-16,,2023-10-11
NCT03172884,Study of Copanlisib in Hepatic or Renal Impairment,https://clinicaltrials.gov/study/NCT03172884,,COMPLETED,YES,"Hepatic Insufficiency, Renal Insufficiency","DRUG: Copanlisib (ALIQOPA, BAY80-6946)",Bayer,,INTERVENTIONAL,2017-06-14,2020-03-13,2020-05-15,2017-06-01,2021-04-01,2021-04-28
NCT03145038,Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects,https://clinicaltrials.gov/study/NCT03145038,,COMPLETED,NO,Pharmacokinetics,"DRUG: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|DRUG: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|DRUG: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast",Bayer,,INTERVENTIONAL,2017-05-16,2017-08-29,2017-10-09,2017-05-09,,2021-12-29
NCT03136666,"Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.",https://clinicaltrials.gov/study/NCT03136666,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil",Bayer,,INTERVENTIONAL,2010-04-19,2010-06-07,2010-06-07,2017-05-02,,2017-05-02
NCT03128320,The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure,https://clinicaltrials.gov/study/NCT03128320,,COMPLETED,NO,Diabetic Foot,DRUG: BAY1193397|DRUG: BAY1193397|DRUG: Placebo,Bayer,,INTERVENTIONAL,2017-05-25,2019-09-06,2019-10-28,2017-04-25,,2020-08-13
NCT03127735,BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),https://clinicaltrials.gov/study/NCT03127735,,COMPLETED,NO,"Leukemia, Myeloid, Acute",DRUG: BAY1436032,Bayer,,INTERVENTIONAL,2017-06-14,2018-12-06,2019-03-15,2017-04-25,,2019-05-14
NCT03102320,Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03102320,ARCS-Multi,COMPLETED,NO,Neoplasms,DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Anetumab ravtansine (BAY94-9343),Bayer,"ImmunoGen, Inc.|MorphoSys AG",INTERVENTIONAL,2017-05-26,2020-09-16,2021-07-26,2017-04-05,,2022-06-30
NCT03098979,A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction,https://clinicaltrials.gov/study/NCT03098979,PANACHE,COMPLETED,YES,Heart Failure,DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2017-05-10,2018-05-23,2018-06-20,2017-04-04,2019-07-23,2019-07-23
NCT03092999,"Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)",https://clinicaltrials.gov/study/NCT03092999,,COMPLETED,NO,Leiomyoma,DRUG: Vilaprisan (BAY1002670),Bayer,,INTERVENTIONAL,2017-03-28,2017-07-17,2017-07-17,2017-03-28,,2017-08-18
NCT03074058,Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet,https://clinicaltrials.gov/study/NCT03074058,,COMPLETED,NO,Clinical Pharmacology,"DRUG: Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|DRUG: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)",Bayer,,INTERVENTIONAL,2015-06-10,2015-08-04,2015-08-21,2017-03-08,,2017-03-21
NCT03074045,LCS16 vs. COC User Satisfaction and Tolerability Study,https://clinicaltrials.gov/study/NCT03074045,,COMPLETED,NO,Contraception,"DRUG: Levonorgestrel (Kyleena, BAY86-5028)|DRUG: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)",Bayer,,INTERVENTIONAL,2017-03-13,2018-09-03,2022-08-05,2017-03-08,,2023-06-18
NCT03056703,Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets,https://clinicaltrials.gov/study/NCT03056703,Mille,COMPLETED,NO,Pain,"DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)|DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)",Bayer,,INTERVENTIONAL,2014-02,2014-03,2014-03,2017-02-17,,2017-02-17
NCT03054402,"First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845",https://clinicaltrials.gov/study/NCT03054402,,COMPLETED,NO,Pelvic Inflammatory Disease,DRUG: BAY1834845|DRUG: Placebo,Bayer,,INTERVENTIONAL,2017-02-13,2017-11-30,2018-03-29,2017-02-15,,2019-03-27
NCT03048110,Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction,https://clinicaltrials.gov/study/NCT03048110,,COMPLETED,NO,Biological Availability,DRUG: BAY1841788 (ODM-201)|DRUG: Itraconazole|DRUG: Rifampicin,Bayer,"Orion Corporation, Orion Pharma",INTERVENTIONAL,2017-02-15,2017-05-04,2017-07-19,2017-02-09,,2018-07-30
NCT02992288,A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction,https://clinicaltrials.gov/study/NCT02992288,PANTHEON,COMPLETED,YES,Heart Failure,DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2017-02-22,2018-03-28,2018-05-16,2016-12-14,2019-04-23,2019-04-23
NCT02985541,Mirena Extension Trial,https://clinicaltrials.gov/study/NCT02985541,MET,COMPLETED,YES,Contraception,"DRUG: Levonorgestrel IUS (Mirena, BAY86-5028)",Bayer,,INTERVENTIONAL,2016-12-22,2021-05-28,2021-05-28,2016-12-07,2022-04-28,2022-04-28
NCT02976467,"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction",https://clinicaltrials.gov/study/NCT02976467,CHIARA MIA 2,COMPLETED,NO,Myocardial Infarction,DRUG: Fulacimstat (BAY1142524)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2016-12-30,2018-07-31,2018-09-04,2016-11-29,,2019-09-03
NCT02975440,Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan,https://clinicaltrials.gov/study/NCT02975440,,COMPLETED,NO,Endometriosis,DRUG: Rifampicin|DRUG: Midazolam|DRUG: BAY1002670_Vilaprisan,Bayer,,INTERVENTIONAL,2016-11-10,2017-01-27,2017-04-11,2016-11-29,,2017-07-02
NCT02957396,Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT02957396,,COMPLETED,NO,Pharmacokinetics,DRUG: Finerenone (BAY94-8862): 20 mg intact tablet|DRUG: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|DRUG: Finerenone (BAY94-8862): 20 mg suspension,Bayer,,INTERVENTIONAL,2016-11-17,2017-01-13,2017-03-01,2016-11-06,,2017-04-24
NCT02956109,Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers,https://clinicaltrials.gov/study/NCT02956109,,COMPLETED,NO,Pharmacokinetics,DRUG: Finerenone (BAY94-8862): 1 0mg tablet|DRUG: Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|DRUG: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet,Bayer,,INTERVENTIONAL,2016-11-16,2016-12-22,2017-03-17,2016-11-04,,2017-07-11
NCT02940002,BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test,https://clinicaltrials.gov/study/NCT02940002,,COMPLETED,NO,Psoriasis,DRUG: BAY1003803|DRUG: Clobetasol propionate|DRUG: Betamethasone/calcipotriene,Bayer,,INTERVENTIONAL,2016-10-12,2017-01-27,2017-03-17,2016-10-20,,2017-03-21
NCT02894385,"Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)",https://clinicaltrials.gov/study/NCT02894385,,COMPLETED,NO,Pharmacokinetics|Hepatic Insufficiency|Renal Insufficiency,DRUG: BAY1841788,Bayer,"Orion Corporation, Orion Pharma",INTERVENTIONAL,2016-09-13,2017-04-10,2017-12-15,2016-09-09,,2019-01-07
NCT02865538,Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT02865538,RELENT-1,COMPLETED,YES,Post-menopausal Vasomotor Symptoms,DRUG: BAY3427080|DRUG: Placebo (for BAY3427080),Bayer,Nerre Therapeutics Ltd.,INTERVENTIONAL,2016-08-01,2017-03-28,2017-03-28,2016-08-12,2021-02-16,2021-02-16
NCT02824042,Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,https://clinicaltrials.gov/study/NCT02824042,,COMPLETED,NO,Medical Oncology,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Itraconazole,Bayer,,INTERVENTIONAL,2016-09-07,2018-06-27,2019-08-05,2016-07-06,,2020-07-31
NCT02818998,Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02818998,VIOLET,COMPLETED,YES,Macular Edema,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)",Bayer,,INTERVENTIONAL,2016-11-16,2018-11-13,2019-09-24,2016-06-30,2019-12-04,2020-07-31
NCT02817100,"First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080",https://clinicaltrials.gov/study/NCT02817100,,COMPLETED,NO,"Clinical Trials, Phase I as Topic",DRUG: BAY1817080|DRUG: Placebo|DRUG: Itraconazole,Bayer,,INTERVENTIONAL,2016-07-22,2017-05-11,2017-08-23,2016-06-29,,2017-09-06
NCT02799602,Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer,https://clinicaltrials.gov/study/NCT02799602,ARASENS,COMPLETED,YES,Metastatic Hormone-sensitive Prostate Cancer,DRUG: BAY1841788 / darolutamide (ODM-201)|DRUG: Standard ADT (androgen deprivation therapy)|DRUG: Docetaxel|DRUG: Placebo,Bayer,"Orion Corporation, Orion Pharma",INTERVENTIONAL,2016-11-30,2021-10-25,2023-04-11,2016-06-15,2023-02-24,2024-04-16
NCT02751918,Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer,https://clinicaltrials.gov/study/NCT02751918,,COMPLETED,NO,Ovarian Neoplasms,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Pegylated Liposomal Doxorubicin,Bayer,,INTERVENTIONAL,2016-06-08,2019-08-23,2019-10-31,2016-04-26,,2019-11-22
NCT02745743,Phase I Trial of BAY1251152 for Advanced Blood Cancers,https://clinicaltrials.gov/study/NCT02745743,,COMPLETED,NO,Hematologic Neoplasms,DRUG: BAY1251152,Bayer,,INTERVENTIONAL,2016-06-17,2018-08-03,2018-08-03,2016-04-20,,2019-09-19
NCT02696642,Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment,https://clinicaltrials.gov/study/NCT02696642,,COMPLETED,NO,Neoplasms,DRUG: Anetumab ravtansine (BAY94-9343),Bayer,,INTERVENTIONAL,2016-04-14,2018-07-31,2019-08-19,2016-03-02,,2021-07-09
NCT02671097,"Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate",https://clinicaltrials.gov/study/NCT02671097,,COMPLETED,NO,Healthy Volunteers|Pharmacokinetics|Drug Interaction,DRUG: Rosuvastatin|DRUG: BAY1841788 (ODM-201),Bayer,,INTERVENTIONAL,2016-02,2016-05,2016-08,2016-02-02,,2016-09-08
NCT02639091,Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,https://clinicaltrials.gov/study/NCT02639091,,COMPLETED,NO,Medical Oncology,DRUG: BAY 94-9343|DRUG: Pemetrexed|DRUG: Cisplatin,Bayer,,INTERVENTIONAL,2016-02-03,2018-05-23,2019-10-17,2015-12-24,,2019-11-07
NCT02625974,"A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi",https://clinicaltrials.gov/study/NCT02625974,,COMPLETED,YES,Chagas Disease,"DRUG: Nifurtimox (Lampit, BAYA2502)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2016-01-27,2018-07-25,2021-08-10,2015-12-09,2019-10-29,2024-08-19
NCT02617550,Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients,https://clinicaltrials.gov/study/NCT02617550,VENICE,COMPLETED,NO,Coronary Artery Disease,DRUG: Vericiguat (BAY1021189)|DRUG: Placebo|DRUG: Nitroglycerin,Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2015-11-18,2016-05-18,2016-08-11,2015-12-01,,2021-12-29
NCT02610140,Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM),https://clinicaltrials.gov/study/NCT02610140,,COMPLETED,YES,Mesothelioma,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Vinorelbine,Bayer,ImmunoGen and MorphoSys,INTERVENTIONAL,2015-12-03,2017-05-31,2019-09-06,2015-11-20,2020-07-17,2020-11-04
NCT02606864,Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients,https://clinicaltrials.gov/study/NCT02606864,,COMPLETED,NO,Chagas Disease,DRUG: Nifurtimox (BAYa2502),Bayer,,INTERVENTIONAL,2015-12,2016-04,2016-08,2015-11-17,,2016-11-15
NCT02593747,To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup,https://clinicaltrials.gov/study/NCT02593747,Bordeaux,COMPLETED,NO,"Histamine H1 Antagonists, Non-Sedating",DRUG: Loratadine oral solution|DRUG: Loratadine (Claritin peach syrup),Bayer,,INTERVENTIONAL,2015-12,2016-01,2016-03,2015-11-01,,2017-02-13
NCT02592785,"Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT02592785,,COMPLETED,NO,Neoplasms,DRUG: BAY1163877,Bayer,,INTERVENTIONAL,2015-12-15,2017-02-05,2017-12-06,2015-10-30,,2018-04-18
NCT02581878,Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT02581878,,COMPLETED,NO,"Lymphoma, Non-Hodgkin",DRUG: BAY1862864,Bayer,,INTERVENTIONAL,2015-11-20,2019-11-11,2019-11-26,2015-10-21,,2020-11-25
NCT02571569,"A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors",https://clinicaltrials.gov/study/NCT02571569,,COMPLETED,NO,Hemophilia A|Hemophilia B,DRUG: BAY1093884|DRUG: BAY1093884,Bayer,,INTERVENTIONAL,2015-10-28,2018-07-09,2018-10-11,2015-10-08,,2018-10-18
NCT02564718,Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates,https://clinicaltrials.gov/study/NCT02564718,Einstein Jr,COMPLETED,YES,Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2015-11-19,2017-12-18,2017-12-18,2015-10-01,2018-07-10,2018-07-10
NCT02563197,Inhalation Flow Rate-study,https://clinicaltrials.gov/study/NCT02563197,,COMPLETED,NO,Bronchiectasis,DEVICE: T-326 Inhaler,Bayer,Novartis,INTERVENTIONAL,2015-11-23,2016-02-17,2016-04-29,2015-09-30,,2017-04-26
NCT02556268,Interaction With HIV Antiretroviral Agents,https://clinicaltrials.gov/study/NCT02556268,,COMPLETED,NO,HIV-DDI,"DRUG: Riociguat (Adempas, BAY 63-2521)|DRUG: ATRIPLA|DRUG: COMPLERA|DRUG: STRIBILD|DRUG: TRIUMEQ|DRUG: Antiretroviral protease inhibitor",Bayer,,INTERVENTIONAL,2016-02-23,2016-12-07,2016-12-07,2015-09-22,,2017-12-06
NCT02550977,Russia/Ukraine Suppression of Ovarian Activity Study,https://clinicaltrials.gov/study/NCT02550977,,COMPLETED,NO,Contraception,DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,INTERVENTIONAL,2015-09-18,2016-07-15,2016-08-15,2015-09-16,,2017-08-07
NCT02549469,Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily,https://clinicaltrials.gov/study/NCT02549469,,COMPLETED,NO,Pain,"DRUG: Naproxen Sodium ER (BAY117031), 20% HPMC|DRUG: Naproxen Sodium ER (BAY117031), 30% HPMC|DRUG: Naproxen Sodium ER (BAY117031), 40% HPMC|DRUG: Aleve (Naproxen Sodium, BAY117031)",Bayer,,INTERVENTIONAL,2007-03,2007-05,2007-05,2015-09-15,,2015-09-15
NCT02545452,"Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring",https://clinicaltrials.gov/study/NCT02545452,,COMPLETED,NO,Endometriosis,DRUG: Anastrozole / Levonorgestrel (BAY98-7196)|DRUG: Gyno-Daktarin|DRUG: Sobelin vaginal creme|DRUG: Patentex oval|OTHER: Tampon,Bayer,,INTERVENTIONAL,2015-09-15,2016-03-14,2016-07-29,2015-09-10,,2017-07-24
NCT02545049,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,https://clinicaltrials.gov/study/NCT02545049,FIGARO-DKD,COMPLETED,YES,Diabetic Kidney Disease,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2015-09-17,2021-02-02,2021-02-02,2015-09-09,2022-04-15,2022-04-15
NCT02540993,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,https://clinicaltrials.gov/study/NCT02540993,FIDELIO-DKD,COMPLETED,YES,Chronic Kidney Disease,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2015-09-17,2020-04-14,2020-04-14,2015-09-04,2021-07-19,2023-07-24
NCT02540954,Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD),https://clinicaltrials.gov/study/NCT02540954,,COMPLETED,YES,Macular Degeneration,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)",Bayer,,INTERVENTIONAL,2015-09-29,2019-12-24,2020-06-04,2015-09-04,2021-04-08,2021-06-11
NCT02538393,Relative Bioavailability of Sorafenib Tablet for Oral Suspension,https://clinicaltrials.gov/study/NCT02538393,,COMPLETED,NO,Biological Availability,DRUG: Sorafenib (BAY43-9006) Film-coated tablet|DRUG: Sorafenib (BAY43-9006) Oral suspension,Bayer,,INTERVENTIONAL,2015-11-20,2016-03-15,2016-06-15,2015-09-02,,2017-06-01
NCT02537457,Bioequivalence Study of Rivaroxaban,https://clinicaltrials.gov/study/NCT02537457,,COMPLETED,NO,"Embolism, Atrial Fibrillation and Venous Thrombosis","DRUG: Rivaroxaban (BAY 59-7939)|DRUG: Rivaroxaban (Xarelto, BAY 59-7939)",Bayer,,INTERVENTIONAL,2014-01,2014-03,2014-04,2015-09-01,,2015-09-01
NCT02537405,Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects,https://clinicaltrials.gov/study/NCT02537405,,COMPLETED,NO,"Embolism, Atrial Fibrillation and Venous Thrombosis","DRUG: Rivaroxaban (BAY 59-7939)|DRUG: Rivaroxaban (Xarelto, BAY 59-7939)",Bayer,,INTERVENTIONAL,2014-02,2014-03,2014-04,2015-09-01,,2015-09-01
NCT02504216,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,https://clinicaltrials.gov/study/NCT02504216,VOYAGER PAD,COMPLETED,YES,Peripheral Artery Disease,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban-Placebo",Bayer,"Janssen Research & Development, LLC|Colorado Prevention Center",INTERVENTIONAL,2015-08-18,2019-11-27,2020-01-09,2015-07-21,2020-12-08,2020-12-08
NCT02497716,Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children,https://clinicaltrials.gov/study/NCT02497716,,COMPLETED,NO,Thrombosis,"DRUG: Rivaroxaban (Xarelto, BAY59-7939",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2015-11-04,2018-05-22,2018-05-22,2015-07-14,,2019-04-16
NCT02485119,Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT02485119,,COMPLETED,NO,Neoplasms,DRUG: BAY94-9343,Bayer,,INTERVENTIONAL,2015-08-14,2017-04-28,2017-07-04,2015-06-30,,2018-06-04
NCT02483208,Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate,https://clinicaltrials.gov/study/NCT02483208,,COMPLETED,NO,Hemophilia A,DRUG: BAY81-8973|DRUG: Advate,Bayer,,INTERVENTIONAL,2015-06,2015-07,2015-12,2015-06-26,,2016-02-17
NCT02465814,Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids,https://clinicaltrials.gov/study/NCT02465814,ASTEROID 2,COMPLETED,NO,Leiomyoma,DRUG: Vilaprisan (BAY1002670)|DRUG: Vilaprisan (BAY1002670|DRUG: Vilaprisan (BAY1002670|DRUG: Vilaprisan (BAY1002670)|DRUG: Ulipristal|DRUG: Ulipristal|DRUG: Ulipristal,Bayer,,INTERVENTIONAL,2015-06,2016-10,2016-10,2015-06-09,,2016-11-22
NCT02465502,Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT02465502,,COMPLETED,NO,Colorectal Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2015-07-21,2017-05-02,2017-12-11,2015-06-08,,2018-11-07
NCT02457351,Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,https://clinicaltrials.gov/study/NCT02457351,,COMPLETED,NO,Medical Oncology,DRUG: Roniciclib (BAY 1000394)|DRUG: Itraconazole (Sporanox),Bayer,,INTERVENTIONAL,2015-07,2016-02,2016-04,2015-05-29,,2016-05-23
NCT02456129,Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan,https://clinicaltrials.gov/study/NCT02456129,,COMPLETED,NO,"Clinical Trial, Phase I",DRUG: Vilaprisan (BAY1002670)|DRUG: [14C] Vilaprisan|OTHER: Itraconazole(ITZ),Bayer,,INTERVENTIONAL,2015-07,2015-09,2016-02,2015-05-28,,2016-03-02
NCT02452515,A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction,https://clinicaltrials.gov/study/NCT02452515,CHIARA MIA 1,COMPLETED,NO,Heart Failure,DRUG: BAY1142524|DRUG: BAY1142524|DRUG: BAY1142524|DRUG: BAY1142524|DRUG: Placebo,Bayer,,INTERVENTIONAL,2015-07,2016-01,2016-03,2015-05-22,,2017-11-07
NCT02442063,Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions,https://clinicaltrials.gov/study/NCT02442063,,COMPLETED,NO,Neoplasms|Bone Diseases,"DRUG: Radium Ra 223 dichloride (Xofigo, BAY88-8223)|DRUG: paclitaxel",Bayer,,INTERVENTIONAL,2015-08,2016-10,2016-10,2015-05-13,,2016-11-30
NCT02434640,"Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women",https://clinicaltrials.gov/study/NCT02434640,,COMPLETED,NO,Endometriosis,DRUG: BAY1128688|DRUG: Placebo|DRUG: BAY1128688,Bayer,,INTERVENTIONAL,2015-04,2015-12,2016-04,2015-05-05,,2016-05-19
NCT02403401,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,https://clinicaltrials.gov/study/NCT02403401,,COMPLETED,NO,Contraception,DRUG: Levonorgestrel (BAY98-7196),Bayer,,INTERVENTIONAL,2015-05-15,2016-07-07,2016-07-07,2015-03-31,,2021-04-08
NCT02398513,Regorafenib Phase I Study in Mainland Chinese Patients,https://clinicaltrials.gov/study/NCT02398513,,COMPLETED,NO,Oncology,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2015-04,2015-11,2016-06,2015-03-25,,2016-08-01
NCT02396316,Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients,https://clinicaltrials.gov/study/NCT02396316,VEGA,COMPLETED,YES,"Glaucoma, Neovascular","DRUG: Aflibercept (Eylea, BAY 86-5321)|DRUG: Sham Injection",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2015-04-02,2016-06-16,2016-09-06,2015-03-24,2017-07-21,2017-09-15
NCT02394093,To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.,https://clinicaltrials.gov/study/NCT02394093,Icicle,COMPLETED,NO,"Pharmacology, Clinical","DRUG: Aspirin (Acetylsalicylic acid, BAYe4465)|DRUG: Aspirin (Acetylsalicylic acid, BAYe4465)|DRUG: Aspirin (Acetylsalicylic acid, BAYe4465)",Bayer,,INTERVENTIONAL,2015-02,2015-03,2015-03,2015-03-20,,2016-09-19
NCT02391116,Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),https://clinicaltrials.gov/study/NCT02391116,,COMPLETED,YES,"Diffuse, Large B-Cell, Lymphoma","DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,INTERVENTIONAL,2015-05-08,2016-07-05,2018-01-19,2015-03-18,2018-01-08,2019-01-04
NCT02390154,Roniciclib Mass Balance Study,https://clinicaltrials.gov/study/NCT02390154,,COMPLETED,NO,Neoplasms,DRUG: roniciclib (BAY 1000394)|DRUG: roniciclib (BAY 1000394),Bayer,,INTERVENTIONAL,2015-04,2016-03,2016-06,2015-03-17,,2016-07-15
NCT02369016,Phase III Copanlisib in Rituximab-refractory iNHL,https://clinicaltrials.gov/study/NCT02369016,CHRONOS-2,COMPLETED,YES,"Lymphoma, Non-Hodgkin",DRUG: Copanlisib (BAY 80-6946),Bayer,,INTERVENTIONAL,2015-09-22,2022-10-26,2022-10-26,2015-02-23,2023-11-18,2023-11-18
NCT02367027,Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions,https://clinicaltrials.gov/study/NCT02367027,,COMPLETED,NO,Pharmacokinetics,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2015-02,2015-04,2015-06,2015-02-20,,2015-06-10
NCT02366949,Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,https://clinicaltrials.gov/study/NCT02366949,,COMPLETED,NO,Medical Oncology,DRUG: BAY1217389|DRUG: Paclitaxel,Bayer,,INTERVENTIONAL,2015-02-27,2018-03-30,2019-04-18,2015-02-19,,2020-04-07
NCT02363855,Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects,https://clinicaltrials.gov/study/NCT02363855,,COMPLETED,NO,Prostatic Neoplasms,DRUG: BAY 1841788(ODM-201),Bayer,,INTERVENTIONAL,2015-02-23,2015-11-19,2018-01-18,2015-02-16,,2018-01-25
NCT02345382,Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia,https://clinicaltrials.gov/study/NCT02345382,,COMPLETED,NO,Leukemia,"DRUG: Atuveciclib, BAY1143572",Bayer,,INTERVENTIONAL,2015-02-19,2016-09-14,2017-07-30,2015-01-26,,2018-06-25
NCT02342665,"Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL",https://clinicaltrials.gov/study/NCT02342665,,COMPLETED,NO,Lymphoma Non-Hodgkin,DRUG: Copanlisib (BAY80-6946),Bayer,,INTERVENTIONAL,2015-04-21,2018-09-14,2022-02-10,2015-01-21,,2023-01-20
NCT02332031,Sorafenib Drug Drug Interaction Study in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT02332031,,COMPLETED,NO,Drug Interactions,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Levothyroxine",Bayer,,INTERVENTIONAL,2015-02,2015-06,2015-09,2015-01-06,,2015-10-12
NCT02312973,"To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects",https://clinicaltrials.gov/study/NCT02312973,,COMPLETED,NO,"Renal Insufficiency, Chronic",DRUG: Molidustat(BAY85-3934)|DRUG: Molidustat(BAY85-3934),Bayer,,INTERVENTIONAL,2015-01-14,2015-12-02,2016-06-01,2014-12-09,,2021-01-25
NCT02309411,EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis,https://clinicaltrials.gov/study/NCT02309411,EINSTEINJr,COMPLETED,YES,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2015-01-15,2017-04-05,2017-04-05,2014-12-05,2018-06-13,2018-08-21
NCT02283762,Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis,https://clinicaltrials.gov/study/NCT02283762,,COMPLETED,YES,"Scleroderma, Systemic","DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2015-01-15,2017-12-15,2019-03-28,2014-11-05,2019-01-25,2020-02-05
NCT02262663,"Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan",https://clinicaltrials.gov/study/NCT02262663,,COMPLETED,NO,"Clinical Trial, Phase I",DRUG: Vilaprisan (BAY1002670),Bayer,,INTERVENTIONAL,2014-10,2015-09,2015-12,2014-10-13,,2016-03-16
NCT02258451,Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT02258451,,COMPLETED,YES,Breast Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Placebo (saline)|DRUG: Exemestane|DRUG: Everolimus",Bayer,,INTERVENTIONAL,2015-06-04,2020-01-22,2022-10-28,2014-10-07,2022-03-10,2023-11-24
NCT02253420,COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients,https://clinicaltrials.gov/study/NCT02253420,,COMPLETED,NO,Medical Oncology,DRUG: Copanlisib (BAY80-6946)|DRUG: Itraconazole|DRUG: Rifampin|DRUG: Copanlisib (BAY80-6946),Bayer,,INTERVENTIONAL,2014-10-08,2018-03-12,2019-08-13,2014-10-01,,2020-12-14
NCT02234843,EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis,https://clinicaltrials.gov/study/NCT02234843,EINSTEIN Jr,COMPLETED,YES,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Standard of Care",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2014-11-13,2019-01-30,2019-01-30,2014-09-09,2020-04-01,2020-04-01
NCT02229461,Naproxen Sodium/ASA Platelet Study,https://clinicaltrials.gov/study/NCT02229461,Kontakt,COMPLETED,YES,Hematology,"DRUG: Naproxen Sodium (Aleve, BAY117031)|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)",Bayer,,INTERVENTIONAL,2015-02,2015-05,2015-05,2014-09-01,2016-06-10,2016-07-15
NCT02212080,"First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784",https://clinicaltrials.gov/study/NCT02212080,,COMPLETED,NO,"Clinical Trials, Phase I as Topic",DRUG: BAY1214784|DRUG: Placebo,Bayer,,INTERVENTIONAL,2014-09,2015-03,2015-03,2014-08-08,,2015-03-11
NCT02203331,"Bay98-7196, Dose Finding / POC Study",https://clinicaltrials.gov/study/NCT02203331,,COMPLETED,YES,Endometriosis,DRUG: Placebo|DRUG: Levonorgestrel|DRUG: Anastrozole|DRUG: Lupron / Leuprolide acetate,Bayer,,INTERVENTIONAL,2014-10-16,2016-10-24,2016-10-24,2014-07-29,2018-01-04,2023-11-07
NCT02200614,Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT02200614,ARAMIS,COMPLETED,YES,Prostate Cancer Non-Metastatic|Castration-Resistant,"DRUG: Darolutamide (Nubeqa, BAY1841788)|DRUG: Placebo",Bayer,"Orion Corporation, Orion Pharma",INTERVENTIONAL,2014-09-12,2018-09-03,2021-06-14,2014-07-25,2019-10-29,2022-06-28
NCT02170038,Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol,https://clinicaltrials.gov/study/NCT02170038,,COMPLETED,NO,Pharmacokinetics,DRUG: Microgynon|DRUG: Noristerat(BAY86-6308),Bayer,,INTERVENTIONAL,2014-06,2014-12,2015-03,2014-06-23,,2016-02-18
NCT02159326,Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women,https://clinicaltrials.gov/study/NCT02159326,,COMPLETED,NO,Drug Interactions,"DRUG: Microgynon|DRUG: Riociguat (Adempas,BAY63-2521)",Bayer,,INTERVENTIONAL,2014-06,2015-03,2015-07,2014-06-09,,2015-08-14
NCT02159313,Relative Bioavailability Study,https://clinicaltrials.gov/study/NCT02159313,,COMPLETED,NO,Healthy Volunteers,"DRUG: Riociguat(Adempas,BAY63-2521)",Bayer,,INTERVENTIONAL,2014-06,2014-09,2015-01,2014-06-09,,2016-02-18
NCT02155582,Copanlisib Pharmacodynamic Study,https://clinicaltrials.gov/study/NCT02155582,,COMPLETED,NO,Non Hodgkin Lymphoma,DRUG: Copanlisib (BAY80-6946),Bayer,,INTERVENTIONAL,2014-08-12,2016-10-04,2017-03-16,2014-06-04,,2017-06-16
NCT02131662,"Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap",https://clinicaltrials.gov/study/NCT02131662,ASTEROID 1,COMPLETED,YES,Leiomyoma,DRUG: BAY1002670|DRUG: BAY1002670|DRUG: BAY1002670|DRUG: BAY1002670|DRUG: Placebo,Bayer,,INTERVENTIONAL,2014-05-15,2016-05-04,2016-05-04,2014-05-06,2017-12-08,2017-12-08
NCT02122913,A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer,https://clinicaltrials.gov/study/NCT02122913,,COMPLETED,NO,Solid Tumors Harboring NTRK Fusion,"DRUG: Larotrectinib (Vitrakvi, BAY2757556)",Bayer,,INTERVENTIONAL,2014-05-04,2017-02-01,2021-04-09,2014-04-25,,2023-11-07
NCT02119221,Copanlisib Mass Balance Study,https://clinicaltrials.gov/study/NCT02119221,,COMPLETED,NO,Healthy Volunteers,DRUG: Copanlisib (BAY80-6946),Bayer,,INTERVENTIONAL,2014-02,2014-04,2014-10,2014-04-21,,2014-10-28
NCT02114658,Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients,https://clinicaltrials.gov/study/NCT02114658,,COMPLETED,NO,Thyroid Carcinoma,"DRUG: Sorafenib (Nexavar,BAY43-9006)",Bayer,,INTERVENTIONAL,2014-04-15,2015-02-23,2016-08-02,2014-04-15,,2017-08-03
NCT02106845,Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.,https://clinicaltrials.gov/study/NCT02106845,,COMPLETED,NO,Neoplasms,"DRUG: Digoxin|DRUG: Rosuvastatin|DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2014-04-22,2015-04-27,2018-06-12,2014-04-08,,2019-06-07
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),https://clinicaltrials.gov/study/NCT02106832,RESPIRE 2,COMPLETED,YES,Bronchiectasis,DRUG: Ciprofloxacin (BAYQ3939) dry powder for inhalation|DRUG: Ciprofloxacin (BAYQ3939) dry powder for inhalation|DRUG: Placebo|DRUG: Placebo,Bayer,Novartis,INTERVENTIONAL,2014-04-30,2016-09-13,2016-10-19,2014-04-08,2017-09-01,2017-10-02
NCT02085148,A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy,https://clinicaltrials.gov/study/NCT02085148,,COMPLETED,NO,Pediatric Oncology,DRUG: Regorafenib (BAY73-4506)|DRUG: Vincristine (Cellcristin®)|DRUG: Irinotecan (Irinotecan Cell pharm®),Bayer,,INTERVENTIONAL,2014-04-11,2019-05-05,2024-03-13,2014-03-12,,2024-04-22
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),https://clinicaltrials.gov/study/NCT02066402,,COMPLETED,YES,Bacterial Infections,DRUG: Tedizolid (BAY119-2631)|DRUG: Placebo Tedizolid (BAY119-2631)|DRUG: Linezolid|DRUG: Placebo Linezolid,Bayer,Merck Sharp & Dohme LLC,INTERVENTIONAL,2014-03-04,2016-03-06,2016-04-18,2014-02-19,2017-06-07,2017-06-07
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),https://clinicaltrials.gov/study/NCT02064439,EinsteinChoice,COMPLETED,YES,Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,DRUG: BAY 59-7939|DRUG: BAY 59-7939|DRUG: ASA,Bayer,"Janssen Scientific Affairs, LLC",INTERVENTIONAL,2014-03-05,2016-09-22,2016-11-04,2014-02-17,2017-12-19,2017-12-19
NCT02064426,Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934,https://clinicaltrials.gov/study/NCT02064426,DIALOGUE5,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934)|BIOLOGICAL: Epoetin alfa/beta,Bayer,,INTERVENTIONAL,2014-03-13,2016-10-19,2016-11-16,2014-02-17,,2019-09-20
NCT02064413,Essure (Model ESS310) Placement Rate Study,https://clinicaltrials.gov/study/NCT02064413,,COMPLETED,NO,Contraception,DEVICE: ESS310 (BAY1454032),Bayer,,INTERVENTIONAL,2014-03-17,2014-10-02,2014-11-26,2014-02-17,,2021-04-08
NCT02055482,Long-term Pre-dialysis Extension in Europe and Asia Pacific,https://clinicaltrials.gov/study/NCT02055482,DIALOGUE 3,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY85-3934)|BIOLOGICAL: Darbepoetin,Bayer,,INTERVENTIONAL,2014-06-24,2016-11-15,2016-12-12,2014-02-05,,2017-11-22
NCT02047890,Japanese BAY1000394 Monotherapy Phase I Study,https://clinicaltrials.gov/study/NCT02047890,,COMPLETED,NO,Neoplasms,DRUG: BAY1000394 (2.5mg)|DRUG: BAY1000394 (5mg),Bayer,,INTERVENTIONAL,2014-05-19,2015-01-06,2018-07-19,2014-01-28,,2019-06-24
NCT02043678,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",https://clinicaltrials.gov/study/NCT02043678,ERA 223,COMPLETED,YES,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Matching placebo (normal saline)|DRUG: Abiraterone|DRUG: Prednisone/Prednisolone",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2014-03-30,2018-02-15,2024-02-08,2014-01-23,2019-03-05,2024-02-26
NCT02040233,Multiple Dose Study in Heart Failure of BAY 1067197,https://clinicaltrials.gov/study/NCT02040233,PARSiFAL,COMPLETED,NO,Heart Failure,DRUG: BAY1067197 (10 mg)|DRUG: BAY1067197|DRUG: Placebo (10 mg)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2014-01-28,2015-01-29,2015-04-02,2014-01-20,,2019-06-21
NCT02034552,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),https://clinicaltrials.gov/study/NCT02034552,,COMPLETED,YES,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Abiraterone acetate|DRUG: Prednisone|DRUG: Enzalutamide",Bayer,,INTERVENTIONAL,2014-03-07,2016-07-15,2018-06-26,2014-01-13,2017-07-02,2019-07-23
NCT02032836,Comparative PK PD Study in PAH Patients (Fox vs. I-Neb),https://clinicaltrials.gov/study/NCT02032836,,COMPLETED,NO,Pulmonary Arterial Hypertension,"DRUG: lloprost(Ventavis,BAYQ6252, 20 µg/mL)|DRUG: lloprost(Ventavis,BAYQ6252, 10 µg/mL)",Bayer,,INTERVENTIONAL,2014-03-10,2015-01-07,2017-09-29,2014-01-10,,2018-09-26
NCT02023697,Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone,https://clinicaltrials.gov/study/NCT02023697,,COMPLETED,YES,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,INTERVENTIONAL,2014-03-10,2017-03-01,2018-08-09,2013-12-30,2018-07-12,2019-07-12
NCT02021409,Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934,https://clinicaltrials.gov/study/NCT02021409,DIALOGUE 2,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: BAY85-3934|BIOLOGICAL: Darbepoetin alfa,Bayer,,INTERVENTIONAL,2014-01-28,2015-10-15,2015-11-23,2013-12-27,,2019-09-19
NCT02021370,15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific),https://clinicaltrials.gov/study/NCT02021370,DIALOGUE 1,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: BAY85-3934|DRUG: Placebo,Bayer,,INTERVENTIONAL,2014-02-10,2015-09-15,2015-09-23,2013-12-27,,2019-09-20
NCT02007629,Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor,https://clinicaltrials.gov/study/NCT02007629,RESPITE,COMPLETED,NO,"Hypertension, Pulmonary","DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,INTERVENTIONAL,2014-02-18,2016-12-29,2016-12-29,2013-12-11,,2019-02-21
NCT02001909,Effect of Neomycin on the Pharmacokinetics of Regorafenib,https://clinicaltrials.gov/study/NCT02001909,,COMPLETED,NO,Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Neomycin",Bayer,,INTERVENTIONAL,2013-12,2014-04,2014-04,2013-12-05,,2015-08-13
NCT01976741,Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib),https://clinicaltrials.gov/study/NCT01976741,,COMPLETED,YES,Neoplasms,DRUG: Rogaratinib (BAY1163877) oral solution|DRUG: Rogaratinib (BAY1163877) oral tablet|DRUG: Rogaratinib (BAY1163877) 800 mg BID,Bayer,,INTERVENTIONAL,2013-12-30,2019-03-11,2020-01-09,2013-11-06,2020-04-28,2021-05-06
NCT01975818,Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934,https://clinicaltrials.gov/study/NCT01975818,DIALOGUE4,COMPLETED,NO,"Anemia|Renal Insufficiency, Chronic",DRUG: Molidustat (BAY 85-3934)|BIOLOGICAL: Epoetin alfa/beta,Bayer,,INTERVENTIONAL,2013-10-28,2015-10-23,2015-12-15,2013-11-05,,2019-09-20
NCT01973868,Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,https://clinicaltrials.gov/study/NCT01973868,,COMPLETED,NO,Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Cetuximab (ERBITUX)",Bayer,,INTERVENTIONAL,2013-11-21,2017-01-31,2018-04-03,2013-11-01,,2019-04-09
NCT01968668,Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan),https://clinicaltrials.gov/study/NCT01968668,,COMPLETED,NO,Diabetic Nephropathies,DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: Placebo|DRUG: BAY 94-8862|DRUG: BAY 94-8862,Bayer,,INTERVENTIONAL,2013-10-28,2014-10-09,2014-11-07,2013-10-24,,2021-07-16
NCT01967225,Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections,https://clinicaltrials.gov/study/NCT01967225,,COMPLETED,YES,"Skin Diseases, Infectious","DRUG: Tedizolid Phosphate (Sivextro, BAY1192631)|DRUG: Linezolid",Bayer,,INTERVENTIONAL,2013-11-23,2016-10-28,2016-10-28,2013-10-22,2018-10-04,2018-10-04
NCT01955694,Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone,https://clinicaltrials.gov/study/NCT01955694,ARTS-HF Japan,COMPLETED,NO,Heart Failure,DRUG: BAY94-8862|DRUG: Eplerenone|DRUG: Placebo,Bayer,,INTERVENTIONAL,2013-11-11,2015-01-23,2015-02-20,2013-10-07,,2021-07-16
NCT01951638,Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED),https://clinicaltrials.gov/study/NCT01951638,,COMPLETED,YES,Heart Failure,DRUG: Vericiguat (BAY1021189) (1.25 mg)|DRUG: Vericiguat (BAY1021189) (5 mg)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2013-11-06,2015-08-18,2015-09-16,2013-09-26,2021-02-12,2021-03-16
NCT01951625,Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED),https://clinicaltrials.gov/study/NCT01951625,,COMPLETED,YES,Heart Failure,DRUG: Vericiguat (BAY1021189) (1.25 mg)|DRUG: Vericiguat (BAY1021189) (5 mg)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2013-11-29,2015-05-14,2015-06-09,2013-09-26,2021-03-25,2021-03-25
NCT01945606,Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker,https://clinicaltrials.gov/study/NCT01945606,,COMPLETED,NO,Heart Failure,DRUG: Placebo (treatment 1)|DRUG: BAY1067197 (treatment 2),Bayer,,INTERVENTIONAL,2013-11-29,2014-09-09,2015-03-17,2013-09-18,,2019-09-19
NCT01940848,Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo,https://clinicaltrials.gov/study/NCT01940848,,COMPLETED,NO,Irritable Bowel Syndrome,"DRUG: STW5 (Iberogast, BAY98-7411)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2013-10-11,2017-10-25,2017-10-25,2013-09-12,,2018-10-29
NCT01938638,Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01938638,,COMPLETED,NO,Neoplasms,DRUG: BAY1143572,Bayer,,INTERVENTIONAL,2013-09-26,2016-08-17,2016-09-19,2013-09-10,,2017-10-20
NCT01934790,Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases,https://clinicaltrials.gov/study/NCT01934790,,COMPLETED,YES,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,INTERVENTIONAL,2013-12-22,2015-06-04,2017-04-12,2013-09-04,2016-09-29,2018-03-26
NCT01929655,Japanese BAY88-8223 Monotherapy Phase II Study,https://clinicaltrials.gov/study/NCT01929655,,COMPLETED,NO,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,INTERVENTIONAL,2013-09-30,2017-05-16,2017-05-16,2013-08-28,,2018-04-24
NCT01927224,Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients,https://clinicaltrials.gov/study/NCT01927224,,COMPLETED,NO,Chagas Disease,DRUG: Nifurtimox (BAYa2502) (4 x 30 mg tablet)|DRUG: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|DRUG: Nifurtimox (BAYa2502) (120 mg tablet),Bayer,,INTERVENTIONAL,2013-11,2014-05,2014-09,2013-08-22,,2015-10-16
NCT01926847,Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator,https://clinicaltrials.gov/study/NCT01926847,DIGIT,COMPLETED,NO,Raynaud Disease,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2013-10,2014-06,2014-06,2013-08-21,,2014-06-16
NCT01925638,Effect of Ketoconazole on the Pharmacokinetics of Refametinib,https://clinicaltrials.gov/study/NCT01925638,,COMPLETED,NO,Drug Interactions,DRUG: BAY86-9766|DRUG: Ketoconazole,Bayer,,INTERVENTIONAL,2013-09,2013-12,2013-12,2013-08-20,,2014-01-08
NCT01921855,Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors,https://clinicaltrials.gov/study/NCT01921855,MATCHBOX,COMPLETED,NO,Hemophilia A|Hemophilia B,DRUG: BAY Factor VII (BAY86-6150)|DRUG: BAY Factor VII (BAY86-6150)|DRUG: BAY Factor VII (BAY86-6150)|DRUG: BAY Factor VII (BAY86-6150)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2009-01,2009-12,2009-12,2013-08-13,,2014-08-21
NCT01915602,Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT01915602,,COMPLETED,NO,"Carcinoma, Hepatocellular",DRUG: Refametinib (BAY86-9766)|DRUG: Sorafenib (BAY43-9006),Bayer,,INTERVENTIONAL,2013-09-27,2015-07-29,2017-02-08,2013-08-05,,2021-04-08
NCT01915589,Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT01915589,,COMPLETED,NO,"Carcinoma, Hepatocellular",DRUG: Refametinib (BAY86-9766),Bayer,,INTERVENTIONAL,2013-09-16,2014-10-08,2014-10-08,2013-08-05,,2021-04-08
NCT01915576,Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,https://clinicaltrials.gov/study/NCT01915576,,COMPLETED,NO,Neoplasms,DRUG: BAY1125976|DRUG: BAY1125976|DRUG: BAY1125976,Bayer,,INTERVENTIONAL,2013-09,2016-07,2016-12,2013-08-05,,2016-12-28
NCT01902264,Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception,https://clinicaltrials.gov/study/NCT01902264,,COMPLETED,NO,Contraception,"DRUG: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)",Bayer,,INTERVENTIONAL,2013-08,2015-02,2015-02,2013-07-18,,2016-04-29
NCT01892904,Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea,https://clinicaltrials.gov/study/NCT01892904,,COMPLETED,NO,Dysmenorrhea,DRUG: EE20/DRSP(BAY86-5300),Bayer,,INTERVENTIONAL,2013-07,2015-01,2015-08,2013-07-08,,2015-09-09
NCT01890434,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),https://clinicaltrials.gov/study/NCT01890434,GadaCAD 2,COMPLETED,YES,Coronary Artery Disease,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2013-08-26,2016-08-06,2016-11-10,2013-07-01,2018-05-16,2019-07-31
NCT01890421,Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),https://clinicaltrials.gov/study/NCT01890421,GadaCAD 1,COMPLETED,YES,Coronary Artery Disease,"DRUG: Gadobutrol (Gadovist, Gadavist, BAY86-4875)",Bayer,,INTERVENTIONAL,2013-07-19,2015-04-10,2017-08-31,2013-07-01,2018-05-16,2018-05-16
NCT01885104,Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003),https://clinicaltrials.gov/study/NCT01885104,,COMPLETED,YES,Constipation,DRUG: Polyethylene Glycol (PEG 3350)|DRUG: Placebo|DRUG: Bisacodyl laxative tablets (rescue medication),Bayer,,INTERVENTIONAL,2013-04,2013-09,2013-10,2013-06-24,2014-09-25,2015-03-11
NCT01881217,"First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors",https://clinicaltrials.gov/study/NCT01881217,,COMPLETED,NO,Neoplasms,DRUG: BAY1179470,Bayer,,INTERVENTIONAL,2013-06-28,2016-03-18,2016-08-16,2013-06-19,,2017-09-14
NCT01874431,Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy,https://clinicaltrials.gov/study/NCT01874431,ARTS-DN,COMPLETED,YES,Diabetic Nephropathies,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2013-06-12,2014-07-09,2014-08-07,2013-06-11,2021-05-04,2021-07-01
NCT01853800,Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet,https://clinicaltrials.gov/study/NCT01853800,,COMPLETED,NO,Biological Availability,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2013-05,2013-07,2013-08,2013-05-15,,2017-01-23
NCT01853319,Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy,https://clinicaltrials.gov/study/NCT01853319,REGARD,COMPLETED,NO,Colorectal Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73- 4506)",Bayer,,INTERVENTIONAL,2013-07-24,2015-04-24,2018-06-11,2013-05-15,,2019-04-22
NCT01853046,Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,https://clinicaltrials.gov/study/NCT01853046,,COMPLETED,YES,Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2013-06,2015-07,2015-11,2013-05-14,2017-02-20,2017-02-20
NCT01839357,Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter,https://clinicaltrials.gov/study/NCT01839357,X-TRA,COMPLETED,NO,Atrial Fibrillation,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2013-08,2014-11,2014-12,2013-04-24,,2016-07-25
NCT01822080,Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients,https://clinicaltrials.gov/study/NCT01822080,,COMPLETED,NO,Endometriosis,"DRUG: Dienogest (Visanne, BAY86-5258)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2013-03,2015-04,2015-11,2013-04-02,,2015-11-25
NCT01818544,Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis,https://clinicaltrials.gov/study/NCT01818544,,COMPLETED,NO,Bronchiectasis,DRUG: BAY85-8501|DRUG: Placebo,Bayer,,INTERVENTIONAL,2013-04,2014-06,2014-06,2013-03-26,,2015-07-09
NCT01816815,"Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670",https://clinicaltrials.gov/study/NCT01816815,,COMPLETED,NO,Leiomyoma,DRUG: BAY1002670|DRUG: Placebo,Bayer,,INTERVENTIONAL,2011-11,2012-10,2013-01,2013-03-22,,2014-04-21
NCT01810770,Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis,https://clinicaltrials.gov/study/NCT01810770,,COMPLETED,NO,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,INTERVENTIONAL,2013-03-26,2017-09-25,2017-09-25,2013-03-14,,2018-09-19
NCT01807221,Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone,https://clinicaltrials.gov/study/NCT01807221,ARTS-HF,COMPLETED,YES,Heart Failure,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo|DRUG: Inspra (eplerenone),Bayer,,INTERVENTIONAL,2013-06-17,2014-11-11,2014-12-09,2013-03-08,2021-06-15,2021-07-06
NCT01799993,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,https://clinicaltrials.gov/study/NCT01799993,INHALE 1,COMPLETED,YES,"Pneumonia, Bacterial",DRUG: Amikacin Inhalation Solution (BAY41-6551)|DRUG: Aerosolized Placebo,Bayer,Nektar Therapeutics,INTERVENTIONAL,2013-04-13,2017-04-07,2017-04-07,2013-02-27,2018-06-26,2018-07-23
NCT01798108,Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases,https://clinicaltrials.gov/study/NCT01798108,,COMPLETED,NO,Neoplasm Metastasis,RADIATION: Radium-223 dichloride (BAY88-8223),Bayer,,INTERVENTIONAL,2001-08-14,2003-06-25,2003-06-25,2013-02-25,,2017-05-19
NCT01788358,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,https://clinicaltrials.gov/study/NCT01788358,,COMPLETED,YES,Hypertension,DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106),Bayer,,INTERVENTIONAL,2013-02-14,2014-05-01,2014-05-01,2013-02-11,2015-08-17,2017-10-24
NCT01783886,Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement,https://clinicaltrials.gov/study/NCT01783886,VIVID EAST,COMPLETED,YES,Macular Edema,"BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2013-02,2015-03,2015-03,2013-02-05,2016-04-05,2016-05-12
NCT01776424,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,https://clinicaltrials.gov/study/NCT01776424,COMPASS,COMPLETED,YES,Prevention & Control,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Aspirin|DRUG: Aspirin placebo|DRUG: Rivaroxaban placebo|DRUG: Pantoprazole|DRUG: Pantoprazole placebo",Bayer,"Population Health Research Institute|Janssen Research & Development, LLC",INTERVENTIONAL,2013-02-28,2017-07-21,2021-06-15,2013-01-28,2018-10-05,2022-11-28
NCT01775618,Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A,https://clinicaltrials.gov/study/NCT01775618,,COMPLETED,NO,Hemophilia A,BIOLOGICAL: BAY94-9027|BIOLOGICAL: BAY94-9027|BIOLOGICAL: BAY94-9027,Bayer,,INTERVENTIONAL,2013-05-29,2015-03-19,2020-02-19,2013-01-25,,2020-08-21
NCT01774344,Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT01774344,RESORCE,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2013-05-14,2016-02-29,2019-07-05,2013-01-24,2017-06-05,2020-08-20
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),https://clinicaltrials.gov/study/NCT01764841,RESPIRE 1,COMPLETED,YES,Bronchiectasis,DRUG: Ciprofloxacin DPI (BAYQ3939)|DRUG: Placebo,Bayer,Novartis,INTERVENTIONAL,2013-05-02,2016-03-09,2016-03-09,2013-01-10,2017-05-24,2018-01-24
NCT01764828,BAY86-9766 Plus Gemcitabine Phase I Study in Asian,https://clinicaltrials.gov/study/NCT01764828,,COMPLETED,NO,Neoplasms,DRUG: Refametinib (BAY86-9766)|DRUG: Gemcitabine,Bayer,,INTERVENTIONAL,2013-02-05,2014-12-18,2015-02-10,2013-01-10,,2018-11-01
NCT01728740,Bioequivalence Study for Acarbose / Metformin FDC,https://clinicaltrials.gov/study/NCT01728740,,COMPLETED,NO,"Diabetes Mellitus, Type II","DRUG: Acarbose/Metformin FDC (BAY81-9783)|DRUG: Acarbose (Glucobay, BAYG5421)|DRUG: Metformin",Bayer,,INTERVENTIONAL,2012-09,2012-12,2012-12,2012-11-20,,2012-12-19
NCT01728311,Open Label Study of BAY1082439 in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01728311,,COMPLETED,NO,Neoplasms,DRUG: BAY1082439,Bayer,,INTERVENTIONAL,2012-11-21,2016-06-03,2017-02-06,2012-11-19,,2018-01-30
NCT01723475,First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer,https://clinicaltrials.gov/study/NCT01723475,,COMPLETED,NO,Prostatic Neoplasms,BIOLOGICAL: BAY2010112|BIOLOGICAL: BAY2010112,Bayer,,INTERVENTIONAL,2012-11-02,2018-07-18,2018-09-26,2012-11-08,,2019-09-27
NCT01697111,Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis,https://clinicaltrials.gov/study/NCT01697111,,COMPLETED,NO,Endometriosis,DRUG: EE20/DRSP(BAY86-5300)|DRUG: Placebo|DRUG: Dienogest,Bayer,,INTERVENTIONAL,2012-10,2014-03,2014-12,2012-10-02,,2016-02-18
NCT01687920,Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets,https://clinicaltrials.gov/study/NCT01687920,,COMPLETED,NO,Heart Failure,DRUG: BAY94-8862 (1.25mg)|DRUG: BAY94-8862 (2.5mg)|DRUG: BAY94-8862 (5mg)|DRUG: BAY94-8862 (7.5mg)|DRUG: BAY94-8862 (10mg),Bayer,,INTERVENTIONAL,2012-09-17,2012-11-28,2013-03-21,2012-09-19,,2022-02-07
NCT01684423,Oral Rivaroxaban in Children With Venous Thrombosis,https://clinicaltrials.gov/study/NCT01684423,EINSTEINJunior,COMPLETED,YES,Venous Thrombosis,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Active comparator|DRUG: Rivaroxaban (BAY59-7939) suspension",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2013-02-19,2016-09-01,2016-09-01,2012-09-13,2017-09-21,2017-09-21
NCT01679587,"Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)",https://clinicaltrials.gov/study/NCT01679587,,COMPLETED,NO,Kidney Diseases,DRUG: Molidustat (BAY85-3934)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2012-09,2013-02,2013-07,2012-09-06,,2016-05-02
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,https://clinicaltrials.gov/study/NCT01674647,X-VERT,COMPLETED,YES,Atrial Fibrillation,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Vitamin K antagonist (VKA)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2012-10,2014-01,2014-01,2012-08-29,2015-02-03,2015-04-30
NCT01666678,"Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination",https://clinicaltrials.gov/study/NCT01666678,Morpheus PK,COMPLETED,NO,Therapeutic Equivalence,"DRUG: BAY98-7111|DRUG: Naproxen Sodium (Aleve, BAYH6689)|DRUG: Diphenhydramine HCl|DRUG: BAY98-7111",Bayer,,INTERVENTIONAL,2012-01,2012-02,2012-03,2012-08-16,,2014-08-21
NCT01660841,Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging,https://clinicaltrials.gov/study/NCT01660841,,COMPLETED,NO,Magnetic Resonance Imaging,"DRUG: Gadobutrol (Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2012-09,2013-08,2013-08,2012-08-09,,2014-10-01
NCT01660451,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",https://clinicaltrials.gov/study/NCT01660451,,COMPLETED,YES,"Lymphoma, Non-Hodgkin","DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,INTERVENTIONAL,2012-11-19,2016-06-22,2023-05-18,2012-08-08,2018-01-08,2024-07-17
NCT01653639,Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222,https://clinicaltrials.gov/study/NCT01653639,,COMPLETED,NO,Hemophilia A,"BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,,INTERVENTIONAL,2012-07,2012-12,2012-12,2012-07-31,,2014-01-10
NCT01638923,Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding,https://clinicaltrials.gov/study/NCT01638923,,COMPLETED,NO,Metrorrhagia,"DRUG: EV/DNG (Qlaira, Natazia, BAY86-5027)|DRUG: placebo",Bayer,,INTERVENTIONAL,2012-06,2015-06,2015-06,2012-07-12,,2015-07-10
NCT01638910,Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects,https://clinicaltrials.gov/study/NCT01638910,,COMPLETED,NO,Contraception,"DRUG: EV/DNG (Qlaira, BAY86-5027)",Bayer,,INTERVENTIONAL,2012-06,2014-11,2014-11,2012-07-12,,2014-12-17
NCT01625390,A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150,https://clinicaltrials.gov/study/NCT01625390,,COMPLETED,NO,"Hemophilia A, Hemophilia B",DRUG: BAY86-6150|DRUG: eptacog alfa [activated]|DRUG: BAY86-6150,Bayer,,INTERVENTIONAL,2012-06,2014-03,2014-03,2012-06-21,,2015-07-01
NCT01618370,Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases,https://clinicaltrials.gov/study/NCT01618370,,COMPLETED,NO,Prostatic Neoplasms,DRUG: Radium-223 dichloride (BAY88-8223),Bayer,,INTERVENTIONAL,2012-07-22,2014-08-13,2016-02-28,2012-06-13,,2017-03-31
NCT01595022,FR01 and FR20 IUS (Intrauterine System) Wearing Study,https://clinicaltrials.gov/study/NCT01595022,,COMPLETED,NO,Contraception,DRUG: Placebo: Flexi ring FR01|DRUG: Placebo: Flexi ring FR20|DRUG: Placebo: Ultra low dose levonorgestrel contraceptive system (LCS),Bayer,,INTERVENTIONAL,2010-01,2010-09,2010-09,2012-05-09,,2015-04-03
NCT01585870,"Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination",https://clinicaltrials.gov/study/NCT01585870,,COMPLETED,NO,Neoplasms,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Eribulin",Bayer,"Onyx Therapeutics, Inc.",INTERVENTIONAL,2012-07,2015-09,2015-09,2012-04-26,,2015-10-27
NCT01584830,Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,https://clinicaltrials.gov/study/NCT01584830,CONCUR,COMPLETED,NO,Colorectal Neoplasms,DRUG: Regorafenib (BAY73-4506)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2012-04,2013-11,2016-01,2012-04-25,,2016-02-08
NCT01580293,A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A,https://clinicaltrials.gov/study/NCT01580293,PROTECT-VIII,COMPLETED,YES,Hemophilia A,BIOLOGICAL: BAY94-9027,Bayer,,INTERVENTIONAL,2012-04-23,2014-06-13,2019-11-21,2012-04-19,2018-12-06,2023-11-07
NCT01565746,"Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients",https://clinicaltrials.gov/study/NCT01565746,,COMPLETED,NO,Prostatic Neoplasms,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,INTERVENTIONAL,2012-03,2012-10,2016-04,2012-03-29,,2016-10-17
NCT01561794,"A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia",https://clinicaltrials.gov/study/NCT01561794,,COMPLETED,NO,Pneumonia,"DRUG: Ciprofloxacin (Cipro, BAYQ3939)",Bayer,,INTERVENTIONAL,2012-05,2015-03,2015-03,2012-03-23,,2015-04-27
NCT01554631,A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg,https://clinicaltrials.gov/study/NCT01554631,,COMPLETED,NO,"Diabetes Mellitus, Type 2","DRUG: Acarbose (Glucobay ODT, BAYG5421)|DRUG: Acarbose (Glucobay, BAYG5421)",Bayer,,INTERVENTIONAL,2012-03,2012-05,2012-05,2012-03-15,,2013-06-14
NCT01544166,Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive),https://clinicaltrials.gov/study/NCT01544166,,COMPLETED,YES,Magnetic Resonance Imaging,"DRUG: Gadobutrol (Gadavist, BAY86-4875)",Bayer,,INTERVENTIONAL,2012-05-16,2013-11-28,2013-11-28,2012-03-05,2014-11-26,2020-12-16
NCT01538667,"Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases",https://clinicaltrials.gov/study/NCT01538667,,COMPLETED,NO,Respiratory System,"DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)",Bayer,,INTERVENTIONAL,2012-04,2012-07,2012-07,2012-02-24,,2014-08-21
NCT01518387,Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients,https://clinicaltrials.gov/study/NCT01518387,,COMPLETED,NO,Hyperphosphatemia,DRUG: Lanthanum Carbonate (BAY77-1931),Bayer,,INTERVENTIONAL,2006-01,2006-07,2006-07,2012-01-26,,2016-03-14
NCT01516840,Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients,https://clinicaltrials.gov/study/NCT01516840,,COMPLETED,NO,Deep Vein Thrombosis,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Unfractionated heparin|DRUG: Warfarin",Bayer,"Janssen Scientific Affairs, LLC",INTERVENTIONAL,2012-03,2013-12,2014-01,2012-01-25,,2017-01-18
NCT01516814,Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients,https://clinicaltrials.gov/study/NCT01516814,,COMPLETED,NO,Pulmonary Embolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Unfractionated heparin|DRUG: Warfarin",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2012-02,2013-10,2013-11,2012-01-25,,2017-01-23
NCT01514851,Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate,https://clinicaltrials.gov/study/NCT01514851,,COMPLETED,NO,Hyperphosphatemia,DRUG: Lanthanum carbonate (BAY77-1931)|DRUG: Calcium carbonate,Bayer,,INTERVENTIONAL,2006-01,2006-05,2006-05,2012-01-23,,2012-06-08
NCT01512966,Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema),https://clinicaltrials.gov/study/NCT01512966,VIVID-Japan,COMPLETED,NO,Macular Edema,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321),Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2012-01,2013-09,2013-09,2012-01-20,,2014-10-09
NCT01507051,Switching Study From Warfarin to Rivaroxaban,https://clinicaltrials.gov/study/NCT01507051,,COMPLETED,YES,Venous Thrombosis,"DRUG: Warfarin (Coumadin)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Placebo|DRUG: Vitamin K (Konakion)",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2008-11,2009-11,2009-11,2012-01-10,2012-04-26,2015-02-09
NCT01495858,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,https://clinicaltrials.gov/study/NCT01495858,Morpheus/DPH,COMPLETED,YES,"Pain, Postoperative",DRUG: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|DRUG: Naproxen Sodium 440 mg (BAYH6689)|DRUG: DPH 50 mg,Bayer,,INTERVENTIONAL,2011-12,2012-02,2012-02,2011-12-20,2014-06-17,2015-06-08
NCT01490294,Myocardial Perfusion MRI,https://clinicaltrials.gov/study/NCT01490294,,COMPLETED,YES,Myocardial Perfusion Imaging|Magnetic Resonance Imaging,"DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2004-03,2006-05,2006-05,2011-12-12,2012-06-28,2014-05-22
NCT01489488,Relative Bioavailability and Food Effect Study,https://clinicaltrials.gov/study/NCT01489488,,COMPLETED,NO,"Pharmacology, Clinical",DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521),Bayer,,INTERVENTIONAL,2012-01,2012-04,2012-05,2011-12-09,,2015-07-01
NCT01482910,VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration),https://clinicaltrials.gov/study/NCT01482910,,COMPLETED,YES,Macular Degeneration,"BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|DRUG: Visudyne",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2011-12,2014-03,2014-08,2011-12-01,2015-03-13,2016-11-04
NCT01473108,"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862",https://clinicaltrials.gov/study/NCT01473108,,COMPLETED,NO,Clinical Pharmacology,DRUG: Finerenone (BAY 94-8862) PEG solution|DRUG: Finerenone (BAY 94-8862) immediate release tablet|DRUG: Eplerenone (Inspra®)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2010-03-29,2010-11-30,2011-05-17,2011-11-17,,2022-02-09
NCT01469169,"Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study",https://clinicaltrials.gov/study/NCT01469169,IBUKI,COMPLETED,NO,"Hypertension, Pulmonary","DRUG: Iloprost (Ventavis inhaled, BAYQ6256)",Bayer,,INTERVENTIONAL,2012-06-19,2014-12-26,2016-12-14,2011-11-10,,2017-12-07
NCT01460537,Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01460537,,COMPLETED,NO,Neoplasms,DRUG: Gemcitabine|DRUG: BAY80-6946|DRUG: Cisplatin|DRUG: NaCl|DRUG: BAY80-6964 fixed dose,Bayer,,INTERVENTIONAL,2011-11-18,2015-07-20,2015-12-18,2011-10-27,,2017-10-04
NCT01458028,Age and Gender Effects on the Pharmacokinetics of BAY85-3934,https://clinicaltrials.gov/study/NCT01458028,,COMPLETED,NO,Anemia,DRUG: BAY85-3934|DRUG: Placebo,Bayer,,INTERVENTIONAL,2011-09,2011-12,2011-12,2011-10-24,,2014-05-06
NCT01453400,Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain,https://clinicaltrials.gov/study/NCT01453400,Tarot,COMPLETED,NO,Pharyngitis,"DRUG: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|DRUG: Acetaminophen + placebo|DRUG: Placebo",Bayer,,INTERVENTIONAL,2011-09-27,2012-04-05,2012-04-06,2011-10-17,,2018-12-07
NCT01442792,Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention,https://clinicaltrials.gov/study/NCT01442792,X-PLORER,COMPLETED,NO,Cardiovascular Disease|Coronary Artery Disease,"DRUG: UFH|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939) and UFH",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2011-10-12,2013-01-29,2013-03-04,2011-09-29,,2022-06-23
NCT01439152,Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.,https://clinicaltrials.gov/study/NCT01439152,,COMPLETED,NO,Oncology,DRUG: BAY94-9343|DRUG: BAY94-9343 (Expansion)|DRUG: BAY94-9343 (1.8 mg/kg)|DRUG: BAY94-9343 (2.2 mg/kg),Bayer,,INTERVENTIONAL,2011-09-07,2016-12-31,2019-07-30,2011-09-23,,2021-07-09
NCT01436526,"Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban",https://clinicaltrials.gov/study/NCT01436526,,COMPLETED,YES,Therapeutic Equivalency,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2009-08,2009-09,2009-09,2011-09-19,2011-12-22,2015-04-22
NCT01434160,LCS12 Adolescent Study,https://clinicaltrials.gov/study/NCT01434160,,COMPLETED,NO,Contraception,"DRUG: Skyla (Levonorgestrel, BAY86-5028)",Bayer,,INTERVENTIONAL,2011-09,2013-06,2015-05,2011-09-14,,2015-07-27
NCT01427803,Actual Use Trial of Naproxen Sodium,https://clinicaltrials.gov/study/NCT01427803,Kiefer AUT,COMPLETED,YES,Pain,DRUG: Naproxen Sodium ER (BAYH6689),Bayer,,INTERVENTIONAL,2011-09,2011-12,2011-12,2011-09-02,2013-05-20,2015-10-15
NCT01420094,Evaluate Onset of Action of a Fast Release Aspirin,https://clinicaltrials.gov/study/NCT01420094,TAROT compare,COMPLETED,NO,Healthy Subjects,"DRUG: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|DRUG: Acetaminophen (Tylenol extra strength)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2011-06-16,2011-09-08,2011-09-08,2011-08-19,,2018-12-19
NCT01413958,Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1),https://clinicaltrials.gov/study/NCT01413958,,COMPLETED,YES,Seasonal Allergic Rhinitis,DRUG: Phenylephrine|DRUG: Placebo|DRUG: Loratadine,Bayer,,INTERVENTIONAL,2011-08,2011-10,2011-10,2011-08-10,2013-01-29,2015-03-11
NCT01411410,Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01411410,,COMPLETED,NO,Neoplasms,DRUG: Paclitaxel|DRUG: Copanlisib (BAY80-6946),Bayer,,INTERVENTIONAL,2011-08-24,2014-10-22,2015-06-29,2011-08-08,,2017-10-11
NCT01408511,HPA Axis Study in Adults,https://clinicaltrials.gov/study/NCT01408511,,COMPLETED,NO,Atopic Dermatitis|Eczema,DRUG: Mapracorat,Bayer,,INTERVENTIONAL,2011-07-19,2011-12-15,2011-12-21,2011-08-03,,2023-10-31
NCT01407510,HPA Axis Study in Japanese Adults,https://clinicaltrials.gov/study/NCT01407510,,COMPLETED,NO,Atopic Dermatitis|Eczema,DRUG: Mapracorat,Bayer,,INTERVENTIONAL,2011-05-09,2011-09-16,2012-04-15,2011-08-02,,2023-09-21
NCT01404390,Japanese BAY80-6946 Monotherapy Phase I Study,https://clinicaltrials.gov/study/NCT01404390,,COMPLETED,NO,Neoplasms,DRUG: BAY80-6946|DRUG: BAY80-6946,Bayer,,INTERVENTIONAL,2011-08-18,2012-03-22,2012-07-12,2011-07-28,,2017-12-14
NCT01397097,LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study,https://clinicaltrials.gov/study/NCT01397097,,COMPLETED,NO,Contraception,DRUG: LNG-IUS (BAY 86-5028)|DRUG: 68 mg etonorgestrel implant for subdermal use (Nexplanon),Bayer,,INTERVENTIONAL,2011-09,2013-06,2015-04,2011-07-19,,2016-07-25
NCT01392521,Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01392521,,COMPLETED,NO,Neoplasms,DRUG: Copanlisib + Refametinib (BAY86-9766)|DRUG: Copanlisib + Refametinib (BAY86-9766),Bayer,,INTERVENTIONAL,2011-07,2014-02,2014-04,2011-07-12,,2015-04-17
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,https://clinicaltrials.gov/study/NCT01389284,VERNE,COMPLETED,YES,"Pain, Postoperative","DRUG: Naproxen Sodium ER (BAYH6689)|DRUG: Naproxen Sodium IR (Aleve, BAYH6689)|DRUG: Naproxen Sodium ER Placebo|DRUG: Naproxen Sodium IR Placebo",Bayer,,INTERVENTIONAL,2011-06,2011-09,2011-09,2011-07-08,2013-05-07,2015-08-25
NCT01388153,A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet,https://clinicaltrials.gov/study/NCT01388153,,COMPLETED,NO,"Diabetes Mellitus, Type 2","DRUG: Acarbose (Glucobay ODT, BAYG5421)|DRUG: Acarbose (Glucobay ODT, BAYG5421)|DRUG: Acarbose (Glucobay, BAYG5421)",Bayer,,INTERVENTIONAL,2011-06,2011-07,2011-08,2011-07-06,,2013-08-28
NCT01383486,Self Selection Trial of Naproxen Sodium,https://clinicaltrials.gov/study/NCT01383486,KEIFER SST,COMPLETED,YES,Pain,DRUG: Naproxen sodium ER (BAYH6689)|DRUG: Advil,Bayer,,INTERVENTIONAL,2011-07,2011-08,2011-08,2011-06-28,2012-11-29,2015-10-15
NCT01365052,Safety Trial of Naproxen Sodium/ Diphenhydramine,https://clinicaltrials.gov/study/NCT01365052,MUST,COMPLETED,YES,Pain,DRUG: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2011-05,2011-07,2011-07,2011-06-03,2014-06-16,2015-06-08
NCT01361399,Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold,https://clinicaltrials.gov/study/NCT01361399,,COMPLETED,NO,Common Cold|Pharyngitis|Tonsillitis,"DRUG: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Lidocain|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-11-30,2005-05-28,2005-05-28,2011-05-26,,2023-10-18
NCT01359787,Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD),https://clinicaltrials.gov/study/NCT01359787,,COMPLETED,NO,Atopic Dermatitis|Eczema,DRUG: Mapracorat|DRUG: Vehicle without active,Bayer,,INTERVENTIONAL,2011-05,2011-09,2011-09,2011-05-25,,2015-01-21
NCT01355367,High Dose BAYA1040 CR: a Long Term Extension Study,https://clinicaltrials.gov/study/NCT01355367,,COMPLETED,NO,Hypertension,"DRUG: Nifedipine (Adalat, BAYA1040)",Bayer,,INTERVENTIONAL,2011-01,2011-09,2012-04,2011-05-18,,2014-01-29
NCT01354418,Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED),https://clinicaltrials.gov/study/NCT01354418,,COMPLETED,NO,Nasal Congestion,DRUG: Phenylephrine HCl Extended Release|DRUG: Phenylephrine HCl Immediate Release,Bayer,,INTERVENTIONAL,2011-05,2011-06,2011-07,2011-05-16,,2015-02-23
NCT01350609,"Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed",https://clinicaltrials.gov/study/NCT01350609,,COMPLETED,NO,"Hypertension, Essential","DRUG: Nifedipine/Candesartan (BAY 98-7106)|DRUG: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)",Bayer,,INTERVENTIONAL,2011-04,2011-08,2011-09,2011-05-10,,2015-12-10
NCT01348880,Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study,https://clinicaltrials.gov/study/NCT01348880,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Vardenafil ODT, (Staxyn, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline|Merck Sharp & Dohme LLC,INTERVENTIONAL,2011-05,2011-12,2011-12,2011-05-06,,2014-05-19
NCT01345656,BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease,https://clinicaltrials.gov/study/NCT01345656,ARTS,COMPLETED,NO,Heart Failure,DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: Placebo|DRUG: Spironolactone,Bayer,,INTERVENTIONAL,2011-05-09,2012-05-30,2012-07-16,2011-05-02,,2022-02-10
NCT01344460,Gadobutrol Enhanced MRA of the Renal Arteries,https://clinicaltrials.gov/study/NCT01344460,GRAMS,COMPLETED,YES,Renal Artery Obstruction,"DRUG: Gadobutrol (Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2011-05,2012-07,2012-07,2011-04-29,2015-08-26,2015-08-26
NCT01344447,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,https://clinicaltrials.gov/study/NCT01344447,GEMSAV,COMPLETED,YES,Carotid Stenosis,"DRUG: Gadobutrol (Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2011-05-12,2014-05-28,2014-05-28,2011-04-29,2015-08-26,2019-01-04
NCT01339104,"Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity",https://clinicaltrials.gov/study/NCT01339104,,COMPLETED,NO,Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2011-04,2013-08,2013-08,2011-04-20,,2014-10-01
NCT01337804,A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12),https://clinicaltrials.gov/study/NCT01337804,,COMPLETED,NO,Heartburn,DRUG: omeprazole/sodium bicarbonate|DRUG: omeprazole magnesium,Bayer,,INTERVENTIONAL,2011-01,2011-01,2011-01,2011-04-19,,2015-02-23
NCT01335256,Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01335256,,COMPLETED,NO,Neoplasms,DRUG: BAY1000394,Bayer,,INTERVENTIONAL,2010-12,2011-09,2011-09,2011-04-14,,2013-05-03
NCT01332942,Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease),https://clinicaltrials.gov/study/NCT01332942,,COMPLETED,NO,Anemia,DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934,Bayer,,INTERVENTIONAL,2011-04,2013-05,2013-12,2011-04-11,,2015-07-14
NCT01331681,Intravitreal Aflibercept Injection in Vision Impairment Due to DME,https://clinicaltrials.gov/study/NCT01331681,VIVID-DME,COMPLETED,YES,Diabetes Mellitus|Macular Edema,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation (Control),Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2011-05-09,2013-06-03,2015-03-30,2011-04-08,2014-09-09,2023-11-27
NCT01330017,Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed),https://clinicaltrials.gov/study/NCT01330017,,COMPLETED,YES,Rhinitis|Seasonal Rhinitis,DRUG: Phenylephrine HCl|DRUG: Placebo|DRUG: Loratadine,Bayer,,INTERVENTIONAL,2011-03,2011-05,2011-06,2011-04-06,2012-11-07,2015-03-11
NCT01322438,Effect of Rifampin on the Pharmacokinetics of BAY73-4506,https://clinicaltrials.gov/study/NCT01322438,,COMPLETED,NO,Neoplasms,DRUG: Regorafenib (BAY73-4506) + rifampin,Bayer,,INTERVENTIONAL,2011-03,2011-06,2011-06,2011-03-24,,2014-12-19
NCT01320709,Effect of Piroxicam on Ovulation,https://clinicaltrials.gov/study/NCT01320709,,COMPLETED,NO,"Contraception, Postcoital",DRUG: Piroxicam ( BAYl1902)|DRUG: Piroxicam ( BAYl1902)|DRUG: Placebo|DRUG: Piroxicam ( BAYl1902),Bayer,,INTERVENTIONAL,2011-03,2012-03,2012-05,2011-03-22,,2015-07-10
NCT01318551,Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects,https://clinicaltrials.gov/study/NCT01318551,,COMPLETED,NO,Anemia,DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934,Bayer,,INTERVENTIONAL,2011-03-16,2013-09-05,2014-08-14,2011-03-18,,2021-01-27
NCT01318265,Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics,https://clinicaltrials.gov/study/NCT01318265,,COMPLETED,NO,Pharmacokinetics,DRUG: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole,Bayer,,INTERVENTIONAL,2011-03,2011-07,2011-07,2011-03-18,,2014-11-02
NCT01311648,BAY81-8973 Pediatric Safety and Efficacy Trial,https://clinicaltrials.gov/study/NCT01311648,,COMPLETED,YES,Haemophilia A,"BIOLOGICAL: Recombinant Factor VIII (Kovaltry, BAY81-8973)|BIOLOGICAL: Recombinant Factor VIII (Kovaltry, BAY81-8973)",Bayer,,INTERVENTIONAL,2011-06-09,2019-09-09,2020-10-27,2011-03-09,2020-11-03,2023-12-05
NCT01303783,Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension,https://clinicaltrials.gov/study/NCT01303783,DISTINCT,COMPLETED,NO,"Hypertension, Essential","DRUG: Candesartan cilexetil (Atacand), 4 mg|DRUG: Candesartan cilexetil (Atacand), 8 mg|DRUG: Nifedipine GITS (Adalat, BAYA1040), 20 mg|DRUG: Nifedipine GITS (Adalat, BAYA1040), 30 mg|DRUG: Nifedipine GITS (Adalat, BAYA1040), 60 mg|DRUG: Placebo|DRUG: Candesartan cilexetil (Atacand), 16 mg|DRUG: Candesartan cilexetil (Atacand), 32 mg",Bayer,,INTERVENTIONAL,2011-04,2012-05,2012-05,2011-02-25,,2017-04-18
NCT01294215,High Dose BAYA1040_Nifedipine: a Long Term Combination Study,https://clinicaltrials.gov/study/NCT01294215,,COMPLETED,NO,Hypertension,"DRUG: Nifedipine (Adalat, BAYA1040)",Bayer,,INTERVENTIONAL,2011-02,2011-11,2012-06,2011-02-11,,2014-06-23
NCT01289821,First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib,https://clinicaltrials.gov/study/NCT01289821,,COMPLETED,YES,Colorectal Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Oxaliplatin|DRUG: Folinic acid|DRUG: 5-FU (mFOLFOX6)",Bayer,,INTERVENTIONAL,2011-02,2012-03,2014-06,2011-02-04,2013-09-04,2017-03-15
NCT01287598,BAY73-4506 Probe Substrate Study,https://clinicaltrials.gov/study/NCT01287598,,COMPLETED,NO,Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Warfarin|DRUG: Omeprazole|DRUG: Midazolam|DRUG: Rosiglitazone",Bayer,,INTERVENTIONAL,2011-08-02,2018-07-03,2018-07-30,2011-02-01,,2019-07-10
NCT01287260,High Dose BAYA1040_Nifedipine: a Dose-comparative Study,https://clinicaltrials.gov/study/NCT01287260,,COMPLETED,NO,Hypertension,"DRUG: Nifedipine (Adalat, BAYA1040)|DRUG: Nifedipine (Adalat, BAYA1040)",Bayer,,INTERVENTIONAL,2011-01,2011-08,2011-08,2011-02-01,,2014-01-29
NCT01283724,Visanne Study to Assess Safety in Adolescents,https://clinicaltrials.gov/study/NCT01283724,VISADO,COMPLETED,NO,Endometriosis,"DRUG: Dienogest (Visanne, BAY86-5258)",Bayer,,INTERVENTIONAL,2011-03,2013-03,2014-06,2011-01-26,,2015-08-13
NCT01280591,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,https://clinicaltrials.gov/study/NCT01280591,Morpheus II,COMPLETED,YES,"Pain, Postoperative",DRUG: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|DRUG: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|DRUG: Naproxen sodium 440 mg (BAYH6689)|DRUG: DPH 50 mg,Bayer,,INTERVENTIONAL,2010-10,2011-01,2011-02,2011-01-21,2014-06-17,2015-06-08
NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),https://clinicaltrials.gov/study/NCT01271712,GRID,COMPLETED,YES,Gastrointestinal Stromal Tumors,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Placebo|DRUG: Best supportive care",Bayer,,INTERVENTIONAL,2011-01-04,2012-01-26,2019-04-15,2011-01-07,2013-10-25,2021-01-29
NCT01258660,Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate,https://clinicaltrials.gov/study/NCT01258660,,COMPLETED,YES,Contraception,DRUG: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|DRUG: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid,Bayer,,INTERVENTIONAL,2006-12,2008-01,2008-01,2010-12-13,2011-05-13,2013-09-20
NCT01257984,Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function,https://clinicaltrials.gov/study/NCT01257984,,COMPLETED,NO,Contraception,DRUG: BAY86-5300|DRUG: BAY86-5300,Bayer,,INTERVENTIONAL,2010-12,2012-08,2012-09,2010-12-10,,2014-10-28
NCT01254292,LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study,https://clinicaltrials.gov/study/NCT01254292,,COMPLETED,YES,Contraception,"DRUG: Levonorgestrel IUD (LCS, BAY86-5028)|DRUG: Yasmin (EE30/DRSP, BAY86-5131)",Bayer,,INTERVENTIONAL,2011-01-06,2013-01-08,2014-05-28,2010-12-06,2014-04-07,2017-09-25
NCT01253174,Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin),https://clinicaltrials.gov/study/NCT01253174,,COMPLETED,YES,Contraception,"DRUG: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|DRUG: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|DRUG: L-5-MTHF Ca 0.451 mg (Metafolin)",Bayer,,INTERVENTIONAL,2006-08,2007-07,2007-07,2010-12-03,2011-05-09,2013-08-07
NCT01253187,Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin),https://clinicaltrials.gov/study/NCT01253187,,COMPLETED,YES,Contraception,"DRUG: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|DRUG: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|DRUG: L-5-MTHF 0.451mg (Metafolin)",Bayer,,INTERVENTIONAL,2006-10,2007-09,2007-09,2010-12-03,2011-05-09,2013-08-07
NCT01251640,Combination With Gemcitabine in Advanced Pancreatic Cancer,https://clinicaltrials.gov/study/NCT01251640,BAGPAC,COMPLETED,NO,Pancreatic Neoplasms,DRUG: BAY86-9766+Gemcitabine,Bayer,,INTERVENTIONAL,2011-01-01,2013-02-11,2013-08-01,2010-12-02,,2021-04-08
NCT01249664,VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV),https://clinicaltrials.gov/study/NCT01249664,Myrror,COMPLETED,YES,"Myopia, Pathological",BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|PROCEDURE: No Drug,Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2010-12,2013-02,2013-08,2010-11-30,2014-04-01,2014-05-05
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,https://clinicaltrials.gov/study/NCT01234337,,COMPLETED,YES,Breast Cancer,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Capecitabine",Bayer,"Onyx Therapeutics, Inc.",INTERVENTIONAL,2011-02-21,2014-05-12,2017-10-20,2010-11-04,2015-09-03,2018-11-06
NCT01233258,A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A,https://clinicaltrials.gov/study/NCT01233258,Leopold II,COMPLETED,YES,Hemophilia A,BIOLOGICAL: rFVIII (BAY81-8973) on demand|BIOLOGICAL: rFVIII (BAY81-8973) prophylaxis low-dose|BIOLOGICAL: rFVIII (BAY81-8973) prophylaxis high-dose,Bayer,,INTERVENTIONAL,2011-01,2012-12,2012-12,2010-11-03,2014-02-11,2016-11-28
NCT01228513,Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD),https://clinicaltrials.gov/study/NCT01228513,,COMPLETED,NO,Atopic Dermatitis,DRUG: ZK245186|DRUG: Placebo (vehicle without active ingredient),Bayer,,INTERVENTIONAL,2010-11,2011-07,2012-04,2010-10-26,,2016-01-21
NCT01227603,Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions,https://clinicaltrials.gov/study/NCT01227603,,COMPLETED,NO,"Hypertension, Essential","DRUG: Nifedipine-candesartan FDC (BAY 98-7106)|DRUG: Nifedipine GITS (Adalat LA, BAYA1040)|DRUG: Candesartan (Atacand)",Bayer,,INTERVENTIONAL,2010-11,2011-03,2011-07,2010-10-25,,2015-12-10
NCT01212445,Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515),https://clinicaltrials.gov/study/NCT01212445,,COMPLETED,YES,Constipation,"DRUG: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)",Bayer,,INTERVENTIONAL,2010-10,2011-11,2011-11,2010-09-30,2013-03-11,2016-03-15
NCT01206972,Dose-confirmatory Bridging Study in Total Knee Replacement,https://clinicaltrials.gov/study/NCT01206972,,COMPLETED,NO,Venous Thromboembolism,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,"Janssen Scientific Affairs, LLC",INTERVENTIONAL,2010-10,2011-05,2011-06,2010-09-22,,2017-01-18
NCT01205932,Dose-confirmatory Bridging Study in Total Hip Replacement,https://clinicaltrials.gov/study/NCT01205932,,COMPLETED,NO,Venous Thromboembolism,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2010-09,2011-06,2011-08,2010-09-21,,2017-01-23
NCT01204190,"Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.",https://clinicaltrials.gov/study/NCT01204190,,COMPLETED,NO,Contraception,DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,INTERVENTIONAL,2010-09,2011-07,2011-08,2010-09-17,,2014-11-04
NCT01204177,Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.,https://clinicaltrials.gov/study/NCT01204177,BASIL,COMPLETED,NO,"Carcinoma, Hepatocellular",DRUG: BAY86-9766 MEK Inhibitor + Sorafenib,Bayer,,INTERVENTIONAL,2010-12,2011-08,2013-08,2010-09-17,,2013-09-06
NCT01188252,Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01188252,,COMPLETED,NO,Neoplasms,DRUG: Roniciclib (BAY1000394),Bayer,,INTERVENTIONAL,2010-08,2016-06,2016-12,2010-08-25,,2017-01-09
NCT01187628,Long-term Study in Chronic Kidney Disease (Extension From Study 14817),https://clinicaltrials.gov/study/NCT01187628,,COMPLETED,NO,Hyperphosphatemia,"DRUG: Fosrenol (Lanthanum Carbonate, BAY77-1931)",Bayer,Shire,INTERVENTIONAL,2010-09,2013-04,2013-04,2010-08-24,,2015-04-03
NCT01184820,Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration,https://clinicaltrials.gov/study/NCT01184820,,COMPLETED,NO,Hemophilia A,"BIOLOGICAL: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))",Bayer,,INTERVENTIONAL,2010-10-13,2011-10-10,2011-10-10,2010-08-19,,2018-09-07
NCT01179334,Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.,https://clinicaltrials.gov/study/NCT01179334,PATENT PLUS,COMPLETED,YES,Pulmonary Hypertension,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo|DRUG: Sildenafil",Bayer,,INTERVENTIONAL,2010-08,2012-06,2013-05,2010-08-11,2013-12-25,2016-08-29
NCT01179295,Japanese BAY86-9766 Monotherapy Phase I Study,https://clinicaltrials.gov/study/NCT01179295,,COMPLETED,NO,Neoplasms,DRUG: BAY86-9766|DRUG: BAY86-9766|DRUG: BAY86-9766|DRUG: BAY86-9766,Bayer,,INTERVENTIONAL,2010-11-19,2012-04-27,2012-04-27,2010-08-11,,2017-06-20
NCT01168895,"Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder",https://clinicaltrials.gov/study/NCT01168895,,COMPLETED,NO,"Infection|Pulmonary Disease, Chronic Obstructive","DRUG: Cipro Inhale (Ciprofloxacin, BAYQ3939)|DRUG: Cipro Inhale (Ciprofloxacin, BAYQ3939)",Bayer,,INTERVENTIONAL,2010-07,2010-09,2010-09,2010-07-23,,2014-04-14
NCT01168817,Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors,https://clinicaltrials.gov/study/NCT01168817,,COMPLETED,NO,Erectile Dysfunction,DRUG: BAY60-4552 plus Vardenafil|DRUG: Vardenafil|DRUG: Placebo,Bayer,,INTERVENTIONAL,2010-08,2011-05,2011-05,2010-07-23,,2014-11-04
NCT01160692,A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment,https://clinicaltrials.gov/study/NCT01160692,,COMPLETED,NO,Age-Related Memory Disorders,DIETARY_SUPPLEMENT: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|OTHER: Placebo,Bayer,,INTERVENTIONAL,2006-02,2008-07,2008-07,2010-07-12,,2010-08-02
NCT01145859,Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects,https://clinicaltrials.gov/study/NCT01145859,,COMPLETED,NO,Venous Thrombosis|Pediatrics,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",INTERVENTIONAL,2010-11,2015-07,2015-07,2010-06-17,,2015-08-06
NCT01122602,Evaluate Analgesic Efficacy of Fast Release Aspirin,https://clinicaltrials.gov/study/NCT01122602,TAROT,COMPLETED,NO,"Drugs, Investigational","DRUG: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|DRUG: Acetylsalicyclic acid (Aspirin, BAYE4465)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2010-04-29,2010-07-29,2010-08-06,2010-05-13,,2018-12-19
NCT01117636,Evaluate Analgesic Efficacy of Fast Release Aspirin,https://clinicaltrials.gov/study/NCT01117636,TAROT,COMPLETED,NO,"Drugs, Investigational","DRUG: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2010-04-28,2010-07-07,2010-07-07,2010-05-05,,2018-12-19
NCT01117623,Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01117623,,COMPLETED,YES,Neoplasm,"DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|DRUG: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|DRUG: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|DRUG: NSCLC expansion cohort: Regorafenib 100 mg",Bayer,,INTERVENTIONAL,2007-02,2013-11,2013-11,2010-05-05,2015-01-19,2015-11-18
NCT01110629,Study in Chronic Kidney Disease (CKD) Not on Dialysis,https://clinicaltrials.gov/study/NCT01110629,,COMPLETED,NO,Hyperphosphatemia,"DRUG: Fosrenol (Lanthanum Carbonate, BAY77-1931)|DRUG: Placebo",Bayer,Shire,INTERVENTIONAL,2010-06,2011-11,2011-11,2010-04-26,,2014-10-15
NCT01110590,"Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552",https://clinicaltrials.gov/study/NCT01110590,,COMPLETED,NO,Erectile Dysfunction,DRUG: BAY60-4552 + Vardenafil|DRUG: BAY60-4552 + Vardenafil|DRUG: BAY60-4552 + Vardenafil|DRUG: Placebo,Bayer,,INTERVENTIONAL,2010-01,2010-04,2010-05,2010-04-26,,2013-02-22
NCT01106352,A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC),https://clinicaltrials.gov/study/NCT01106352,,COMPLETED,YES,Bone Metastases|Castration-Resistant Prostate Cancer,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Docetaxel",Bayer,,INTERVENTIONAL,2010-07,2015-06,2015-06,2010-04-19,2016-11-09,2017-01-04
NCT01105208,Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension,https://clinicaltrials.gov/study/NCT01105208,,COMPLETED,NO,Anti-Infective Agents,"DRUG: Cephalexin suspension (Optocef, BAYO5448 )|DRUG: Cephalexin suspension (Keflex)",Bayer,Corporación Bonima S.A. de C.V.,INTERVENTIONAL,2010-03,2010-03,2010-03,2010-04-16,,2014-05-20
NCT01104584,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI),https://clinicaltrials.gov/study/NCT01104584,GEMMA 2,COMPLETED,YES,Breast Cancer,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2010-05,2011-09,2012-01,2010-04-15,2014-11-11,2014-11-11
NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,https://clinicaltrials.gov/study/NCT01103323,,COMPLETED,YES,Metastatic Colorectal Cancer,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Placebo|OTHER: Best Supportive Care (BSC)",Bayer,,INTERVENTIONAL,2010-04,2011-07,2014-01,2010-04-14,2012-11-19,2015-06-24
NCT01096498,Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel,https://clinicaltrials.gov/study/NCT01096498,LEVEQ-2,COMPLETED,NO,"Contraception|Contraception, Postcoital",DRUG: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|DRUG: Levonorgestrel (Postday),Bayer,,INTERVENTIONAL,2009-02,2009-03,2009-03,2010-03-31,,2013-06-11
NCT01096485,Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel,https://clinicaltrials.gov/study/NCT01096485,LEVEQ-1,COMPLETED,NO,"Contraception|Contraception, Postcoital",DRUG: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|DRUG: Levonorgestrel (Postday),Bayer,,INTERVENTIONAL,2009-02,2009-03,2009-03,2010-03-31,,2013-06-11
NCT01096030,"Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors",https://clinicaltrials.gov/study/NCT01096030,,COMPLETED,NO,Neoplasms,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2010-07,2012-11,2012-11,2010-03-30,,2013-11-19
NCT01083264,"Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites",https://clinicaltrials.gov/study/NCT01083264,,COMPLETED,NO,Contraception,DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,INTERVENTIONAL,2009-10,2010-05,2010-05,2010-03-09,,2014-06-23
NCT01081353,Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin,https://clinicaltrials.gov/study/NCT01081353,,COMPLETED,NO,Pharmacokinetics,DRUG: Acetylsalicylic Acid (Aspirin BAY1019036)|DRUG: Alka Seltzer Extra Strength|DRUG: Aspirin Migraine|DRUG: Aspirin Aspro,Bayer,,INTERVENTIONAL,2010-02,2010-03,2010-03,2010-03-05,,2014-06-26
NCT01077076,Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED),https://clinicaltrials.gov/study/NCT01077076,,COMPLETED,YES,Intragastric Acidity,DRUG: Zegerid|DRUG: Prilosec OTC™ Tablets|OTHER: Placebo,Bayer,,INTERVENTIONAL,2008-12,2009-03,2009-03,2010-02-26,2010-04-02,2015-03-11
NCT01076582,Comparative Trial in Hormone Withdrawal Associated Symptoms,https://clinicaltrials.gov/study/NCT01076582,,COMPLETED,NO,Oral Contraceptive,"DRUG: EE20/DRSP (YAZ, BAY86-5300)|DRUG: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)",Bayer,,INTERVENTIONAL,2010-04,2011-10,2011-10,2010-02-26,,2014-10-28
NCT01073904,Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg,https://clinicaltrials.gov/study/NCT01073904,LEVEQ-3,COMPLETED,NO,"Contraceptives, Postcoital",DRUG: Levonorgestrel Emergency Pill (BAY86-5028)|DRUG: Postinor 2,Bayer,,INTERVENTIONAL,2009-09,2009-09,2009-09,2010-02-23,,2014-04-03
NCT01073891,"Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults",https://clinicaltrials.gov/study/NCT01073891,,COMPLETED,NO,Healthy,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Moxifloxacin (BAY12-8039)|DRUG: Moxifloxacin (BAY12-8039)",Bayer,,INTERVENTIONAL,2010-05,2010-11,2011-01,2010-02-23,,2015-07-01
NCT01073553,Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules,https://clinicaltrials.gov/study/NCT01073553,,COMPLETED,NO,Anti-Infective Agents,"DRUG: Cephalexin capsules (Optocef, BAYO5448 )|DRUG: Cephalexin capsules (Keflex)",Bayer,Corporación Bonima S.A. de C.V.,INTERVENTIONAL,2009-10,2009-10,2009-10,2010-02-23,,2015-04-03
NCT01073540,Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension,https://clinicaltrials.gov/study/NCT01073540,,COMPLETED,NO,Anti-Infective Agents,"DRUG: Cephalexin suspension (Optocef, BAYO5448)|DRUG: Cephalexin suspension (Keflex)",Bayer,Corporación Bonima S.A. de C.V.,INTERVENTIONAL,2009-09,2009-09,2009-09,2010-02-23,,2014-04-03
NCT01072942,"To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)",https://clinicaltrials.gov/study/NCT01072942,,COMPLETED,NO,"Pulmonary Disease, Chronic Obstructive","DRUG: Ciprofloxacin (Cipro InhaIe, BAYQ3939)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2010-01,2010-06,2010-07,2010-02-22,,2014-04-02
NCT01072604,Pharmacokinetic Study Comparing Aspirin and Aspirin Granules,https://clinicaltrials.gov/study/NCT01072604,,COMPLETED,NO,Pharmacokinetics,"DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)|DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)|DRUG: Acetylsalicylic acid (Aspirin, BAYE4465)|DRUG: Acetylsalicylic acid (Aspirin, BAYE4465)",Bayer,,INTERVENTIONAL,2009-07,2009-08,2009-08,2010-02-22,,2014-04-21
NCT01070485,"BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease",https://clinicaltrials.gov/study/NCT01070485,,COMPLETED,NO,Breast Cancer|Bone Metastases,DRUG: Radium-223 chloride (BAY88-8223),Bayer,,INTERVENTIONAL,2010-01,2011-03,2012-01,2010-02-18,,2014-06-25
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,https://clinicaltrials.gov/study/NCT01069900,MOXIPEDIA,COMPLETED,YES,Intraabdominal Infections,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Ertapenem|DRUG: Amoxicillin/Clavulanate|DRUG: Moxifloxacin placebo|DRUG: Ertapenem placebo|DRUG: Amoxicillin/Clavulanate placebo",Bayer,,INTERVENTIONAL,2010-07-21,2015-01-21,2015-01-21,2010-02-17,2015-12-08,2018-03-20
NCT01069328,"Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT01069328,,COMPLETED,NO,"Carcinoma, Non-Small-Cell Lung|Lung Cancer","DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin",Bayer,,INTERVENTIONAL,2006-07,2011-09,2011-10,2010-02-17,,2013-11-13
NCT01067976,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI,https://clinicaltrials.gov/study/NCT01067976,,COMPLETED,YES,Breast Cancer|Diagnostic Imaging,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2010-02,2011-07,2012-01,2010-02-12,2014-11-11,2014-11-11
NCT01062360,Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine,https://clinicaltrials.gov/study/NCT01062360,,COMPLETED,NO,Common Cold|Pharyngitis,"DRUG: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Pseudoephedrine|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-12-23,2007-05-14,2007-05-14,2010-02-04,,2017-09-01
NCT01053676,Bioequivalence Study of BAY77-1931 Granule,https://clinicaltrials.gov/study/NCT01053676,,COMPLETED,NO,Hyperphosphatemia,"DRUG: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|DRUG: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet",Bayer,,INTERVENTIONAL,2010-01,2010-04,2010-04,2010-01-21,,2014-06-23
NCT01052298,Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT01052298,,COMPLETED,NO,"Disease, Pulmonary","DRUG: Ciprofloxacin (Cipro inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro inhale, BAYQ3939)|DRUG: Placebo",Bayer,Novartis,INTERVENTIONAL,2009-04,2009-09,2009-09,2010-01-20,,2013-05-30
NCT01050829,Gadobutrol Magnevist-controlled Body Study,https://clinicaltrials.gov/study/NCT01050829,,COMPLETED,NO,Magnetic Resonance Imaging,"DRUG: Gadobutrol (Gadovist, BAY86-4875)|DRUG: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)",Bayer,,INTERVENTIONAL,2010-01,2011-04,2011-04,2010-01-15,,2014-12-30
NCT01049022,"Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",https://clinicaltrials.gov/study/NCT01049022,,COMPLETED,NO,Infections,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Moxifloxacin (Avelox, BAY12-8039)",Bayer,,INTERVENTIONAL,2010-05,2012-12,2013-08,2010-01-14,,2015-07-22
NCT01045902,"BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia",https://clinicaltrials.gov/study/NCT01045902,,COMPLETED,NO,"Pneumonia, Aspiration|Lung Abscess","DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Sulbactam/Ampicillin",Bayer,,INTERVENTIONAL,2001-02,,2005-01,2010-01-11,,2010-01-11
NCT01035164,Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers,https://clinicaltrials.gov/study/NCT01035164,,COMPLETED,NO,Positron-Emission Tomography|Alzheimer's Disease,DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101),Bayer,,INTERVENTIONAL,2007-06,2010-01,2010-01,2009-12-18,,2015-01-08
NCT01031355,Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium,https://clinicaltrials.gov/study/NCT01031355,,COMPLETED,NO,Contraception|Ovulation Inhibition,DRUG: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|DRUG: Estradiol Valerate (EV) (BAY86-4980)|DRUG: Levomefolate Calcium (BAY86-7660),Bayer,,INTERVENTIONAL,2009-12,2010-02,2010-03,2009-12-14,,2014-02-20
NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,https://clinicaltrials.gov/study/NCT01031199,,COMPLETED,NO,Positron-Emission Tomography|Multiple Sclerosis,DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101),Bayer,,INTERVENTIONAL,2009-01,2009-12,2009-12,2009-12-14,,2014-04-02
NCT01029340,Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A,https://clinicaltrials.gov/study/NCT01029340,Leopold I,COMPLETED,YES,Blood Coagulation Disorders|Hemophilia A,"BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)|BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)",Bayer,,INTERVENTIONAL,2009-12,2012-06,2013-03,2009-12-09,2013-11-18,2016-11-28
NCT01028755,To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT01028755,,COMPLETED,NO,Neoplasms,DRUG: BAY79-4620,Bayer,,INTERVENTIONAL,2009-11,2013-04,2013-04,2009-12-09,,2015-01-21
NCT01028079,"Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain",https://clinicaltrials.gov/study/NCT01028079,,COMPLETED,NO,Low Back Pain,"DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Ibuprofen|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-11,,2006-12,2009-12-09,,2009-12-09
NCT01021436,"Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia",https://clinicaltrials.gov/study/NCT01021436,,COMPLETED,NO,Pneumonia,DRUG: Amikacin inhalation solution (BAY41-6551),Bayer,Nektar Therapeutics,INTERVENTIONAL,2007-03,2007-08,2007-08,2009-11-30,,2016-02-18
NCT01014247,Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation,https://clinicaltrials.gov/study/NCT01014247,,COMPLETED,NO,QTc Evaluation|Electrocardiography,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-11,2010-06,2010-06,2009-11-16,,2013-06-03
NCT01013909,Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo,https://clinicaltrials.gov/study/NCT01013909,Porsche,COMPLETED,NO,Tinea Pedis,DRUG: Bifonazole spray once daily|DRUG: Bifonazole spray twice daily|DRUG: Placebo|DRUG: Placebo|DRUG: Lamisil Once,Bayer,,INTERVENTIONAL,2009-12,2010-05,2010-05,2009-11-16,,2015-01-27
NCT01012973,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),https://clinicaltrials.gov/study/NCT01012973,GALILEO,COMPLETED,YES,Retinal Vein Occlusion,"BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|OTHER: Sham treatment",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2009-10,2011-02,2012-02,2009-11-13,2012-11-22,2014-11-02
NCT01010100,Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care,https://clinicaltrials.gov/study/NCT01010100,,COMPLETED,NO,Diabetes Mellitus,"DRUG: Acarbose (Glucobay, BAYG5421)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2000-08,2007-05,2007-05,2009-11-09,,2010-12-28
NCT01009359,"Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",https://clinicaltrials.gov/study/NCT01009359,,COMPLETED,NO,Diagnostic Imaging,DRUG: F-18 DPA-714 (BAY85-8102)|DRUG: F-18 DPA-714 (BAY85-8102)|DRUG: F-18 DPA-714 (BAY85-8102),Bayer,,INTERVENTIONAL,2009-10,2010-07,2010-10,2009-11-06,,2013-07-31
NCT01007578,Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease,https://clinicaltrials.gov/study/NCT01007578,,COMPLETED,NO,Peripheral Arterial Disease|Stenotic Femoro-popliteal Arteries|Occluded Femoro-popliteal Arteries|Atherosclerosis,DEVICE: Paclitaxel-coated balloon catheter angioplasty,Bayer,,INTERVENTIONAL,2007-09-15,2007-12-15,2007-12-15,2009-11-04,,2023-09-21
NCT01005719,Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED),https://clinicaltrials.gov/study/NCT01005719,,COMPLETED,YES,Human Experimentation,DRUG: Zegerid|DRUG: Prevacid®,Bayer,,INTERVENTIONAL,2009-09,2010-01,2010-01,2009-11-01,2011-01-28,2015-03-11
NCT01004445,A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS),https://clinicaltrials.gov/study/NCT01004445,,COMPLETED,NO,Pneumonia,DRUG: Amikacin (BAY41-6551)|DRUG: Amikacin (BAY41-6551)|DRUG: Placebo,Bayer,Nektar Therapeutics,INTERVENTIONAL,2005-05,2006-06,2006-06,2009-10-30,,2011-04-08
NCT01003015,Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT01003015,,COMPLETED,NO,"Carcinoma, Hepatocellular",DRUG: BAY73-4506,Bayer,,INTERVENTIONAL,2009-09,2010-11,2013-03,2009-10-28,,2015-04-03
NCT01002378,The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib,https://clinicaltrials.gov/study/NCT01002378,,COMPLETED,NO,Dietary Fats|Pharmacokinetics,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2009-10,2010-02,2010-02,2009-10-27,,2013-05-23
NCT01001975,Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED),https://clinicaltrials.gov/study/NCT01001975,PFA and SPF,COMPLETED,YES,Sun Protection,DRUG: Sunscreen Test Code: V53-028|DRUG: Sunscreen Test Code: V53-030|DRUG: Standard SPF 4 Sunscreen,Bayer,,INTERVENTIONAL,2009-07,2009-08,2009-08,2009-10-27,2010-12-07,2015-03-11
NCT00984789,Birth Control Patch Study,https://clinicaltrials.gov/study/NCT00984789,,COMPLETED,NO,Contraception,DRUG: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|DRUG: Norelgestromin/Ethinylestradiol (EVRA),Bayer,Parexel,INTERVENTIONAL,2009-05,2010-09,2010-09,2009-09-25,,2014-04-02
NCT00984282,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,https://clinicaltrials.gov/study/NCT00984282,,COMPLETED,YES,Thyroid Neoplasms,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,Amgen,INTERVENTIONAL,2009-10-15,2012-08-31,2017-08-30,2009-09-25,2013-12-10,2018-09-13
NCT00980135,Sinecort Pilot Efficacy Study,https://clinicaltrials.gov/study/NCT00980135,Sinecort Pilot,COMPLETED,NO,Atopic Dermatitis,DEVICE: Sinecort cream|DRUG: Hydrocortison cream|OTHER: Untreated skin,Bayer,,INTERVENTIONAL,2009-11,2010-05,2010-05,2009-09-18,,2014-04-02
NCT00976209,Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED),https://clinicaltrials.gov/study/NCT00976209,,COMPLETED,YES,Vasomotor Rhinitis|Seasonal Allergic Rhinitis,"DRUG: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|DRUG: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg",Bayer,,INTERVENTIONAL,2009-08,2009-11,2009-11,2009-09-14,2011-03-25,2015-03-11
NCT00973323,BAY59-7939 Japanese in Atrial Fibrillation (2nd),https://clinicaltrials.gov/study/NCT00973323,,COMPLETED,NO,Atrial Fibrillation,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Warfarin",Bayer,,INTERVENTIONAL,2005-09,,2006-03,2009-09-09,,2014-12-30
NCT00973245,BAY59-7939 in Atrial Fibrillation Once Daily (OD),https://clinicaltrials.gov/study/NCT00973245,,COMPLETED,NO,Atrial Fibrillation,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Warfarin",Bayer,,INTERVENTIONAL,2006-07,,2007-01,2009-09-09,,2014-12-30
NCT00969449,Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan,https://clinicaltrials.gov/study/NCT00969449,,COMPLETED,NO,Pharmacokinetics,"DRUG: Naproxen Sodium, (BAY H6689)|DRUG: Naprelan, (BAY H6689)",Bayer,,INTERVENTIONAL,2009-04,2009-05,2009-05,2009-09-01,,2014-05-20
NCT00963443,Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold,https://clinicaltrials.gov/study/NCT00963443,,COMPLETED,NO,Common Cold,"DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Pseudoephedrine|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-09,2012-03,2012-03,2009-08-21,,2014-12-05
NCT00962611,"BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00962611,,COMPLETED,NO,Neoplasms,"DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,INTERVENTIONAL,2009-11-19,2016-02-23,2016-02-23,2009-08-20,,2017-10-06
NCT00961831,"Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients",https://clinicaltrials.gov/study/NCT00961831,,COMPLETED,NO,Neoplasm,DRUG: F-18 (BAY85-8050)|DRUG: F-18 (BAY85-8050),Bayer,,INTERVENTIONAL,2009-04-15,2009-12-16,2009-12-16,2009-08-19,,2022-10-12
NCT00961038,Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT00961038,,COMPLETED,NO,"Pulmonary Disease, Chronic Obstructive","DRUG: Ciprofloxacin (PulmoSphere, BAYQ3939)|DRUG: Ciprofloxacin (PulmoSphere, BAYQ3939)|DRUG: Placebo",Bayer,Novartis Pharmaceuticals,INTERVENTIONAL,2009-08,2010-03,2010-03,2009-08-18,,2014-04-01
NCT00960258,Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.,https://clinicaltrials.gov/study/NCT00960258,,COMPLETED,NO,Tumors,DRUG: Regorafenib (BAY73-4506),Bayer,,INTERVENTIONAL,2009-07-01,2010-04-26,2013-11-11,2009-08-17,,2017-09-27
NCT00944632,Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis,https://clinicaltrials.gov/study/NCT00944632,,COMPLETED,NO,Atopic Dermatitis,DRUG: ZK 245186|DRUG: Placebo (vehicle ointment),Bayer,,INTERVENTIONAL,2009-07-15,2010-09-15,2010-09-15,2009-07-23,,2023-06-07
NCT00941863,"Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)",https://clinicaltrials.gov/study/NCT00941863,,COMPLETED,YES,Carcinoma,DRUG: Sorafenib 100 mg (50-mg tablet)|DRUG: Sorafenib 200 mg (50-mg tablet)|DRUG: Sorafenib 400 mg (50-mg tablet)|DRUG: Sorafenib 400 mg (200-mg tablet)|DRUG: Sorafenib 400 mg (Expansion),Bayer,Amgen,INTERVENTIONAL,2002-07,2005-05,2008-04,2009-07-20,2010-10-08,2016-03-22
NCT00941057,Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium,https://clinicaltrials.gov/study/NCT00941057,,COMPLETED,NO,"Pharmacology, Clinical","DRUG: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|DRUG: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|DRUG: BAY 86-7660,levomefolate calcium",Bayer,,INTERVENTIONAL,2009-09,2009-12,2010-01,2009-07-17,,2016-08-01
NCT00937391,Contrast-enhanced MRI in Children 2 Months to <2 Years,https://clinicaltrials.gov/study/NCT00937391,,COMPLETED,YES,Magnetic Resonance Imaging,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-6661)",Bayer,,INTERVENTIONAL,2010-01,2010-09,2010-09,2009-07-13,2011-10-13,2015-11-18
NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",https://clinicaltrials.gov/study/NCT00934882,,COMPLETED,NO,Colorectal Neoplasms,DRUG: Regorafenib (BAY73-4506),Bayer,,INTERVENTIONAL,2009-08,2012-04,2012-04,2009-07-08,,2014-06-02
NCT00933179,FC Patch Low: Metabolism Study,https://clinicaltrials.gov/study/NCT00933179,,COMPLETED,NO,Contraception,"DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: EE/Levonorgestrel (Microgynon, BAY86-4977)",Bayer,,INTERVENTIONAL,2009-06,2010-09,2010-09,2009-07-07,,2014-11-14
NCT00930982,Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis,https://clinicaltrials.gov/study/NCT00930982,,COMPLETED,YES,Bronchiectasis,"DRUG: Ciprofloxacin (Cipro, BAYQ3939)|DRUG: Placebo",Bayer,Novartis,INTERVENTIONAL,2009-06,2010-09,2010-09,2009-07-02,2012-01-30,2014-12-12
NCT00920985,US Cycle Control and Blood Pressure Study,https://clinicaltrials.gov/study/NCT00920985,,COMPLETED,NO,Contraception,"DRUG: Gestodene/EE (FC Patch Low, BAY86-5016)|DRUG: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A",Bayer,,INTERVENTIONAL,2009-06,2010-08,2010-09,2009-06-16,,2015-10-09
NCT00915915,Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD),https://clinicaltrials.gov/study/NCT00915915,,COMPLETED,NO,Contraception|Ovulation Inhibition,DRUG: Ethinylestradiol/Gestodene (BAY86-5016)|DRUG: Ethinylestradiol/Gestodene (BAY86-5016),Bayer,,INTERVENTIONAL,2009-06,2010-04,2010-04,2009-06-08,,2014-10-28
NCT00914693,EU/LA Pearl Index Study - Transdermal Contraceptive Patch,https://clinicaltrials.gov/study/NCT00914693,,COMPLETED,NO,Contraception,DRUG: Ethinylestradiol/Gestodene (BAY86-5016),Bayer,,INTERVENTIONAL,2009-04,2011-09,2011-09,2009-06-05,,2014-12-05
NCT00910637,Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles,https://clinicaltrials.gov/study/NCT00910637,,COMPLETED,NO,Contraception,DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,INTERVENTIONAL,2009-05-01,2010-12-13,2010-12-13,2009-06-01,,2021-04-08
NCT00910429,BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension,https://clinicaltrials.gov/study/NCT00910429,CHEST-2,COMPLETED,YES,Pulmonary Hypertension,"DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,INTERVENTIONAL,2009-07-01,2019-08-19,2019-08-19,2009-05-29,2020-10-22,2023-11-07
NCT00910351,Cipro Inhaler for Cystic Fibrosis Children Ages 6-12,https://clinicaltrials.gov/study/NCT00910351,,COMPLETED,NO,Pseudomonas Infection,"DRUG: Ciprofloxacin (Cipro, BAYQ3939)",Bayer,,INTERVENTIONAL,2009-07,2010-10,2010-10,2009-05-29,,2013-11-21
NCT00910065,"BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)",https://clinicaltrials.gov/study/NCT00910065,ACUTE,COMPLETED,NO,Acute Coronary Syndrome,"DRUG: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|DRUG: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|DRUG: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet",Bayer,,INTERVENTIONAL,2011-03,2014-04,2014-07,2009-05-29,,2015-06-25
NCT00909857,Effect on Primary Dysmenorrhea,https://clinicaltrials.gov/study/NCT00909857,,COMPLETED,YES,Primary Dysmenorrhea,"DRUG: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Ethinyl estradiol, Levonorgestrel (Miranova)|DRUG: Placebo Match to SH T00658ID|DRUG: Placebo Match to SH D593B",Bayer,,INTERVENTIONAL,2009-04,2010-11,2010-11,2009-05-29,2012-02-27,2015-08-24
NCT00901901,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00901901,SEARCH,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Erlotinib (Tarceva)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-05-21,2012-04-17,2018-05-23,2009-05-14,2013-09-30,2019-05-30
NCT00896571,Transdermal Contraceptive Patch - Endometrial Effects Study,https://clinicaltrials.gov/study/NCT00896571,,COMPLETED,NO,Contraception,DRUG: Ethinylestradiol/Gestogene (BAY86-5016),Bayer,,INTERVENTIONAL,2009-07,2011-05,2011-08,2009-05-11,,2014-11-26
NCT00893217,BEYOND Pilot Study,https://clinicaltrials.gov/study/NCT00893217,,COMPLETED,NO,Multiple Sclerosis|Relapsing-Remitting,"DRUG: Betaseron (Interferon beta-1b, BAY86-5046)|DRUG: Betaseron (Interferon beta-1b, BAY86-5046)",Bayer,,INTERVENTIONAL,2002-11,,2003-06,2009-05-05,,2009-11-09
NCT00885937,Comparative Safety Study of New Sinecort Formulation Versus Positive Control,https://clinicaltrials.gov/study/NCT00885937,,COMPLETED,NO,Healthy,"DRUG: Dexpanthenol (Sinecort, BAY81-2996)|DRUG: Positive control, Na-laurylsulfat-solution|DEVICE: Untreated skin under application chamber",Bayer,,INTERVENTIONAL,2009-04,2009-05,2009-05,2009-04-22,,2014-06-23
NCT00884260,GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China,https://clinicaltrials.gov/study/NCT00884260,,COMPLETED,NO,Contraception,"DRUG: Levonorgestrel IUS (LCS, BAY86-5028)",Bayer,,INTERVENTIONAL,2009-04,2013-06,2013-06,2009-04-20,,2014-08-21
NCT00874120,Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED),https://clinicaltrials.gov/study/NCT00874120,,COMPLETED,YES,Blood Pressure|Human Experimentation,DRUG: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|DRUG: Placebo,Bayer,,INTERVENTIONAL,2008-12,2009-02,2009-02,2009-04-02,2010-07-05,2015-03-11
NCT00873483,US Ovulation Inhibition Study in Obese Women,https://clinicaltrials.gov/study/NCT00873483,,COMPLETED,NO,Contraception,DRUG: Ethinylestradiol/Gestodene (BAY86-5016),Bayer,,INTERVENTIONAL,2009-04-30,2010-03-03,2010-03-03,2009-04-01,,2021-04-08
NCT00865709,Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects,https://clinicaltrials.gov/study/NCT00865709,,COMPLETED,YES,Metastatic Colorectal Cancer,"DRUG: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|DRUG: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)",Bayer,Amgen,INTERVENTIONAL,2009-03,2011-01,2012-02,2009-03-19,2012-03-20,2014-12-11
NCT00863746,A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).,https://clinicaltrials.gov/study/NCT00863746,MISSION,COMPLETED,YES,Carcinoma|Non-Small-Cell Lung,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-04,2012-03,2013-04,2009-03-18,2013-07-30,2015-01-19
NCT00863681,BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension,https://clinicaltrials.gov/study/NCT00863681,PATENT-2,COMPLETED,YES,"Hypertension, Pulmonary",DRUG: Riociguat (BAY63-2521),Bayer,,INTERVENTIONAL,2009-03-12,2019-08-19,2019-08-19,2009-03-18,2020-10-22,2023-11-07
NCT00862459,Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI),https://clinicaltrials.gov/study/NCT00862459,,COMPLETED,YES,Brain Diseases|Spinal Cord Diseases,"DRUG: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|DRUG: OptiMARK~0.1 mmol/kg BW",Bayer,,INTERVENTIONAL,2005-08,2007-03,2007-03,2009-03-17,2012-01-30,2014-01-13
NCT00855660,Effect of Riociguat on Bone Metabolism,https://clinicaltrials.gov/study/NCT00855660,,COMPLETED,NO,"Pharmacology, Clinical","DRUG: Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-03,2009-12,2010-07,2009-03-04,,2016-01-11
NCT00855465,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,https://clinicaltrials.gov/study/NCT00855465,CHEST-1,COMPLETED,YES,Pulmonary Hypertension,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-02-23,2012-06-27,2012-06-27,2009-03-04,2014-03-11,2023-11-21
NCT00855218,"A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).",https://clinicaltrials.gov/study/NCT00855218,,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-03,2011-07,2013-02,2009-03-04,2012-09-24,2017-08-18
NCT00839826,ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial,https://clinicaltrials.gov/study/NCT00839826,ODiXaHip,COMPLETED,NO,Thromboembolism|Prevention,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,INTERVENTIONAL,2002-12,2003-11,2003-11,2009-02-10,,2014-12-17
NCT00839462,Efficacy of Dexpanthenol in Thermic Erythema,https://clinicaltrials.gov/study/NCT00839462,,COMPLETED,NO,Erythema,"DRUG: Dexpanthenol foam spray, new formulation|DRUG: Dexpanthenol foam spray, old formulation",Bayer,,INTERVENTIONAL,2007-09,2007-09,2007-09,2009-02-09,,2013-10-21
NCT00839280,Moisturizing Effect of Two Dexpanthenol Formulations,https://clinicaltrials.gov/study/NCT00839280,,COMPLETED,NO,Skin Abnormalities,"DRUG: Dexpanthenol foam spray, new formulation|DRUG: Dexpanthenol foam spray, old formulation",Bayer,,INTERVENTIONAL,2007-08,2007-09,2007-09,2009-02-09,,2014-10-15
NCT00839163,Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT),https://clinicaltrials.gov/study/NCT00839163,,COMPLETED,NO,Venous Thrombosis|Deep Vein Thrombosis,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Enoxaparin/Vitamin K-Antagonist",Bayer,,INTERVENTIONAL,2004-03,2005-10,2005-10,2009-02-09,,2023-09-07
NCT00829231,Hepatic Impairment Study,https://clinicaltrials.gov/study/NCT00829231,,COMPLETED,NO,Liver Disease,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2009-01,2009-07,2009-07,2009-01-26,,2014-11-02
NCT00828971,A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs,https://clinicaltrials.gov/study/NCT00828971,MERAK,COMPLETED,NO,Infectious Diseases,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Amoxicilline/clavulanic",Bayer,,INTERVENTIONAL,2008-11,2009-09,2009-10,2009-01-26,,2014-12-08
NCT00824187,YAZ Premenstrual Dysphoric Disorder (PMDD) in China,https://clinicaltrials.gov/study/NCT00824187,,COMPLETED,NO,Premenstrual Dysphoric Disorder ( PMDD),"DRUG: EE20/DRSP(YAZ, BAY86-5300)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-01,2011-01,2011-01,2009-01-16,,2014-04-02
NCT00819312,"YAZ, Oral Contraceptive Registration in China",https://clinicaltrials.gov/study/NCT00819312,,COMPLETED,NO,Contraception,"DRUG: YAZ (SH T00186, BAY86-5300)",Bayer,,INTERVENTIONAL,2008-12,2011-01,2011-01,2009-01-08,,2013-01-29
NCT00818519,GA YAZ ACNE in China Phase III,https://clinicaltrials.gov/study/NCT00818519,,COMPLETED,YES,Acne Vulgaris,"DRUG: EE20/Drospirenone (YAZ, BAY86-5300)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2008-12,2010-05,2010-05,2009-01-07,2011-06-09,2015-08-25
NCT00818415,Naproxen Sodium ER Pharmacokinetic Study,https://clinicaltrials.gov/study/NCT00818415,,COMPLETED,NO,Pain,"DRUG: Naproxen sodium ER (BAYH6689)|DRUG: Commercial Naproxen (Aleve, BAYH6689)",Bayer,,INTERVENTIONAL,2008-11,2008-11,2008-11,2009-01-07,,2014-05-19
NCT00810693,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),https://clinicaltrials.gov/study/NCT00810693,PATENT-1,COMPLETED,YES,Pulmonary Hypertension,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2008-12-17,2012-05-14,2012-05-14,2008-12-18,2014-02-26,2023-11-22
NCT00805415,Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens,https://clinicaltrials.gov/study/NCT00805415,,COMPLETED,NO,Ovulation Inhibition,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|DRUG: EV/DNG (SH T00658L)",Bayer,,INTERVENTIONAL,2003-03,2004-02,2004-02,2008-12-09,,2011-07-15
NCT00791778,Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer,https://clinicaltrials.gov/study/NCT00791778,,COMPLETED,YES,Ovarian Neoplasms,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2008-11,2011-07,2012-12,2008-11-17,2012-11-30,2015-09-28
NCT00786422,Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer,https://clinicaltrials.gov/study/NCT00786422,,COMPLETED,YES,Venous Thrombosis|Deep Vein Thrombosis,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2009-05,2011-05,2011-06,2008-11-06,2014-06-13,2015-11-18
NCT00786253,Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00786253,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,INTERVENTIONAL,2005-10,,2007-01,2008-11-06,,2014-10-28
NCT00785226,RDEA119 and Sorafenib Combination Dose Escalation Study,https://clinicaltrials.gov/study/NCT00785226,,COMPLETED,NO,Advanced Cancer,DRUG: RDEA119|DRUG: Sorafenib,Bayer,,INTERVENTIONAL,2008-11,2012-04,2012-04,2008-11-05,,2016-10-17
NCT00781820,Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste,https://clinicaltrials.gov/study/NCT00781820,,COMPLETED,NO,Onychomycosis,DRUG: Bifonazole cream 1%|DRUG: Placebo cream,Bayer,,INTERVENTIONAL,2008-10,2010-01,2010-01,2008-10-29,,2013-06-11
NCT00779064,"BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status",https://clinicaltrials.gov/study/NCT00779064,,COMPLETED,NO,Atrial Fibrillation,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939),Bayer,,INTERVENTIONAL,2004-07,2005-06,2005-06,2008-10-24,,2014-12-25
NCT00778609,Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache,https://clinicaltrials.gov/study/NCT00778609,,COMPLETED,NO,Oral Contraceptive|Headache|Pelvic Pain,"DRUG: EV/DNG (Qlaira, BAY86-5027)|DRUG: Encapsulated Microgynon + Placebo",Bayer,,INTERVENTIONAL,2008-12,2010-12,2010-12,2008-10-23,,2016-01-14
NCT00769496,BAY 77-1931 Long-term Extension From Phase II Study,https://clinicaltrials.gov/study/NCT00769496,,COMPLETED,NO,Hyperphosphatemia,DRUG: BAY 77-1931,Bayer,,INTERVENTIONAL,2005-01,2008-05,2008-05,2008-10-09,,2013-01-23
NCT00769171,Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections),https://clinicaltrials.gov/study/NCT00769171,DRAGON,COMPLETED,NO,"Infection, Intra-abdominal","DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Ceftriaxone + Metronidazole",Bayer,,INTERVENTIONAL,2005-10,2006-12,2007-01,2008-10-08,,2014-12-18
NCT00768560,"Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study",https://clinicaltrials.gov/study/NCT00768560,,COMPLETED,YES,Hypertension,"DRUG: Nifedipine (Adalat CR, BAYA1040) 80mg OD|DRUG: Nifedipine (Adalat CR, BAYA1040) 40mg BID|DRUG: Nifedipine (Adalat CR, BAYA1040) 40mg OD",Bayer,,INTERVENTIONAL,2008-01,2008-05,2008-05,2008-10-08,2010-02-02,2015-06-08
NCT00767637,Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone,https://clinicaltrials.gov/study/NCT00767637,,COMPLETED,NO,Hyperphosphatemia|Dialysis,DRUG: Lanthanum Carbonate (BAY77-1931),Bayer,,INTERVENTIONAL,2005-06,2008-10,2008-10,2008-10-07,,2014-06-20
NCT00765206,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED),https://clinicaltrials.gov/study/NCT00765206,,COMPLETED,YES,Gastric Acid|Human Experimentation,DRUG: Omeprazole/sodium bicarbonate|DRUG: omeprazole magnesium (20 mg equivalent),Bayer,"Bausch Health Americas, Inc.",INTERVENTIONAL,2008-05,2008-08,2008-08,2008-10-02,2010-04-30,2015-03-11
NCT00764881,Effects of SH T00658ID on Libido,https://clinicaltrials.gov/study/NCT00764881,,COMPLETED,YES,Contraception|Libido,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|DRUG: Microgynon|DRUG: Placebo",Bayer,,INTERVENTIONAL,2009-01,2010-07,2010-07,2008-10-02,2012-04-03,2014-12-30
NCT00761462,BAY 0 9867 Cipro Pediatric Use Study (QUIP),https://clinicaltrials.gov/study/NCT00761462,,COMPLETED,YES,Infectious Diseases,DRUG: Ciprofloxacin|DRUG: Non-quinolone antibiotic,Bayer,,INTERVENTIONAL,1999-10,2008-01,2008-01,2008-09-29,2009-04-14,2015-07-31
NCT00755053,Comparative Efficacy of Ovule vs Tablet,https://clinicaltrials.gov/study/NCT00755053,,COMPLETED,NO,Clotrimazole|Ovulen|Vulvovaginal Candidiasis,"DRUG: Clotrimazole, vaginal ovule|DRUG: Clotrimazole, vaginal tablet",Bayer,,INTERVENTIONAL,2008-09,2009-05,2009-05,2008-09-18,,2015-08-06
NCT00754871,Pharmacodynamic Characterization of Dienogest,https://clinicaltrials.gov/study/NCT00754871,,COMPLETED,NO,Pharmacodynamics,DRUG: Dienogest (81150037)|DRUG: Dienogest (81150231)|DRUG: Dienogest (SH T00660A)|DRUG: Dienogest (81150746),Bayer,,INTERVENTIONAL,2008-09,2009-07,2009-09,2008-09-18,,2015-01-27
NCT00754065,To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada),https://clinicaltrials.gov/study/NCT00754065,,COMPLETED,YES,Contraception,"DRUG: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Ortho Tri Cyclen Lo",Bayer,,INTERVENTIONAL,2008-09-08,2011-05-10,2011-05-10,2008-09-17,2012-08-28,2024-11-20
NCT00751556,Single/Multiple Dose Bioavailability Trial,https://clinicaltrials.gov/study/NCT00751556,,COMPLETED,NO,Healthy,DRUG: Naproxen Sodium 660mg|DRUG: Commercial Aleve 220 mg,Bayer,,INTERVENTIONAL,2008-02,2008-03,2008-03,2008-09-12,,2014-04-21
NCT00751400,Naproxen Sodium Extended-Release Actual Use Study,https://clinicaltrials.gov/study/NCT00751400,,COMPLETED,YES,Pain,DRUG: Naproxen Sodium ER (BAYH6689),Bayer,"Pegus Research, Inc.",INTERVENTIONAL,2008-07,2008-11,2008-11,2008-09-12,2011-05-17,2015-08-25
NCT00751205,Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC),https://clinicaltrials.gov/study/NCT00751205,,COMPLETED,NO,Prostate Cancer|Ovarian Cancer,"DRUG: Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|DRUG: Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid",Bayer,,INTERVENTIONAL,2008-08,2010-02,2010-08,2008-09-11,,2014-10-28
NCT00748046,Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton,https://clinicaltrials.gov/study/NCT00748046,,COMPLETED,NO,Prostate Cancer|Metastases|Pharmacokinetics,DRUG: Radium-223 chloride (BAY88-8223),Bayer,,INTERVENTIONAL,2008-08,2009-10,2009-10,2008-09-08,,2014-06-25
NCT00720057,Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.,https://clinicaltrials.gov/study/NCT00720057,,COMPLETED,YES,Toothache,DRUG: Naproxen Sodium ER (BAYH6689)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2008-06,2008-08,2008-08,2008-07-22,2011-01-25,2015-08-25
NCT00717561,A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia,https://clinicaltrials.gov/study/NCT00717561,,COMPLETED,NO,Pneumonia,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin",Bayer,,INTERVENTIONAL,2008-02,2009-05,2009-06,2008-07-17,,2014-11-04
NCT00709852,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging,https://clinicaltrials.gov/study/NCT00709852,,COMPLETED,YES,Diagnostic Imaging|Central Nervous System Diseases,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadoteridol (ProHance)",Bayer,,INTERVENTIONAL,2008-06,2009-04,2009-04,2008-07-03,2012-03-06,2014-12-30
NCT00699751,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,https://clinicaltrials.gov/study/NCT00699751,ALSYMPCA,COMPLETED,YES,Hormone Refractory Prostate Cancer|Bone Metastases,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Placebo|DRUG: Best standard of care (BSoC)",Bayer,,INTERVENTIONAL,2008-06,2011-07,2014-02,2008-06-18,2014-05-07,2016-05-27
NCT00692770,Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM),https://clinicaltrials.gov/study/NCT00692770,STORM,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2008-08-15,2013-11-29,2014-11-28,2008-06-06,2014-12-01,2018-08-08
NCT00692016,Fast & Fed Pharmacokinetic (PK) Study,https://clinicaltrials.gov/study/NCT00692016,Keifer,COMPLETED,NO,Bioavailability,DRUG: Naproxen sodium|DRUG: Naproxen sodium,Bayer,,INTERVENTIONAL,2008-01,2008-02,2008-03,2008-06-06,,2013-05-03
NCT00683865,Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.,https://clinicaltrials.gov/study/NCT00683865,MAIDEN,COMPLETED,NO,Pelvic Inflammatory Disease,"DRUG: Ofloxacin|DRUG: Avelox (Moxifloxacin, BAY12-8039)",Bayer,,INTERVENTIONAL,2003-04,2004-10,2004-10,2008-05-26,,2014-10-15
NCT00682019,Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks,https://clinicaltrials.gov/study/NCT00682019,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2003-12,,2004-08,2008-05-21,,2013-10-14
NCT00681551,Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis,https://clinicaltrials.gov/study/NCT00681551,,COMPLETED,NO,Brain Neoplasms,DRUG: Magnevist (SH L 451A)|DRUG: Magnevist (SH L 451A),Bayer,,INTERVENTIONAL,2003-02,,2004-03,2008-05-21,,2014-12-15
NCT00680654,Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID,https://clinicaltrials.gov/study/NCT00680654,,COMPLETED,NO,"Hypertension, Pulmonary","DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,INTERVENTIONAL,2008-10,2009-08,2009-11,2008-05-20,,2015-12-16
NCT00678704,BAY38-9456 - Pivotal Trial for Diabetes Patient,https://clinicaltrials.gov/study/NCT00678704,,COMPLETED,NO,Erectile Dysfunction|Diabetes Mellitus,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-01,,2004-11,2008-05-15,,2014-12-19
NCT00674115,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED),https://clinicaltrials.gov/study/NCT00674115,,COMPLETED,YES,Gastric Acid|Human Experimentation,DRUG: Omeprazole/sodium bicarbonate|DRUG: omeprazole magnesium|DRUG: sodium bicarbonate,Bayer,"Bausch Health Americas, Inc.",INTERVENTIONAL,2008-04,2008-06,2008-06,2008-05-07,2010-04-30,2015-03-11
NCT00673686,Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D,https://clinicaltrials.gov/study/NCT00673686,,COMPLETED,NO,"Contraceptives, Oral","DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|DRUG: Yasminelle (SH T 00186 D)",Bayer,,INTERVENTIONAL,2004-05,2005-02,2005-02,2008-05-07,,2014-10-13
NCT00670215,"BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis",https://clinicaltrials.gov/study/NCT00670215,,COMPLETED,NO,Bacterial Infections,DRUG: Ciprofloxacin single dose|DRUG: Ciprofloxacin triple dose,Bayer,,INTERVENTIONAL,2004-04,,2004-10,2008-05-01,,2014-12-19
NCT00668122,Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections,https://clinicaltrials.gov/study/NCT00668122,EMERON,COMPLETED,NO,Urinary Tract Infection,"DRUG: Cipro XR (Ciprofloxacin, BAYQ3939)|DRUG: Cipro IR (Ciprofloxacin, BAYQ3939)",Bayer,,INTERVENTIONAL,2004-03,,2006-01,2008-04-28,,2009-06-30
NCT00668109,"Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia",https://clinicaltrials.gov/study/NCT00668109,LUTECIA,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Tadalafil",Bayer,,INTERVENTIONAL,2003-12,2004-06,2004-06,2008-04-28,,2014-12-23
NCT00668057,BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.,https://clinicaltrials.gov/study/NCT00668057,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo|DRUG: Placebo|DRUG: Placebo",Bayer,,INTERVENTIONAL,2002-12,2003-09,2003-09,2008-04-28,,2015-03-06
NCT00668031,Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement,https://clinicaltrials.gov/study/NCT00668031,,COMPLETED,NO,"Blood Loss, Surgical","DRUG: Trasylol (Aprotinin, BAYA0128)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-02,2006-01,2006-01,2008-04-28,,2014-12-30
NCT00668044,Ciprofloxacin on Burned Patients,https://clinicaltrials.gov/study/NCT00668044,,COMPLETED,NO,Burns|Bacterial Infections,DRUG: Ciprofloxacin (BAYO9867)|DRUG: Ciprofloxacin (BAYO9867),Bayer,,INTERVENTIONAL,2002-11,2003-11,2003-11,2008-04-28,,2009-10-27
NCT00668018,Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours,https://clinicaltrials.gov/study/NCT00668018,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,INTERVENTIONAL,2003-01,2003-10,2003-10,2008-04-28,,2014-12-23
NCT00668005,Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension,https://clinicaltrials.gov/study/NCT00668005,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2003-02,,2003-09,2008-04-28,,2014-12-16
NCT00667537,PK in Pts With HRPC & Skeletal Metastes,https://clinicaltrials.gov/study/NCT00667537,,COMPLETED,NO,Prostatic Neoplasms,"DRUG: Radium-223 chloride (Xofigo®, BAY88-8223) injection",Bayer,,INTERVENTIONAL,2007-07,2008-12,2008-12,2008-04-28,,2015-12-14
NCT00667199,"BAY88-8223, Does Response Study in HRPC Patients",https://clinicaltrials.gov/study/NCT00667199,,COMPLETED,NO,Hormone Refractory Prostate Cancer|Bone Metastases,DRUG: Radium-223 dichloride (BAY88-8223),Bayer,,INTERVENTIONAL,2005-05-30,2008-04-01,2009-10-06,2008-04-28,,2023-04-19
NCT00666809,Vardenafil in Tinnitus,https://clinicaltrials.gov/study/NCT00666809,,COMPLETED,NO,Tinnitus,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2006-10,,2007-05,2008-04-25,,2014-12-09
NCT00665496,A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00665496,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2003-06,,2003-11,2008-04-24,,2014-12-17
NCT00664326,A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC,https://clinicaltrials.gov/study/NCT00664326,,COMPLETED,YES,"Carcinoma, Renal Cell","DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,INTERVENTIONAL,2008-04-30,2009-05-31,2019-04-02,2008-04-22,2012-11-28,2021-01-29
NCT00663741,Sorafenib Gastric Cancer Asian Phase I Study,https://clinicaltrials.gov/study/NCT00663741,,COMPLETED,NO,Gastric Cancer,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2008-05,2010-03,2010-04,2008-04-22,,2013-06-11
NCT00661700,"A Double-blind ""Preferred"" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction",https://clinicaltrials.gov/study/NCT00661700,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2003-04,2004-05,2004-05,2008-04-18,,2014-11-18
NCT00661596,"Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction",https://clinicaltrials.gov/study/NCT00661596,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2003-05,2004-01,2004-01,2008-04-18,,2014-12-30
NCT00661375,BAY43-9006 Phase II Study for Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00661375,,COMPLETED,NO,"Carcinoma, Renal Cell","DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,INTERVENTIONAL,2004-11,2006-03,2006-03,2008-04-18,,2014-12-25
NCT00661297,"Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil",https://clinicaltrials.gov/study/NCT00661297,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2003-06,,2004-01,2008-04-18,,2014-12-02
NCT00661219,Depression Related Improvement With Vardenafil for Erectile Response,https://clinicaltrials.gov/study/NCT00661219,DRIVER,COMPLETED,NO,Erectile Dysfunction|Depression,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2002-12,2003-11,2003-11,2008-04-18,,2014-12-23
NCT00661180,Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec,https://clinicaltrials.gov/study/NCT00661180,ORACLE,COMPLETED,NO,Chronic Myelogenous Leukemia,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,INTERVENTIONAL,2004-01,2005-02,2005-02,2008-04-18,,2014-12-23
NCT00661115,To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.,https://clinicaltrials.gov/study/NCT00661115,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2003-05,2004-02,2004-02,2008-04-18,,2014-12-16
NCT00658177,Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00658177,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2003-06,,2004-02,2008-04-14,,2014-12-02
NCT00657839,Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia,https://clinicaltrials.gov/study/NCT00657839,,COMPLETED,NO,Benign Prostatic Hyperplasia,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-10,,2006-06,2008-04-14,,2014-10-28
NCT00657644,Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00657644,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,Amgen,INTERVENTIONAL,2003-08,2004-03,2004-03,2008-04-14,,2014-12-25
NCT00657254,Extension Program for Bay 43-9006,https://clinicaltrials.gov/study/NCT00657254,,COMPLETED,NO,Neoplasm|Metastasis,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,INTERVENTIONAL,2002-12,2005-06,2005-06,2008-04-14,,2014-12-23
NCT00657033,Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00657033,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2003-10,,2004-08,2008-04-14,,2013-10-14
NCT00656981,Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne,https://clinicaltrials.gov/study/NCT00656981,,COMPLETED,NO,Acne Vulgaris,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2003-01,,2004-06,2008-04-14,,2014-12-30
NCT00656188,Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00656188,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2002-10,2003-05,2003-05,2008-04-10,,2013-10-10
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",https://clinicaltrials.gov/study/NCT00655629,,COMPLETED,YES,Erectile Dysfunction,"DRUG: Vardenafil ODT (STAXYN, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline|Schering-Plough,INTERVENTIONAL,2008-04,2009-02,2009-02,2008-04-10,2011-01-21,2014-08-01
NCT00654914,A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00654914,VIS,COMPLETED,NO,Erectile Dysfunction,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,INTERVENTIONAL,2003-05,2004-02,2004-02,2008-04-09,,2014-12-23
NCT00654680,Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury,https://clinicaltrials.gov/study/NCT00654680,,COMPLETED,NO,Erectile Dysfunction,"DRUG: Vardenafil (Levitra, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,INTERVENTIONAL,2002-10,2004-01,2004-01,2008-04-09,,2013-09-30
NCT00653614,Cycle Control and Safety of E2-DRSP,https://clinicaltrials.gov/study/NCT00653614,,COMPLETED,NO,"Contraceptive, Oral, Hormonal",DRUG: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|DRUG: E2/DRSP (BAY 86-4891) dose 2 (80458739)|DRUG: E2/DRSP (BAY 86-4891) dose 3 (80458755)|DRUG: E2/DRSP (BAY 86-4891) dose 4 (80458720)|DRUG: E2/DRSP (BAY 86-4891) dose 5 (80458712)|DRUG: DRSP (ZK 30595) dose 1 (SH T04984F)|DRUG: DRSP (ZK 30595) dose 2 (80458690)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2008-03,2009-06,2009-06,2008-04-07,,2015-04-23
NCT00652418,Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography,https://clinicaltrials.gov/study/NCT00652418,,COMPLETED,NO,Magnetic Resonance Angiography|Peripheral Vascular Diseases|Peripheral Arterial Diseases,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)",Bayer,,INTERVENTIONAL,2004-07,2004-10,2004-10,2008-04-03,,2013-10-14
NCT00652262,BAY38-9456 - Supportive Trial for Spinal Injury,https://clinicaltrials.gov/study/NCT00652262,,COMPLETED,NO,Erectile Dysfunction|Sexual Dysfunction|Spinal Cord Injury,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,INTERVENTIONAL,2004-03,,2004-11,2008-04-03,,2014-12-23
NCT00651599,Treatment of Vasomotor Symptoms in Korean Post Menopausal Women,https://clinicaltrials.gov/study/NCT00651599,,COMPLETED,NO,Vasomotor Symptoms,"DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-07,,2005-05,2008-04-03,,2014-12-31
NCT00651469,Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.,https://clinicaltrials.gov/study/NCT00651469,,COMPLETED,NO,Acne Vulgaris,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2003-01,,2004-07,2008-04-02,,2014-12-30
NCT00645788,Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis,https://clinicaltrials.gov/study/NCT00645788,,COMPLETED,YES,Cystic Fibrosis,"DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Placebo|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Placebo",Bayer,Novartis,INTERVENTIONAL,2008-05,2011-01,2011-01,2008-03-28,2012-07-03,2014-06-09
NCT00640315,Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.,https://clinicaltrials.gov/study/NCT00640315,,COMPLETED,YES,"Hypertension, Pulmonary|Pulmonary Disease, Chronic Obstructive","DRUG: Riociguat (Adempas, BAY63-2521) 1.0 mg|DRUG: Riociguat (Adempas, BAY63-2521) 2.5 mg",Bayer,,INTERVENTIONAL,2008-08,2009-09,2009-09,2008-03-21,2014-02-28,2016-12-28
NCT00637377,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD),https://clinicaltrials.gov/study/NCT00637377,VIEW 2,COMPLETED,YES,Macular Degeneration,"DRUG: Ranibizumab|BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)",Bayer,Regeneron Pharmaceuticals,INTERVENTIONAL,2008-04,2010-09,2011-08,2008-03-18,2012-01-23,2014-12-12
NCT00631969,Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00631969,,COMPLETED,YES,Erectile Dysfunction,"DRUG: Vardenafil ODT (STAXYN, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline|Schering-Plough,INTERVENTIONAL,2008-04,2009-01,2009-01,2008-03-10,2011-01-21,2014-12-30
NCT00631124,"A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles",https://clinicaltrials.gov/study/NCT00631124,,COMPLETED,NO,Contraception,DRUG: BAY86-4891 (Estradiol / Drospirenone)|DRUG: BAY86-4891 (Estradiol / Drospirenone),Bayer,,INTERVENTIONAL,2008-02,2008-10,2008-12,2008-03-07,,2014-12-02
NCT00629837,Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980,https://clinicaltrials.gov/study/NCT00629837,,COMPLETED,NO,Hemophilia A,"BIOLOGICAL: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|BIOLOGICAL: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,,INTERVENTIONAL,2005-09,,2006-03,2008-03-06,,2014-11-18
NCT00625378,Sorafenib Long Term Extension Program,https://clinicaltrials.gov/study/NCT00625378,STEP,COMPLETED,YES,Neoplasms,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,ICON Clinical Research,INTERVENTIONAL,2007-12-21,2021-09-24,2021-09-24,2008-02-28,2022-09-01,2022-09-01
NCT00624130,Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers,https://clinicaltrials.gov/study/NCT00624130,,COMPLETED,NO,Contraception,DRUG: Yasmin 20|DRUG: Mercilon,Bayer,,INTERVENTIONAL,2004-03,,2005-06,2008-02-26,,2014-12-31
NCT00623480,Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment,https://clinicaltrials.gov/study/NCT00623480,SPINART,COMPLETED,YES,Hemophilia A,"BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,,INTERVENTIONAL,2008-03,2011-09,2013-11,2008-02-26,2013-08-07,2014-11-17
NCT00623467,Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging,https://clinicaltrials.gov/study/NCT00623467,,COMPLETED,YES,Central Nervous System Diseases,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2007-12,2008-12,2008-12,2008-02-26,2011-10-06,2014-02-10
NCT00618982,Sorafenib Dose Escalation in Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00618982,,COMPLETED,YES,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2008-02,2009-04,2011-01,2008-02-20,2010-05-27,2015-12-24
NCT00610194,Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients,https://clinicaltrials.gov/study/NCT00610194,,COMPLETED,NO,Advanced Cancer,DRUG: RDEA119,Bayer,,INTERVENTIONAL,2007-11-28,2010-11-24,2012-08-01,2008-02-07,,2023-10-18
NCT00606125,Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT00606125,,COMPLETED,NO,Neoplasms,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,INTERVENTIONAL,2007-05,2008-07,2009-02,2008-02-01,,2014-06-23
NCT00606060,BAY14-2222 Continuous Infusion in Surgeries,https://clinicaltrials.gov/study/NCT00606060,,COMPLETED,NO,Hemophilia,DRUG: Kogenate (BAY14-2222),Bayer,,INTERVENTIONAL,2004-07,,2005-05,2008-02-01,,2010-04-13
NCT00586495,Long-term Extension From RCC Phase II (11515),https://clinicaltrials.gov/study/NCT00586495,,COMPLETED,YES,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2005-12,2008-06,2008-07,2008-01-04,2010-02-02,2013-12-13
NCT00586105,Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC),https://clinicaltrials.gov/study/NCT00586105,,COMPLETED,YES,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2005-12,2008-05,2008-05,2008-01-04,2010-10-01,2014-04-16
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,https://clinicaltrials.gov/study/NCT00571649,MAGELLAN,COMPLETED,YES,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin|DRUG: Rivaroxaban placebo|DRUG: Enoxaparin placebo",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2007-12,2010-08,2010-11,2007-12-12,2012-06-27,2016-09-15
NCT00569244,SH T00186 in the Treatment of Primary Dysmenorrhea,https://clinicaltrials.gov/study/NCT00569244,,COMPLETED,NO,Primary Dysmenorrhea,DRUG: Drug: YAZ flex (SH T00186D)|DRUG: YAZ (SH T00186D),Bayer,,INTERVENTIONAL,2007-12,2009-12,2009-12,2007-12-07,,2014-10-29
NCT00568945,Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.,https://clinicaltrials.gov/study/NCT00568945,,COMPLETED,NO,Atrial Fibrillation,DRUG: Capadenoson (BAY68-4986),Bayer,,INTERVENTIONAL,2008-01,2008-11,2008-12,2007-12-06,,2014-10-29
NCT00567164,Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ,https://clinicaltrials.gov/study/NCT00567164,,COMPLETED,YES,"Contraception|Ovulation Inhibition|Contraceptives, Oral","DRUG: EE20/DRSP (BAY86-5300)|DRUG: EE20/DRSP (BAY86-5300)|DRUG: EE20/DRSP (YAZ, BAY86-5300)",Bayer,,INTERVENTIONAL,2007-10,2009-11,2009-11,2007-12-04,2014-03-12,2014-03-12
NCT00566384,Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido,https://clinicaltrials.gov/study/NCT00566384,,COMPLETED,NO,Libido,"DRUG: Dehydroepiandrosterone, BAY86-5314|DRUG: Placebo",Bayer,,INTERVENTIONAL,2007-11,2009-04,2009-04,2007-12-03,,2014-12-02
NCT00565565,Single Dose Escalation Study in Patients With Chronic Heart Failure,https://clinicaltrials.gov/study/NCT00565565,,COMPLETED,NO,Heart Failure,DRUG: BAY60-4552,Bayer,,INTERVENTIONAL,2007-10,2008-12,2009-04,2007-11-30,,2016-08-10
NCT00562913,Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin,https://clinicaltrials.gov/study/NCT00562913,,COMPLETED,NO,Cancer,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,INTERVENTIONAL,2007-12,2009-06,2010-03,2007-11-26,,2013-11-26
NCT00562523,Sorafenib/Docetaxel Dose Escalation Trial,https://clinicaltrials.gov/study/NCT00562523,,COMPLETED,NO,Neoplasms,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,Amgen,INTERVENTIONAL,2007-11,2009-03,2009-03,2007-11-22,,2013-05-23
NCT00555919,ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00555919,,COMPLETED,NO,Metastatic Breast Cancer,"DRUG: Lonaprisan (ZK 230211, BAY86-5044)|DRUG: Lonaprisan (ZK 230211, BAY86-5044)",Bayer,,INTERVENTIONAL,2008-03,2010-04,2011-03,2007-11-09,,2014-10-10
NCT00537836,ZK283197 for Treatment of Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT00537836,,COMPLETED,NO,Vasomotor System,DRUG: BAY 86-5310 (ZK 283197)|DRUG: Placebo|DRUG: 17ß-estradiol,Bayer,,INTERVENTIONAL,2007-10,2008-12,2008-12,2007-10-01,,2015-04-09
NCT00528112,Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study,https://clinicaltrials.gov/study/NCT00528112,,COMPLETED,YES,Contraception,DRUG: LCS12|DRUG: LCS16,Bayer,,INTERVENTIONAL,2007-08,2011-07,2013-06,2007-09-12,2012-09-24,2017-01-25
NCT00526188,Efficacy and Safety of Primovist in Chinese Patients,https://clinicaltrials.gov/study/NCT00526188,,COMPLETED,YES,Known or Suspected Focal Liver Lesions,"DRUG: Gadoxetic Acid Disodium (Primovist, BAY86-4873)",Bayer,,INTERVENTIONAL,2007-08,2008-08,2008-08,2007-09-10,2009-12-30,2015-05-01
NCT00522951,SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study,https://clinicaltrials.gov/study/NCT00522951,,COMPLETED,YES,Brain Metastases,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: ProHance",Bayer,,INTERVENTIONAL,2007-08,2008-08,2008-08,2007-08-30,2011-08-03,2017-08-28
NCT00522873,Endometrial Safety Study,https://clinicaltrials.gov/study/NCT00522873,,COMPLETED,YES,Postmenopause,DRUG: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|DRUG: 0.5mg NETA / 1.0mg E2 (Activella),Bayer,"Laboratorium für Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco",INTERVENTIONAL,2007-08,2009-08,2009-08,2007-08-30,2012-06-28,2014-12-31
NCT00511797,SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study,https://clinicaltrials.gov/study/NCT00511797,,COMPLETED,YES,Dysmenorrhea,DRUG: SH T04740B|DRUG: SH T00186DF|DRUG: SH T04740F|DRUG: Placebo,Bayer,,INTERVENTIONAL,2007-07,2009-01,2009-01,2007-08-06,2010-10-04,2017-01-26
NCT00501059,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,https://clinicaltrials.gov/study/NCT00501059,ARRIVE,COMPLETED,YES,Moderate Risk of CVD,"DRUG: Aspirin (Acetylsalicylic acid, BAYE4465)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2007-07-05,2016-11-15,2016-11-15,2007-07-13,2018-01-08,2018-10-26
NCT00494871,Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation,https://clinicaltrials.gov/study/NCT00494871,,COMPLETED,YES,Atrial Fibrillation,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Warfarin|DRUG: Rivaroxaban placebo|DRUG: Warfarin placebo",Bayer,"Janssen R&D, L.L.C.",INTERVENTIONAL,2007-06,2009-12,2010-01,2007-07-02,2012-04-19,2015-04-20
NCT00494299,Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE),https://clinicaltrials.gov/study/NCT00494299,,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2006-04,2009-07,2010-11,2007-06-29,2011-01-20,2013-12-20
NCT00492986,"An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma",https://clinicaltrials.gov/study/NCT00492986,,COMPLETED,NO,"Carcinoma, Renal Cell","DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,INTERVENTIONAL,2005-10,2008-11,2008-11,2007-06-27,,2014-12-30
NCT00492752,"A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",https://clinicaltrials.gov/study/NCT00492752,,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-10,2007-03,2009-07,2007-06-27,2011-01-13,2014-04-16
NCT00492726,Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem,https://clinicaltrials.gov/study/NCT00492726,,COMPLETED,YES,Infection,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Ertapenem intravenous",Bayer,,INTERVENTIONAL,2006-07,2009-02,2009-02,2007-06-27,2010-03-03,2014-11-07
NCT00492635,Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED,https://clinicaltrials.gov/study/NCT00492635,,COMPLETED,NO,"Erectile Dysfunction|Sexual Dysfunction, Physiological","DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-12,2007-09,2007-09,2007-06-27,,2014-10-28
NCT00492297,"A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma",https://clinicaltrials.gov/study/NCT00492297,,COMPLETED,YES,Melanoma,"DRUG: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)",Bayer,,INTERVENTIONAL,2005-04,2008-06,2008-07,2007-06-27,2011-01-25,2014-10-31
NCT00492024,BAY12-8039: 5 Days for Sinusitis vs Placebo,https://clinicaltrials.gov/study/NCT00492024,,COMPLETED,YES,Sinusitis,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-01,2008-03,2008-03,2007-06-27,2009-12-02,2013-11-26
NCT00478881,A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function,https://clinicaltrials.gov/study/NCT00478881,,COMPLETED,YES,Overactive Bladder|Detrusor Overactivity,"DRUG: Vardenafil HCl (Levitra, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2007-08,2008-11,2008-11,2007-05-25,2009-12-24,2014-12-11
NCT00473460,Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis,https://clinicaltrials.gov/study/NCT00473460,,COMPLETED,NO,"Lung Diseases|Bronchitis, Chronic","DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-10,2007-01,2007-01,2007-05-15,,2014-10-28
NCT00471991,Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition,https://clinicaltrials.gov/study/NCT00471991,,COMPLETED,NO,Oral Contraceptive,DRUG: SH T04769G|DRUG: Ethinyl estradiol / dienogest (SH D00659 AF),Bayer,,INTERVENTIONAL,2007-04,2007-12,2007-12,2007-05-10,,2013-01-25
NCT00468819,A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children,https://clinicaltrials.gov/study/NCT00468819,,COMPLETED,YES,Magnetic Resonance Imaging,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,INTERVENTIONAL,2007-05,2008-04,2008-04,2007-05-03,2011-09-05,2015-07-22
NCT00468481,Efficacy and Safety Study for an Oral Contraceptive Containing Folate,https://clinicaltrials.gov/study/NCT00468481,,COMPLETED,YES,Neural Tube Defects|Contraception|Oral Contraceptives (OC),DRUG: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|DRUG: Drospirenone/Ethinylestradiol (Yaz),Bayer,,INTERVENTIONAL,2007-04,2008-08,2008-09,2007-05-02,2011-01-25,2014-04-23
NCT00463450,Efficacy of Gynodian® Depot in Women With Impaired Well-being,https://clinicaltrials.gov/study/NCT00463450,,COMPLETED,NO,Hormone Replacement Therapy,DRUG: Gynodian® Depot (BAY86-5032)|DRUG: BAY86-4980,Bayer,Navitas Life Sciences GmbH|LKF Laboratory,INTERVENTIONAL,2002-05,,2004-04,2007-04-20,,2014-12-30
NCT00461305,Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea,https://clinicaltrials.gov/study/NCT00461305,,COMPLETED,YES,Dysmenorrhea,DRUG: DRSP 3 mg/EE 20 µg (13 cycles)|DRUG: DRSP 3 mg/EE 30 µg (6 cycles),Bayer,,INTERVENTIONAL,2007-02,2009-01,2009-08,2007-04-18,2010-10-01,2013-01-24
NCT00461123,Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy,https://clinicaltrials.gov/study/NCT00461123,,COMPLETED,YES,"Prostatic Hypertrophy, Benign","DRUG: Vardenafil (Levitra, BAY38-9456)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2007-03,2008-06,2008-06,2007-04-17,2010-01-21,2014-12-19
NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,https://clinicaltrials.gov/study/NCT00459667,Beyond,COMPLETED,YES,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,INTERVENTIONAL,2007-05,2008-03,2008-03,2007-04-12,2009-08-17,2015-04-23
NCT00459654,A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer,https://clinicaltrials.gov/study/NCT00459654,,COMPLETED,NO,Prostate Cancer|Neoplasm Metastasis,DRUG: Radium-223 dichloride (BAY88-8223)|DRUG: Saline,Bayer,,INTERVENTIONAL,2004-02,2006-05,2007-05,2007-04-12,,2014-06-25
NCT00454558,An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension,https://clinicaltrials.gov/study/NCT00454558,,COMPLETED,NO,"Hypertension, Pulmonary","DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,INTERVENTIONAL,2007-01,2014-07,2014-09,2007-03-30,,2015-10-16
NCT00453349,A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease,https://clinicaltrials.gov/study/NCT00453349,,COMPLETED,YES,Pelvic Inflammatory Disease,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Levofloxacin & Metronidazole",Bayer,,INTERVENTIONAL,2007-01,2008-05,2008-05,2007-03-28,2009-11-30,2014-09-08
NCT00449033,"A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00449033,NEXUS,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Cisplatin",Bayer,,INTERVENTIONAL,2007-02,2010-04,2011-06,2007-03-19,2011-09-09,2015-04-23
NCT00446199,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT00446199,,COMPLETED,YES,Vasomotor Symptoms|Hot Flashes,DRUG: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)|DRUG: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|DRUG: Estradiol (E2 0.3mg)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2007-03,2008-10,2008-11,2007-03-12,2012-04-18,2015-05-06
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,https://clinicaltrials.gov/study/NCT00440193,,COMPLETED,YES,Venous Thrombosis,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin followed by VKA",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2007-03,2010-04,2010-04,2007-02-26,2013-01-24,2014-02-27
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,https://clinicaltrials.gov/study/NCT00439777,,COMPLETED,YES,Pulmonary Embolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin overlapping with and followed by VKA",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2007-03,2011-09,2011-12,2007-02-26,2013-01-24,2014-02-27
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,https://clinicaltrials.gov/study/NCT00439725,,COMPLETED,YES,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Placebo",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2007-02,2009-08,2009-09,2007-02-26,2012-04-12,2014-11-04
NCT00432302,Investigation of Mass Balance of the Test Drug and Major Metabolites,https://clinicaltrials.gov/study/NCT00432302,,COMPLETED,NO,Neoplasms,"DRUG: Sagopilone (BAY 86-5302, ZK 219477)",Bayer,,INTERVENTIONAL,2007-01,2007-11,2007-11,2007-02-07,,2015-12-14
NCT00431678,"Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia",https://clinicaltrials.gov/study/NCT00431678,,COMPLETED,NO,Pneumonia,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Levofloxacin + Ceftriaxone",Bayer,,INTERVENTIONAL,2004-01,2005-07,2005-07,2007-02-06,,2014-12-17
NCT00420342,Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension,https://clinicaltrials.gov/study/NCT00420342,,COMPLETED,YES,Postmenopause|Hypertension|Pre-Hypertension,"DRUG: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|DRUG: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|DRUG: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)",Bayer,,INTERVENTIONAL,2007-01,2008-09,2008-09,2007-01-11,2010-01-20,2015-06-02
NCT00414687,"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension",https://clinicaltrials.gov/study/NCT00414687,,COMPLETED,NO,"Hypertension, Pulmonary","DRUG: Ventavis (Iloprost, BAYQ6256)",Bayer,,INTERVENTIONAL,1998-07,,2001-05,2006-12-21,,2009-05-15
NCT00402727,Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection,https://clinicaltrials.gov/study/NCT00402727,,COMPLETED,YES,Abscess|Wound Infection|Diabetic Foot|Ulcer,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid",Bayer,,INTERVENTIONAL,2006-09,2008-06,2008-06,2006-11-22,2010-01-11,2014-11-07
NCT00402467,"An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study",https://clinicaltrials.gov/study/NCT00402467,,COMPLETED,NO,Venous Thromboembolism,"DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban, (BAY59-7939)|DRUG: Rivaroxaban, (BAY59-7939)|DRUG: Rivaroxaban, (BAY59-7939)|DRUG: Enoxaparine|DRUG: Enoxaparine",Bayer,,INTERVENTIONAL,2004-02,2004-11,2004-11,2006-11-22,,2014-12-23
NCT00398905,Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement,https://clinicaltrials.gov/study/NCT00398905,ODIXa-HIP2,COMPLETED,NO,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin",Bayer,,INTERVENTIONAL,2004-01,,2004-09,2006-11-14,,2009-05-08
NCT00396786,Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement,https://clinicaltrials.gov/study/NCT00396786,ODIXaHIP-OD,COMPLETED,NO,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin",Bayer,,INTERVENTIONAL,2004-11,2005-07,2005-07,2006-11-07,,2014-10-28
NCT00395772,Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis,https://clinicaltrials.gov/study/NCT00395772,,COMPLETED,NO,Venous Thromboembolism,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: (LMW) Heparin + Vitamin K Antagonist",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INTERVENTIONAL,2004-12,,2005-12,2006-11-03,,2014-10-28
NCT00395733,Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients,https://clinicaltrials.gov/study/NCT00395733,,COMPLETED,YES,Vascular Diseases,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadopentate dimeglumine (Magnevist, BAY86-4882)",Bayer,,INTERVENTIONAL,2006-10,2007-10,2007-10,2006-11-03,2011-08-03,2013-12-18
NCT00395460,Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients,https://clinicaltrials.gov/study/NCT00395460,,COMPLETED,YES,Central Nervous System Diseases,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Magnevist",Bayer,,INTERVENTIONAL,2006-09,2007-04,2007-04,2006-11-03,2011-11-01,2015-06-08
NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",https://clinicaltrials.gov/study/NCT00370071,,COMPLETED,YES,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,INTERVENTIONAL,2006-11,2008-09,2008-09,2006-08-30,2010-02-10,2015-10-29
NCT00367276,Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.,https://clinicaltrials.gov/study/NCT00367276,,COMPLETED,NO,Healthy,"DRUG: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)",Bayer,,INTERVENTIONAL,2002-12,,2004-05,2006-08-22,,2013-10-11
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,https://clinicaltrials.gov/study/NCT00362232,RECORD 4,COMPLETED,YES,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin|DRUG: Placebo: tablet of Rivaroxaban|DRUG: Placebo: syringes of Enoxaparin",Bayer,,INTERVENTIONAL,2006-06,2007-01,2008-01,2006-08-09,2012-06-13,2014-11-04
NCT00361894,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.,https://clinicaltrials.gov/study/NCT00361894,RECORD 3,COMPLETED,NO,Prevention|Venous Thromboembolism,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,INTERVENTIONAL,2006-02,2007-01,2007-01,2006-08-09,,2014-10-27
NCT00360490,Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS),https://clinicaltrials.gov/study/NCT00360490,,COMPLETED,YES,Menorrhagia,"DRUG: Levonorgestrel IUS (Mirena, BAY86-5028)|DRUG: Medroxyprogesterone acetate",Bayer,,INTERVENTIONAL,2006-07,2008-06,2008-06,2006-08-04,2009-11-19,2013-12-09
NCT00359359,A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00359359,,COMPLETED,NO,"Carcinoma, Small Cell","DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Cisplatin",Bayer,,INTERVENTIONAL,2006-07,2009-03,2009-08,2006-08-02,,2014-11-04
NCT00356447,Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.,https://clinicaltrials.gov/study/NCT00356447,,COMPLETED,NO,Vasomotor Symptoms,"DRUG: Estradiol/DRSP (Angeliq, BAY86-4891)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2006-05,2007-10,2007-10,2006-07-26,,2014-10-01
NCT00350051,ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer,https://clinicaltrials.gov/study/NCT00350051,,COMPLETED,NO,Prostate Cancer,DRUG: Sagopilone (ZK 219477) + prednisone,Bayer,,INTERVENTIONAL,2006-08-01,2008-09-24,2009-12-21,2006-07-10,,2021-04-08
NCT00337155,"BAY88-8223, Dose Finding Study in Patients With HRPC",https://clinicaltrials.gov/study/NCT00337155,,COMPLETED,NO,Prostate Cancer|Neoplasm Metastasis,DRUG: Radium-223 dichloride (BAY88-8223),Bayer,,INTERVENTIONAL,2006-05,2008-12,2009-12,2006-06-15,,2023-11-02
NCT00332020,"Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",https://clinicaltrials.gov/study/NCT00332020,RECORD 2,COMPLETED,NO,Prevention|Venous Thromboembolism,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,INTERVENTIONAL,2006-02,2007-05,2007-06,2006-05-31,,2015-01-27
NCT00329628,Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin,https://clinicaltrials.gov/study/NCT00329628,,COMPLETED,NO,Venous Thromboembolism,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,INTERVENTIONAL,2006-02,2007-03,2007-03,2006-05-25,,2014-10-28
NCT00325351,ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer,https://clinicaltrials.gov/study/NCT00325351,,COMPLETED,NO,Ovarian Neoplasms,DRUG: Sagopilone (ZK 219477) + carboplatin,Bayer,,INTERVENTIONAL,2006-08-24,2008-07-08,2009-03-25,2006-05-12,,2021-04-08
NCT00318799,Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters,https://clinicaltrials.gov/study/NCT00318799,,COMPLETED,NO,"Pregnancy, Unplanned","DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|DRUG: SH D01155E",Bayer,,INTERVENTIONAL,2006-04,2007-05,2007-05,2006-04-27,,2013-11-25
NCT00313248,Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer,https://clinicaltrials.gov/study/NCT00313248,,COMPLETED,NO,Breast Neoplasm,DRUG: Sagopilone (ZK 219477)|DRUG: Sagopilone (ZK 219477),Bayer,,INTERVENTIONAL,2006-04,2008-10,2008-11,2006-04-12,,2015-12-10
NCT00310609,Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches,https://clinicaltrials.gov/study/NCT00310609,,COMPLETED,NO,Cardiovascular Abnormalities,DRUG: Gadopentetate dimeglumine (Magnevist),Bayer,,INTERVENTIONAL,2003-12,,2004-10,2006-04-04,,2014-12-30
NCT00310596,Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects,https://clinicaltrials.gov/study/NCT00310596,,COMPLETED,NO,Healthy,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Moxifloxacin (BAY12-8039)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-01,,2004-03,2006-04-04,,2014-12-30
NCT00310557,Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries,https://clinicaltrials.gov/study/NCT00310557,,COMPLETED,NO,Renal Artery Stenosis,DRUG: Gadopentetate dimeglumine (Magnevist),Bayer,,INTERVENTIONAL,2003-12,,2004-12,2006-04-04,,2014-12-30
NCT00310544,Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction,https://clinicaltrials.gov/study/NCT00310544,,COMPLETED,NO,Myocardial Infarction,"DRUG: Magnevist (Gadopentetate dimeglumine, BAY86-4882)|DRUG: Magnevist (Gadopentetate dimeglumine, BAY86-4882)",Bayer,,INTERVENTIONAL,2006-03,,2006-09,2006-04-04,,2014-12-15
NCT00310531,3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women,https://clinicaltrials.gov/study/NCT00310531,,COMPLETED,NO,Osteopenia,"DRUG: Menostar (Estradiol, BAY86-5435)|DRUG: Raloxifene",Bayer,,INTERVENTIONAL,2004-02,,2007-06,2006-04-04,,2014-12-30
NCT00309075,Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries,https://clinicaltrials.gov/study/NCT00309075,,COMPLETED,NO,Stenosis,DRUG: Gadopentetate dimeglumine (Magnevist),Bayer,,INTERVENTIONAL,2003-12,,2004-11,2006-03-31,,2014-12-30
NCT00307866,Identification of Hepatic Lesions,https://clinicaltrials.gov/study/NCT00307866,,COMPLETED,NO,Hepatic Neoplasms,"PROCEDURE: Resovist (BAY86-4884, SH U 555 A)",Bayer,,INTERVENTIONAL,2001-04,,2003-05,2006-03-28,,2009-05-18
NCT00307801,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,https://clinicaltrials.gov/study/NCT00307801,,COMPLETED,YES,Metrorrhagia,"DRUG: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2006-02,2008-05,2008-05,2006-03-28,2011-07-29,2014-12-30
NCT00302666,Bleeding Pattern Study,https://clinicaltrials.gov/study/NCT00302666,,COMPLETED,NO,Oral Contraceptive,"DRUG: Valette (Dienogest/EE30, BAY86-5038)|DRUG: Valette (Dienogest/EE30, BAY86-5038)",Bayer,,INTERVENTIONAL,2003-06,,2005-02,2006-03-14,,2009-05-18
NCT00296855,Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease,https://clinicaltrials.gov/study/NCT00296855,,COMPLETED,NO,Peripheral Vascular Diseases,"DRUG: Vasovist (BAY86-5283, MS-325)",Bayer,,INTERVENTIONAL,2006-02,,2007-02,2006-02-27,,2010-04-23
NCT00293059,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,https://clinicaltrials.gov/study/NCT00293059,,COMPLETED,YES,Metrorrhagia,"DRUG: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-12,2008-05,2008-05,2006-02-17,2011-06-06,2013-11-27
NCT00288691,Menorrhagia Study in Women With Treatment-resistant Menorrhagia,https://clinicaltrials.gov/study/NCT00288691,,COMPLETED,NO,Menorrhagia,DRUG: Asoprisnil (BAY86-5294)|DRUG: Asoprisnil (BAY86-5294)|DRUG: Asoprisnil (BAY86-5294)|DRUG: Placebo,Bayer,TAP Pharmaceutical Products Inc.,INTERVENTIONAL,2001-11,,2004-01,2006-02-08,,2014-12-30
NCT00288249,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00288249,,COMPLETED,NO,"Breast Neoplasms|Breast Cancer, Metastatic","DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)",Bayer,,INTERVENTIONAL,2005-12,2008-03,2009-01,2006-02-07,,2014-12-02
NCT00280657,Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa,https://clinicaltrials.gov/study/NCT00280657,,COMPLETED,NO,Acne Vulgaris,DRUG: Valette|DRUG: Diane|DRUG: Placebo,Bayer,,INTERVENTIONAL,2004-03-10,2005-05-21,2005-05-21,2006-01-23,,2023-06-06
NCT00266032,Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles,https://clinicaltrials.gov/study/NCT00266032,,COMPLETED,YES,Contraception,"DRUG: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|DRUG: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|DRUG: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)",Bayer,,INTERVENTIONAL,2005-12,2008-10,2008-10,2005-12-15,2010-03-03,2014-11-02
NCT00259129,Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients,https://clinicaltrials.gov/study/NCT00259129,,COMPLETED,NO,Neoplasms,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2005-08,2007-02,2008-03,2005-11-29,,2014-11-13
NCT00246688,Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer,https://clinicaltrials.gov/study/NCT00246688,,COMPLETED,NO,Ovarian Neoplasms,"DRUG: Sagopilone (BAY86-5302 , ZK219477)",Bayer,,INTERVENTIONAL,2005-11,2007-06,2007-06,2005-10-30,,2015-12-31
NCT00244140,Ultravist: Safety and Efficacy in Computed Tomography of Head and Body,https://clinicaltrials.gov/study/NCT00244140,,COMPLETED,YES,Computed Tomography|Diagnostic Imaging,DRUG: Iopromide 370 mg I/mL|DRUG: Iopromide 300 mg I/mL,Bayer,,INTERVENTIONAL,2005-10,2008-04,2008-04,2005-10-26,2009-07-20,2014-02-28
NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00235989,,COMPLETED,YES,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)",Bayer,,INTERVENTIONAL,2003-06,2008-01,2008-01,2005-10-12,2009-07-03,2014-05-08
NCT00225199,Efficacy and Safety of SH T00660AA in Treatment of Endometriosis,https://clinicaltrials.gov/study/NCT00225199,,COMPLETED,NO,Endometriosis,"DRUG: Visanne (BAY86-5258, SH T00660AA)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-03,,2006-09,2005-09-23,,2010-04-23
NCT00225186,Safety and Efficacy of SH T00660AA in Treatment of Endometriosis,https://clinicaltrials.gov/study/NCT00225186,,COMPLETED,NO,Endometriosis,"DRUG: Visanne (SH T00660AA , BAY86-5258)",Bayer,,INTERVENTIONAL,2004-07,2008-03,2008-03,2005-09-23,,2014-01-09
NCT00220324,Pearl Index Study With Low Dose Combined Oral Contraceptive,https://clinicaltrials.gov/study/NCT00220324,,COMPLETED,NO,Contraception,DRUG: Minisiston (SH D00342A),Bayer,,INTERVENTIONAL,2004-02,,2005-11,2005-09-22,,2015-04-03
NCT00220298,Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism,https://clinicaltrials.gov/study/NCT00220298,,COMPLETED,NO,Hypogonadism,DRUG: Testosterone undecanoate (TU) - NebidoTM,Bayer,,INTERVENTIONAL,2003-02,2007-10,2007-10,2005-09-22,,2014-12-30
NCT00220285,Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00220285,,COMPLETED,NO,"Non-Hodgkin's Lymphoma|Lymphoma, B-Cell|Lymphoma, Low-Grade","DRUG: Zevalin (SH L 749 , BAY86-5128)|DRUG: Zevalin (SH L 749 , BAY86-5128)",Bayer,,INTERVENTIONAL,2004-08,,2005-10,2005-09-22,,2014-12-30
NCT00206583,Efficacy and Safety Study of an Oral Contraceptive in Healthy Females,https://clinicaltrials.gov/study/NCT00206583,,COMPLETED,NO,Contraception,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)",Bayer,,INTERVENTIONAL,2005-03,2007-06,2007-07,2005-09-21,,2014-10-01
NCT00185484,Efficacy and Safety Oral Contraceptive Study,https://clinicaltrials.gov/study/NCT00185484,,COMPLETED,NO,Contraception,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)",Bayer,,INTERVENTIONAL,2004-03,,2006-01,2005-09-16,,2014-12-31
NCT00185458,Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).,https://clinicaltrials.gov/study/NCT00185458,,COMPLETED,YES,Menopause,DRUG: LNG IUS,Bayer,,INTERVENTIONAL,2000-05,2008-05,2008-05,2005-09-16,2009-11-19,2013-11-27
NCT00185419,A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception,https://clinicaltrials.gov/study/NCT00185419,,COMPLETED,NO,Contraception,DRUG: Yasmin|DRUG: Marvelon,Bayer,,INTERVENTIONAL,2003-11,2006-03,2006-03,2005-09-16,,2009-01-14
NCT00185393,Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy,https://clinicaltrials.gov/study/NCT00185393,,COMPLETED,NO,"Lymphoma, Non-Hodgkin","BIOLOGICAL: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|OTHER: no treatment",Bayer,,INTERVENTIONAL,2001-08,,2007-02,2005-09-16,,2008-12-01
NCT00185380,Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS),https://clinicaltrials.gov/study/NCT00185380,,COMPLETED,YES,Contraception,"DRUG: Levonorgestrel IUS (BAY86-5028, G04209B)|DRUG: Levonorgestrel IUS (BAY86-5028, G04209C)|DRUG: Levonorgestrel IUS (Mirena, BAY86-5028)",Bayer,,INTERVENTIONAL,2005-04,2008-12,2008-12,2005-09-16,2010-03-10,2015-06-10
NCT00185367,Comparative Cycle Control Europe,https://clinicaltrials.gov/study/NCT00185367,,COMPLETED,NO,Contraception,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|DRUG: SH D 593 B (Miranova)",Bayer,,INTERVENTIONAL,2005-03,,2006-09,2005-09-16,,2011-07-15
NCT00185354,FC Patch Comparator Study,https://clinicaltrials.gov/study/NCT00185354,,COMPLETED,NO,Contraception,"DRUG: BAY86-5016, SH P00331F|DRUG: SH P00331N",Bayer,,INTERVENTIONAL,2004-11,2006-04,2006-04,2005-09-16,,2015-12-31
NCT00185341,Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain,https://clinicaltrials.gov/study/NCT00185341,,COMPLETED,NO,Endometriosis,"DRUG: CCR1-Antagonist (BAY86-5047, ZK811752)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-02,2007-02,2007-02,2005-09-16,,2016-05-02
NCT00185315,Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension,https://clinicaltrials.gov/study/NCT00185315,,COMPLETED,NO,"Hypertension, Pulmonary","DRUG: Ventavis (Iloprost, BAYQ6256)",Bayer,,INTERVENTIONAL,2000-02,,2005-08,2005-09-16,,2010-04-20
NCT00185302,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00185302,,COMPLETED,NO,Melanoma,"DRUG: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|DRUG: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)",Bayer,,INTERVENTIONAL,2004-12,2006-07,2006-07,2005-09-16,,2015-12-14
NCT00185289,Study to Investigate Efficacy and Safety of a New Oral Contraceptive,https://clinicaltrials.gov/study/NCT00185289,,COMPLETED,NO,Contraception,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)",Bayer,,INTERVENTIONAL,2004-04,,2006-07,2005-09-16,,2011-07-15
NCT00185276,Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries,https://clinicaltrials.gov/study/NCT00185276,,COMPLETED,NO,Peripheral Vascular Disease,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)",Bayer,,INTERVENTIONAL,2003-03,,2004-08,2005-09-16,,2014-12-30
NCT00185250,Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy,https://clinicaltrials.gov/study/NCT00185250,,COMPLETED,NO,Cardiomyopathies|Heart Diseases,"DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Placebo|DRUG: Placebo",Bayer,,INTERVENTIONAL,2002-12,,2005-11,2005-09-16,,2008-12-19
NCT00185237,Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch,https://clinicaltrials.gov/study/NCT00185237,,COMPLETED,NO,Hot Flashes,DRUG: Menostar (estradiol transdermal delivery system)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2005-07,2006-11,2006-11,2005-09-16,,2014-12-23
NCT00185224,Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive,https://clinicaltrials.gov/study/NCT00185224,,COMPLETED,NO,Contraception,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|DRUG: SH D00264A (Triquilar)",Bayer,,INTERVENTIONAL,2005-03,,2006-03,2005-09-16,,2011-07-15
NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,https://clinicaltrials.gov/study/NCT00185211,,COMPLETED,YES,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,INTERVENTIONAL,2002-08,2008-05,2008-05,2005-09-16,2010-11-30,2013-12-30
NCT00185198,Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM),https://clinicaltrials.gov/study/NCT00185198,,COMPLETED,NO,Androgens (Deficiency)|Male,"DRUG: Testogel (Testosterone, BAYV001915)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-09,2006-09,2007-10,2005-09-16,,2014-04-02
NCT00160069,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer,https://clinicaltrials.gov/study/NCT00160069,,COMPLETED,NO,"Carcinoma, Non Small Cell Lung","DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)",Bayer,,INTERVENTIONAL,2005-08,2008-04,2009-04,2005-09-12,,2014-12-04
NCT00160043,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00160043,,COMPLETED,NO,Non Small Cell Lung Cancer,DRUG: SH T00268C|DRUG: PTK787/ ZK 222584,Bayer,,INTERVENTIONAL,2005-03,2007-08,2008-11,2005-09-12,,2014-12-16
NCT00119639,Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006,https://clinicaltrials.gov/study/NCT00119639,,COMPLETED,NO,Kidney Diseases,"DRUG: Sorafenib (BAY43-9006, Nexavar)",Bayer,,INTERVENTIONAL,2005-06,,2005-12,2005-07-14,,2009-01-16
NCT00117637,BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00117637,,COMPLETED,YES,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Interferon",Bayer,,INTERVENTIONAL,2005-06,2006-09,2009-03,2005-07-08,2010-12-15,2014-10-31
NCT00111020,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00111020,,COMPLETED,NO,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2005-06,2007-06,2008-10,2005-05-17,,2014-08-06
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00111007,,COMPLETED,YES,Melanoma,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Carboplatin/Paclitaxel|DRUG: Placebo",Bayer,Amgen,INTERVENTIONAL,2005-05,2006-09,2009-01,2005-05-17,2011-02-23,2014-10-31
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00110994,,COMPLETED,YES,Cancer|Melanoma,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Dacarbazine",Bayer,Amgen,INTERVENTIONAL,2005-04,2006-10,2008-03,2005-05-17,2011-06-01,2015-06-08
NCT00108953,A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00108953,,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|DRUG: Doxorubicin/Placebo",Bayer,,INTERVENTIONAL,2005-04,2008-04,2008-04,2005-04-22,2009-06-11,2014-10-31
NCT00105443,A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00105443,SHARP,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2005-03,2008-11,2008-11,2005-03-15,2010-09-27,2014-10-31
NCT00102141,Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women,https://clinicaltrials.gov/study/NCT00102141,,COMPLETED,NO,Hypertension|Postmenopause,"DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Placebo",Bayer,,INTERVENTIONAL,2004-04,,2005-07,2005-01-24,,2014-12-15
NCT00101413,BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC),https://clinicaltrials.gov/study/NCT00101413,,COMPLETED,YES,"Cancer|Carcinoma, Non-Small Cell Lung","DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,Amgen,INTERVENTIONAL,2004-04,2005-06,2008-04,2005-01-11,2010-04-08,2013-10-30
NCT00101400,BAY43-9006 - Phase II in Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT00101400,,COMPLETED,YES,Breast Neoplasms|Breast Cancer,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2004-02,2006-01,2008-01,2005-01-11,2009-06-23,2013-12-13
NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,https://clinicaltrials.gov/study/NCT00099502,,COMPLETED,NO,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Copaxone",Bayer,,INTERVENTIONAL,2003-11,,2007-08,2004-12-16,,2008-12-19
NCT00079612,"Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer",https://clinicaltrials.gov/study/NCT00079612,,COMPLETED,NO,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,Amgen,INTERVENTIONAL,2002-09,,2007-01,2004-03-11,,2014-12-19
NCT00073307,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,https://clinicaltrials.gov/study/NCT00073307,,COMPLETED,YES,"Carcinoma, Renal Cell","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,Amgen,INTERVENTIONAL,2003-11,2006-09,2010-04,2003-11-21,2011-12-14,2014-02-06
NCT00059462,Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection,https://clinicaltrials.gov/study/NCT00059462,,COMPLETED,NO,HIV Infections,DRUG: Interleukin-2 SA|DRUG: HAART,Bayer,,INTERVENTIONAL,2002-12,2005-03,2005-03,2003-06-02,,2014-12-23
NCT00044915,Repinotan in Patients With Acute Ischemic Stroke,https://clinicaltrials.gov/study/NCT00044915,,COMPLETED,NO,Stroke|Acute Ischemic Stroke,DRUG: Repinotan HCl (BAYX3702)|DRUG: Placebo,Bayer,,INTERVENTIONAL,2000-12,,2004-09,2002-09-09,,2009-06-12
NCT00044564,Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00044564,,COMPLETED,NO,"Carcinoma, Renal Cell",DRUG: Bay 59-8862,Bayer,,INTERVENTIONAL,2001-12,,2003-01,2002-09-04,,2014-12-19
NCT00044551,"Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00044551,,COMPLETED,NO,"Lymphoma, Non-Hodgkin","DRUG: Taxane (Cytotoxic, BAY59-8862)",Bayer,,INTERVENTIONAL,2002-02,,2003-07,2002-09-04,,2013-10-14
NCT00044538,Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT00044538,,COMPLETED,NO,"Carcinoma, Non-Small-Cell Lung",DRUG: BAY59-8862 (Cytotoxic Taxane),Bayer,,INTERVENTIONAL,2001-12,,2004-06,2002-09-04,,2009-06-22
NCT00044525,Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients,https://clinicaltrials.gov/study/NCT00044525,,COMPLETED,NO,"Breast Neoplasms|Breast Cancer, Metastatic",DRUG: BAY59-8862 (Cytotoxic Taxane),Bayer,,INTERVENTIONAL,2002-04,2004-02,2004-02,2002-09-04,,2014-12-23
NCT00044512,A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00044512,,COMPLETED,YES,"Carcinoma, Hepatocellular","DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,INTERVENTIONAL,2002-08,2008-02,2008-02,2002-09-04,2009-08-06,2014-04-16
NCT00086775,Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00086775,,COMPLETED,NO,Leukemia,BIOLOGICAL: alemtuzumab|BIOLOGICAL: rituximab|DRUG: fludarabine phosphate,Bayer,,INTERVENTIONAL,2003-07,2005-06,2009-10,2004-07-12,,2013-08-02
NCT00002238,Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen,https://clinicaltrials.gov/study/NCT00002238,,COMPLETED,NO,HIV Infections,DRUG: Interferon beta-1b|DRUG: Zidovudine,Bayer,,INTERVENTIONAL,,,,2001-08-31,,2005-06-24
NCT05527457,BAY2586116 Nasal Spray and OSA Severity,https://clinicaltrials.gov/study/NCT05527457,,COMPLETED,NO,"Sleep Apnea, Obstructive",DRUG: BAY2586116|DRUG: Placebo,Flinders University,Bayer,INTERVENTIONAL,2022-08-31,2022-12-20,2022-12-20,2022-09-02,,2023-02-15
NCT04662684,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,https://clinicaltrials.gov/study/NCT04662684,MICHELLE,COMPLETED,NO,Covid19|Venous Thromboembolism,DRUG: Rivaroxaban 10 MG,Science Valley Research Institute,Bayer,INTERVENTIONAL,2020-10-16,2021-07-10,2021-08-30,2020-12-10,,2022-04-06
NCT04644705,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,https://clinicaltrials.gov/study/NCT04644705,NIC-002,COMPLETED,NO,Healthy Volunteers,DRUG: Niclosamide|DRUG: Placebo,Charité Research Organisation GmbH,Bayer,INTERVENTIONAL,2020-11-02,2021-05-03,2021-05-03,2020-11-25,,2021-11-29
NCT04534218,"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT04534218,REPROGRAM-01,COMPLETED,NO,Colo-rectal Cancer|Metastatic Cancer,DRUG: Regorafenib|DRUG: Cyclophosphamide|DRUG: Capecitabine|DRUG: Aspirin,Centre Hospitalier Universitaire de Besancon,Bayer,INTERVENTIONAL,2020-10-16,2023-12-13,2023-12-13,2020-09-01,,2023-12-22
NCT04429503,Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT04429503,PHOTON,COMPLETED,YES,Diabetic Macular Edema|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,DRUG: aflibercept|DRUG: High-dose aflibercept,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2020-06-29,2022-05-30,2024-06-18,2020-06-12,2023-11-21,2024-07-30
NCT04324463,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,https://clinicaltrials.gov/study/NCT04324463,ACTCOVID19,COMPLETED,NO,Coronavirus|Severe Acute Respiratory Syndrome,DRUG: Colchicine|DRUG: Interferon-Beta|DRUG: Aspirin|DRUG: Rivaroxaban,Population Health Research Institute,Bayer,INTERVENTIONAL,2020-04-21,2022-12-30,2022-12-30,2020-03-27,,2024-01-11
NCT04200404,A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors,https://clinicaltrials.gov/study/NCT04200404,,COMPLETED,NO,Advanced Refractory Solid Tumors,DRUG: CS1001|DRUG: Regorafenib,CStone Pharmaceuticals,Bayer,INTERVENTIONAL,2019-12-13,2021-05-13,2021-08-18,2019-12-16,,2022-05-06
NCT04180436,Pharmacokinetics of Rivaroxaban After Bariatric Surgery,https://clinicaltrials.gov/study/NCT04180436,ABSORB,COMPLETED,NO,Bariatric Surgery|Morbid Obesity,DRUG: rivaroxaban 20 mg once daily 8 days,"University Hospital, Brest",Bayer,INTERVENTIONAL,2020-01-15,2022-06-21,2022-06-27,2019-11-27,,2022-07-21
NCT04126317,"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",https://clinicaltrials.gov/study/NCT04126317,CANDELA,COMPLETED,YES,Neovascular (Wet) Age-Related Macular Degeneration,DRUG: aflibercept|DRUG: High-dose aflibercept,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2019-11-04,2021-05-14,2021-11-30,2019-10-15,2023-08-14,2023-08-14
NCT03877055,A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT03877055,,COMPLETED,YES,Mantle Cell Lymphoma (MCL),DRUG: Copanlisib|DRUG: Ibrutinib,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2019-03-13,2022-10-07,2022-10-07,2019-03-15,2022-12-14,2022-12-14
NCT03796377,Rivaroxaban Hypericum Trial,https://clinicaltrials.gov/study/NCT03796377,,COMPLETED,NO,Drug Interaction Study,DRUG: St Johns Wort Extract|DRUG: Rivaroxaban,"Insel Gruppe AG, University Hospital Bern",Bayer,INTERVENTIONAL,2019-02-13,2019-04-09,2019-04-09,2019-01-08,,2020-11-03
NCT03358030,A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis,https://clinicaltrials.gov/study/NCT03358030,EMERALD,COMPLETED,YES,End-stage Renal Disease (ESRD),DRUG: ISIS 416858|DRUG: Placebo,"Ionis Pharmaceuticals, Inc.",Bayer,INTERVENTIONAL,2017-12-26,2019-07-10,2019-07-10,2017-11-30,2023-01-20,2023-01-20
NCT03304418,Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone,https://clinicaltrials.gov/study/NCT03304418,RROPE,COMPLETED,YES,Prostate Cancer Metastatic to Bone,DRUG: Radium Ra 223 Dichloride|RADIATION: Radiation,University of Utah,Bayer,INTERVENTIONAL,2018-02-27,2022-09-30,2023-08-31,2017-10-09,2024-01-30,2024-02-12
NCT03042689,Study of Regorafenib in Patients With Advanced Myeloid Malignancies,https://clinicaltrials.gov/study/NCT03042689,,COMPLETED,NO,Acute Myeloid Leukemia,DRUG: Regorafenib,Massachusetts General Hospital,Bayer,INTERVENTIONAL,2017-04-17,2021-09-01,2023-02-27,2017-02-03,,2024-03-08
NCT03023722,Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03023722,,COMPLETED,YES,Pancreatic Cancer,DRUG: anetumab ravtansine,Yale University,Bayer,INTERVENTIONAL,2017-05-11,2019-08-06,2019-12-11,2017-01-18,2021-01-22,2021-10-28
NCT03002220,Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status,https://clinicaltrials.gov/study/NCT03002220,,COMPLETED,NO,Prostate Cancer,DRUG: radium-223,MedSIR,Bayer,INTERVENTIONAL,2016-11,2020-05-06,,2016-12-23,,2020-11-27
NCT02915835,Riociguat in Scleroderma Associated Digital Ulcers,https://clinicaltrials.gov/study/NCT02915835,RESCUE,COMPLETED,YES,Scleroderma|Digital Ulcers,DRUG: Riociguat|DRUG: Placebo,"Dinesh Khanna, MD, MS",Bayer,INTERVENTIONAL,2016-09,2018-07-24,2018-07-24,2016-09-27,2019-09-24,2019-09-24
NCT02846532,"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure",https://clinicaltrials.gov/study/NCT02846532,UNIVERSE,COMPLETED,YES,Thrombosis,DRUG: Rivaroxaban|DRUG: Acetylsalicylic Acid,"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2016-11-16,2020-07-16,2020-07-16,2016-07-27,2022-03-28,2022-03-28
NCT02835924,Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC,https://clinicaltrials.gov/study/NCT02835924,RE-ARRANGE,COMPLETED,NO,Metastatic Colorectal Cancer,DRUG: Regorafenib,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),Bayer,INTERVENTIONAL,2016-07,2018-09,2019-09,2016-07-18,,2020-03-10
NCT02746185,"Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban",https://clinicaltrials.gov/study/NCT02746185,CASTA-DIVA,COMPLETED,NO,Neoplasm|Venous Thromboembolism,DRUG: rivaroxaban|DRUG: Low-molecular-weight heparin,Assistance Publique - Hôpitaux de Paris,Bayer,INTERVENTIONAL,2016-09,2018-04-25,2018-04-25,2016-04-21,,2018-08-13
NCT02712008,Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02712008,RUBY,COMPLETED,YES,Diabetic Macular Edema,DRUG: REGN910-3|DRUG: Intravitreal Aflibercept Injection (IAI),Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2016-03-02,2017-07-10,2017-07-10,2016-03-17,2018-10-03,2018-10-03
NCT02661711,Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study,https://clinicaltrials.gov/study/NCT02661711,AMOUR,COMPLETED,YES,Macular Oedema|Retinitis Pigmentosa,DRUG: Aflibercept,Moorfields Eye Hospital NHS Foundation Trust,Bayer,INTERVENTIONAL,2016-03,2017-10,2017-10,2016-01-22,2024-05-06,2024-05-06
NCT02651415,Phase II Study of Perindopril and Regorafenib in mCRC,https://clinicaltrials.gov/study/NCT02651415,PARICCA,COMPLETED,YES,Metastatic Colorectal Cancer,DRUG: Regorafenib|DRUG: Perindopril,British Columbia Cancer Agency,Bayer,INTERVENTIONAL,2016-08,2018-03,2018-11-07,2016-01-11,2019-09-12,2019-09-12
NCT02638766,Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST,https://clinicaltrials.gov/study/NCT02638766,REGISTRI,COMPLETED,NO,Gastrointestinal Stromal Tumors,DRUG: regorafenib,Grupo Espanol de Investigacion en Sarcomas,Bayer,INTERVENTIONAL,2015-11,2021-08-31,2021-08-31,2015-12-23,,2023-03-27
NCT02631590,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,https://clinicaltrials.gov/study/NCT02631590,,COMPLETED,YES,Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor,DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Copanlisib,H. Lee Moffitt Cancer Center and Research Institute,Bayer,INTERVENTIONAL,2016-07-05,2019-10-25,2021-03-05,2015-12-16,2020-11-02,2021-08-04
NCT02584465,REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression,https://clinicaltrials.gov/study/NCT02584465,REGOVAR,COMPLETED,NO,Ovarian Carcinoma,DRUG: Tamoxifen|DRUG: Regorafenib,ARCAGY/ GINECO GROUP,Bayer,INTERVENTIONAL,2015-08-28,2021-09-19,2021-09-19,2015-10-22,,2023-09-06
NCT02561923,A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants,https://clinicaltrials.gov/study/NCT02561923,,COMPLETED,NO,Healthy,"DRUG: Rivaroxaban|DRUG: Tranexamic acid|DRUG: Kcentra, a 4-factor PCC|DRUG: Saline","Janssen Scientific Affairs, LLC",Bayer,INTERVENTIONAL,2015-08-27,2016-06-17,2016-06-17,2015-09-28,,2017-06-14
NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,https://clinicaltrials.gov/study/NCT02555878,,COMPLETED,YES,Neoplasms,DRUG: Rivaroxaban|DRUG: Placebo,"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2015-09-11,2018-08-24,2018-08-24,2015-09-22,2019-09-12,2019-09-12
NCT02553889,"A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis",https://clinicaltrials.gov/study/NCT02553889,,COMPLETED,NO,End-stage Renal Disease (ESRD),DRUG: ISIS 416858|DRUG: Placebo,"Ionis Pharmaceuticals, Inc.",Bayer,INTERVENTIONAL,2015-10,2016-11,2016-11,2015-09-18,,2016-12-13
NCT02466802,Study of Regorafenib and Sildenafil for Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02466802,,COMPLETED,NO,Solid Tumor,DRUG: Regorafenib|DRUG: Sildenafil Citrate,Virginia Commonwealth University,Bayer,INTERVENTIONAL,2015-07-01,2019-01-28,2019-01-28,2015-06-09,,2020-02-20
NCT02466009,Regorafenib in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT02466009,,COMPLETED,YES,Metastatic Colorectal Cancer,DRUG: Regorafenib,University of Rochester,Bayer,INTERVENTIONAL,2015-03,2019-07,2022-03-09,2015-06-09,2021-04-06,2024-09-04
NCT02418650,"Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects",https://clinicaltrials.gov/study/NCT02418650,ARIADME,COMPLETED,NO,Healthy,DRUG: ODM-201 300 mg tablet|DRUG: intravenous14C-ODM-201|DRUG: 300 mg 14C-ODM-201 oral solution,"Orion Corporation, Orion Pharma",Bayer,INTERVENTIONAL,2015-03,2015-05,2015-06,2015-04-16,,2015-06-23
NCT02406521,Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets,https://clinicaltrials.gov/study/NCT02406521,,COMPLETED,NO,Metastatic Renal Cell Carcinoma,DRUG: Pazopanib|DRUG: Sorafenib|DRUG: Radium-223,Dana-Farber Cancer Institute,Bayer,INTERVENTIONAL,2015-04,2017-12,2019-12-31,2015-04-02,,2020-03-04
NCT02403596,Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban,https://clinicaltrials.gov/study/NCT02403596,ESPER,COMPLETED,NO,Blood Loss After a Total Hip Replacement,DRUG: Exacyl®|OTHER: Placebo of Exacyl®,"University Hospital, Brest",Bayer,INTERVENTIONAL,2015-10-20,2017-08-29,2017-08-29,2015-03-31,,2018-01-09
NCT02366130,Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT02366130,,COMPLETED,YES,Breast Cancer,DRUG: Ra-223 dichloride|DRUG: Denosumab|DRUG: Hormone Therapy,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2015-02-11,2020-12-16,2020-12-16,2015-02-19,2021-10-07,2021-10-07
NCT02346526,A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT02346526,,COMPLETED,YES,Prostate Cancer|Castration-resistant Prostate Cancer|Castration-resistant Prostate Cancer Metastatic to Bone,PROCEDURE: Blood Tests|PROCEDURE: CT scan|PROCEDURE: FACBC PET/MRI in a subset of participants|DRUG: Radium-223 dichloride|PROCEDURE: bone scan,Massachusetts General Hospital,Bayer,INTERVENTIONAL,2015-04,2019-10,2020-12,2015-01-27,2022-09-29,2022-09-29
NCT02289703,"A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis",https://clinicaltrials.gov/study/NCT02289703,,COMPLETED,NO,End-Stage Renal Disease,DRUG: Rivaroxaban 15 mg,"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2015-01,2015-03,2015-03,2014-11-13,,2017-01-24
NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,https://clinicaltrials.gov/study/NCT02196857,,COMPLETED,YES,Leukemia,DRUG: Azacytidine|DRUG: Sorafenib,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2015-02-06,2018-11-27,2018-11-27,2014-07-22,2020-01-06,2020-01-14
NCT02157077,Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration,https://clinicaltrials.gov/study/NCT02157077,ARI2,COMPLETED,NO,Macular Degeneration|Wet Macular Degeneration|Retinal Degeneration|Retinal Diseases|Eye Diseases,DRUG: Aflibercept,Centre Hospitalier Intercommunal Creteil,Bayer,INTERVENTIONAL,2013-12,2015-12,2015-12,2014-06-05,,2022-12-06
NCT02123524,Rivaroxaban Anticoagulation for Superficial Vein Thrombosis,https://clinicaltrials.gov/study/NCT02123524,RASET,COMPLETED,NO,Symptomatic Superficial Vein Thrombosis,DRUG: Rivaroxaban|DRUG: Placebo,McMaster University,Bayer,INTERVENTIONAL,2014-11-11,2018-12-03,2018-12-03,2014-04-25,,2018-12-04
NCT02115542,Single Agent Regorafenib in Refractory Advanced Biliary Cancers,https://clinicaltrials.gov/study/NCT02115542,,COMPLETED,YES,Cancer of the Bile Duct,DRUG: Regorafenib,H. Lee Moffitt Cancer Center and Research Institute,Bayer,INTERVENTIONAL,2014-06-05,2018-12-10,2021-09-20,2014-04-16,2020-01-13,2021-10-12
NCT02111564,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,https://clinicaltrials.gov/study/NCT02111564,MARINER,COMPLETED,YES,Heart Failure|Respiratory Insufficiency|Stroke Acute|Infectious Diseases|Rheumatic Diseases,"DRUG: Rivaroxaban, 10 mg|DRUG: Rivaroxaban, 7.5 mg|DRUG: Placebo","Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2014-01-07,2018-03-06,2018-05-03,2014-04-11,2019-11-25,2019-11-25
NCT02098538,"Regorafenib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",https://clinicaltrials.gov/study/NCT02098538,,COMPLETED,NO,Adenoid Cystic Carcinoma,DRUG: Regorafenib,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2014-03,2024-11-07,2024-11-07,2014-03-28,,2024-11-12
NCT02097303,Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis,https://clinicaltrials.gov/study/NCT02097303,eRADicAte,COMPLETED,YES,Prostate Cancer,DRUG: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone,"Carolina Research Professionals, LLC",Bayer,INTERVENTIONAL,2014-03,2015-12,2015-12,2014-03-27,2018-02-01,2018-02-01
NCT02094001,Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH,https://clinicaltrials.gov/study/NCT02094001,,COMPLETED,NO,Chronic Thromboembolic Pulmonary Hypertension,"RADIATION: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)",Ottawa Heart Institute Research Corporation,Bayer,INTERVENTIONAL,2014-05,2016-06,2016-06,2014-03-21,,2018-08-29
NCT02080260,A Study of Regorafenib in Advanced Pancreatic Cancer Patients,https://clinicaltrials.gov/study/NCT02080260,,COMPLETED,YES,Pancreatic Cancer,DRUG: regorafenib,Wake Forest University Health Sciences,Bayer,INTERVENTIONAL,2014-06-06,2017-06-28,2017-06-28,2014-03-06,2019-07-19,2022-04-21
NCT02053376,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,https://clinicaltrials.gov/study/NCT02053376,,COMPLETED,YES,Metastatic Biliary Tract Carcinoma,DRUG: Regorafenib,"Nathan Bahary, MD",Bayer,INTERVENTIONAL,2014-01,2018-01-07,2018-05-14,2014-02-03,2019-01-30,2019-01-30
NCT02042534,Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation,https://clinicaltrials.gov/study/NCT02042534,TripleAXEL,COMPLETED,YES,Ischemic Stroke|Transient Ischemic Attack,DRUG: Rivaroxaban|DRUG: Warfarin,Asan Medical Center,Bayer,INTERVENTIONAL,2014-01,2015-12,2015-12,2014-01-23,2017-02-08,2017-02-08
NCT01919294,Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS),https://clinicaltrials.gov/study/NCT01919294,TEREPINS,COMPLETED,NO,Nonalcoholic Steatohepatitis|Hypogonadism,DRUG: testosterone undecanoate,Sheffield Teaching Hospitals NHS Foundation Trust,Bayer,INTERVENTIONAL,2013-07,2017-01-30,2017-01-30,2013-08-09,,2017-04-26
NCT01913639,FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,https://clinicaltrials.gov/study/NCT01913639,,COMPLETED,YES,Esophageal Cancer|Gastric Cancer,DRUG: Regorafenib|DRUG: 5-Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2013-07,2019-06,2019-06,2013-08-01,2020-05-15,2020-05-15
NCT01900743,Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma,https://clinicaltrials.gov/study/NCT01900743,REGO-SARC,COMPLETED,NO,Sarcoma,DRUG: Regorafenib|DRUG: Placebo,Centre Oscar Lambret,Bayer,INTERVENTIONAL,2013-06-05,2020-09-16,2020-09-16,2013-07-16,,2021-04-09
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",https://clinicaltrials.gov/study/NCT01877915,COMMANDER HF,COMPLETED,YES,Heart Failure|Coronary Artery Disease,DRUG: Rivaroxaban|DRUG: Placebo|OTHER: Standard of care for heart failure and coronary artery disease,"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2013-09-10,2018-04-19,2018-04-19,2013-06-14,2019-05-10,2019-05-10
NCT01875380,Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01875380,REFRAME,COMPLETED,NO,Colorectal Neoplasms|Metastatic Disease,DRUG: Regorafenib,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),Bayer,INTERVENTIONAL,2013-06,2016-04,2016-04,2013-06-11,,2017-08-01
NCT01833520,Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma,https://clinicaltrials.gov/study/NCT01833520,,COMPLETED,YES,Sarcoma,DRUG: Ra-223 Dichloride,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2013-10-16,2020-04-08,2020-04-08,2013-04-17,2021-02-02,2021-02-02
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,https://clinicaltrials.gov/study/NCT01830543,PIONEER AF-PCI,COMPLETED,YES,Atrial Fibrillation|Percutaneous Coronary Intervention,DRUG: rivaroxaban 2.5 mg|DRUG: rivaroxaban 15 mg|DRUG: rivaroxaban 10 mg|DRUG: aspirin (ASA)|DRUG: vitamin K antagonist (VKA)|DRUG: clopidogrel|DRUG: prasugrel|DRUG: ticagrelor,"Janssen Scientific Affairs, LLC",Bayer,INTERVENTIONAL,2013-05-10,2016-07-28,2016-07-28,2013-04-12,2017-07-31,2017-09-19
NCT01762150,Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma,https://clinicaltrials.gov/study/NCT01762150,,COMPLETED,NO,Renal Cell Carcinoma,DRUG: Sorafenib|DRUG: Gemcitabine|DRUG: Cisplatin,Peking University Cancer Hospital & Institute,Bayer,INTERVENTIONAL,2011-06,2016-12,2018-06,2013-01-07,,2018-11-20
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,https://clinicaltrials.gov/study/NCT01729871,VENTURE-AF,COMPLETED,YES,Atrial Fibrillation,DRUG: rivaroxaban|DRUG: uninterrupted vitamin K antagonist (VKA),"Janssen Scientific Affairs, LLC",Bayer,INTERVENTIONAL,2013-02,2014-10,2014-10,2012-11-20,2015-11-10,2017-03-06
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),https://clinicaltrials.gov/study/NCT01724606,,COMPLETED,NO,Breast Cancer|Brain Metastases,RADIATION: Whole Brain Radiotherapy (WBRT)|DRUG: Sorafenib,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2012-11-05,2022-03-01,2022-03-01,2012-11-12,,2022-03-07
NCT01656330,A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers,https://clinicaltrials.gov/study/NCT01656330,,COMPLETED,NO,Healthy,DRUG: Rivaroxaban 20 mg twice daily|DRUG: Rivaroxaban 20 mg once daily|DRUG: Profilnine SD|DRUG: Beriplex P/N|OTHER: Saline,"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2012-07,2012-08,2012-08,2012-08-03,,2017-01-24
NCT01640665,Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,https://clinicaltrials.gov/study/NCT01640665,,COMPLETED,NO,Metastatic Breast Cancer|Gastrointestinal Tumors,DRUG: Sorafenib|DRUG: Capecitabine,Yale University,Bayer,INTERVENTIONAL,2012-07,2014-08,2014-08,2012-07-16,,2016-09-16
NCT01624285,Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer,https://clinicaltrials.gov/study/NCT01624285,,COMPLETED,NO,Adult Primary Hepatocellular Carcinoma|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer,DRUG: sorafenib tosylate|OTHER: placebo|OTHER: laboratory biomarker analysis,Jonsson Comprehensive Cancer Center,Bayer,INTERVENTIONAL,2012-07-16,2023-02,2023-02,2012-06-20,,2023-12-14
NCT01608867,A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors,https://clinicaltrials.gov/study/NCT01608867,,COMPLETED,NO,Solid Tumors,BIOLOGICAL: OMP-54F28,"OncoMed Pharmaceuticals, Inc.",Bayer,INTERVENTIONAL,2012-06,2016-08,2017-06,2012-05-31,,2020-08-11
NCT01555463,"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",https://clinicaltrials.gov/study/NCT01555463,,COMPLETED,YES,Papulopustular Rosacea,"DRUG: Azelaic acid foam, 15% (BAY39-6251)|DRUG: Vehicle foam",LEO Pharma,Bayer,INTERVENTIONAL,2012-09,2014-01,2014-01,2012-03-15,2015-01-27,2023-06-09
NCT01521559,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),https://clinicaltrials.gov/study/NCT01521559,VIBRANT,COMPLETED,YES,Branch Retinal Vein Occlusion,PROCEDURE: Macular Laser Photocoagulation|DRUG: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321),Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2012-04,2013-08,2014-03,2012-01-30,2014-11-13,2014-11-13
NCT01519778,A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study,https://clinicaltrials.gov/study/NCT01519778,,COMPLETED,YES,Major Cutaneous Abscess|Cellulitis|Erysipelas,DRUG: TR701 FA,"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Bayer,INTERVENTIONAL,2012-02-15,2012-08-27,2012-08-27,2012-01-27,2015-03-12,2018-08-29
NCT01499953,Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux,https://clinicaltrials.gov/study/NCT01499953,,COMPLETED,YES,Superficial Vein Thrombosis,DRUG: Rivaroxaban|DRUG: Fondaparinux,GWT-TUD GmbH,Bayer,INTERVENTIONAL,2012-04,2016-05,2016-05,2011-12-26,2023-05-15,2023-05-15
NCT01493479,Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma,https://clinicaltrials.gov/study/NCT01493479,FIZZ,COMPLETED,NO,Follicular Lymphoma,DRUG: 90Y Ibritumomab tiuxetan|DRUG: Rituximab,The Christie NHS Foundation Trust,Bayer,INTERVENTIONAL,2007-06-06,2011-01,2015-11-06,2011-12-16,,2019-10-15
NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01471353,SorCape,COMPLETED,YES,Colorectal Cancer Metastatic,DRUG: Sorafenib Plus Capecitabine (SorCape),University of Florida,Bayer,INTERVENTIONAL,2011-11,2015-10,2017-05,2011-11-16,2017-03-30,2020-07-23
NCT01464450,Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants,https://clinicaltrials.gov/study/NCT01464450,,COMPLETED,NO,Pharmacokinetics|Bioavailability|Healthy Participants,DRUG: Rivaroxaban,"Janssen Scientific Affairs, LLC",Bayer,INTERVENTIONAL,2011-10,2011-12,2011-12,2011-11-03,,2017-01-24
NCT01432704,Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),https://clinicaltrials.gov/study/NCT01432704,100207MS-H,COMPLETED,NO,Multiple Sclerosis,DRUG: colecalciferol,University of Turku,Bayer,INTERVENTIONAL,2008-03,2011-05,2011-08,2011-09-13,,2011-09-13
NCT01430533,Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation,https://clinicaltrials.gov/study/NCT01430533,,COMPLETED,NO,Healthy,DRUG: azelaic acid pre foam formulation|DRUG: Vehicle pre foam formulation|DRUG: Water,LEO Pharma,Bayer,INTERVENTIONAL,2011-09,2011-12,2011-12,2011-09-08,,2020-04-01
NCT01430312,21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation,https://clinicaltrials.gov/study/NCT01430312,,COMPLETED,NO,Healthy,DRUG: azelaic acid pre-foam formulation|DRUG: Vehicle pre-foam formulation|DRUG: Water|DRUG: Sodium lauryl sulfate,LEO Pharma,Bayer,INTERVENTIONAL,2011-09,2011-12,2011-12,2011-09-08,,2020-04-01
NCT01400646,A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers,https://clinicaltrials.gov/study/NCT01400646,,COMPLETED,NO,Healthy,DRUG: Rivaroxaban|DRUG: Warfarin|DRUG: Vitamin K|DRUG: Vitamin K|DRUG: Warfarin|DRUG: Warfarin|DRUG: Warfarin,"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2011-10,2012-05,2012-05,2011-07-22,,2017-01-24
NCT01376453,Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer,https://clinicaltrials.gov/study/NCT01376453,,COMPLETED,NO,Rectal Cancer,DRUG: Sorafenib|DRUG: 5-Fluorouracil (5-FU)|RADIATION: Radiation,H. Lee Moffitt Cancer Center and Research Institute,Bayer,INTERVENTIONAL,2011-06,2014-11,2016-03,2011-06-20,,2016-09-12
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01363440,VISTA DME,COMPLETED,YES,Diabetic Macular Edema,DRUG: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2011-05,2013-01,2014-11,2011-06-01,2015-04-20,2016-05-30
NCT01309438,A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function,https://clinicaltrials.gov/study/NCT01309438,,COMPLETED,NO,Healthy|Renal Insufficiency,DRUG: Rivaroxaban (normal renal function)|DRUG: Rivaroxaban (mild and moderate renal impairment)|DRUG: Erythromycin (normal renal function)|DRUG: Erythromycin (mild and moderate renal function),"Janssen Research & Development, LLC",Bayer,INTERVENTIONAL,2011-02,2012-03,2012-03,2011-03-07,,2014-10-08
NCT01305577,Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat,https://clinicaltrials.gov/study/NCT01305577,,COMPLETED,YES,Moderate or Severe Submental Fullness,DRUG: Deoxycholic acid injection|DRUG: Placebo,Kythera Biopharmaceuticals,Bayer,INTERVENTIONAL,2010-12,2012-01,2012-01,2011-02-28,2015-06-15,2015-07-14
NCT01298570,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01298570,,COMPLETED,YES,Colorectal Cancer Metastatic,DRUG: Regorafenib (BAY 73-4506)|DRUG: FOLFIRI|DRUG: Placebo|DRUG: FOLFIRI,UNC Lineberger Comprehensive Cancer Center,Bayer,INTERVENTIONAL,2011-04-07,2016-11-15,2020-10-02,2011-02-17,2018-02-28,2021-01-06
NCT01294644,Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat,https://clinicaltrials.gov/study/NCT01294644,,COMPLETED,YES,Moderate or Severe Submental Fullness,DRUG: Deoxycholic acid injection|DRUG: Placebo,Kythera Biopharmaceuticals,Bayer,INTERVENTIONAL,2011-01,2012-02,2012-02,2011-02-11,2015-06-12,2015-06-12
NCT01257919,"Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea",https://clinicaltrials.gov/study/NCT01257919,,COMPLETED,NO,Papulopustular Rosacea,DRUG: Azelaic Acid Foam|DRUG: Azelaic Acid Gel,LEO Pharma,Bayer,INTERVENTIONAL,2011-01,2011-03,2011-03,2010-12-10,,2023-06-09
NCT01189370,Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer,https://clinicaltrials.gov/study/NCT01189370,,COMPLETED,YES,Renal Cell Cancer,DRUG: sorafenib,University of Kansas Medical Center,Bayer,INTERVENTIONAL,2008-06,2015-04,2015-04,2010-08-26,2017-06-01,2017-06-01
NCT01187212,Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE,https://clinicaltrials.gov/study/NCT01187212,,COMPLETED,NO,Malignant Neoplasm of Stomach|Effects of Chemotherapy,DRUG: Capecitabine/Cisplatin + Sorafenib|DRUG: Capecitabine/Cisplatin,Asan Medical Center,Bayer,INTERVENTIONAL,2010-08,2013-11,2014-08,2010-08-24,,2020-01-07
NCT01094886,Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement,https://clinicaltrials.gov/study/NCT01094886,,COMPLETED,YES,"Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip|Thromboembolism",DRUG: Rivaroxaban,"Ortho-McNeil Janssen Scientific Affairs, LLC",Bayer,INTERVENTIONAL,2010-03,2010-12,2010-12,2010-03-29,2012-02-27,2017-03-17
NCT01082939,"Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",https://clinicaltrials.gov/study/NCT01082939,,COMPLETED,YES,Chronic Lymphocytic Leukemia,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Alemtuzumab|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2002-12,2011-01,2011-01,2010-03-09,2011-10-21,2012-02-20
NCT01025635,"Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea",https://clinicaltrials.gov/study/NCT01025635,,COMPLETED,YES,Papulopustular Rosacea,DRUG: Azelaic acid foam 15%|DRUG: Vehicle foam,LEO Pharma,Bayer,INTERVENTIONAL,2009-12,2010-08,2010-08,2009-12-03,2013-07-01,2020-03-31
NCT00999284,Ophthalmologic Examinations After Infusion of ZK200775,https://clinicaltrials.gov/study/NCT00999284,,COMPLETED,NO,Visual Acuity,DRUG: ZK200775|DRUG: ZK200775|DRUG: Sodium Chloride,"Charite University, Berlin, Germany",Bayer,INTERVENTIONAL,1996-12,1998-04,1998-04,2009-10-21,,2009-10-21
NCT00989469,Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation,https://clinicaltrials.gov/study/NCT00989469,NEXIRI,COMPLETED,NO,Metastatic Colorectal Cancer,DRUG: Nexavar (Sorafenib) and irinotecan (Campto),Institut du Cancer de Montpellier - Val d'Aurelle,Bayer,INTERVENTIONAL,2009-02,2011-02,2012-02,2009-10-05,,2021-06-23
NCT00981162,Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride,https://clinicaltrials.gov/study/NCT00981162,,COMPLETED,NO,"Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: sorafenib tosylate|DRUG: everolimus|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies|OTHER: pharmacological study,Roswell Park Cancer Institute,Bayer,INTERVENTIONAL,2009-08,2011-08,2012-12,2009-09-22,,2022-09-13
NCT00964795,"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",https://clinicaltrials.gov/study/NCT00964795,,COMPLETED,YES,Neovascular Age-related Macular Degeneration,DRUG: Intravitreal Aflibercept Injection 2mg,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2009-12,2013-08,2013-08,2009-08-25,2015-03-23,2015-03-23
NCT00954278,Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00954278,,COMPLETED,NO,"Carcinoma, Non Small Cell Lung",DRUG: sorafenib,"University of Wisconsin, Madison",Bayer,INTERVENTIONAL,2009-07-28,2015-12-23,2015-12-23,2009-08-07,,2019-11-15
NCT00943072,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),https://clinicaltrials.gov/study/NCT00943072,,COMPLETED,YES,Macular Edema Secondary to Central Retinal Vein Occlusion,BIOLOGICAL: VEGF Trap-Eye 2.0mg|DRUG: Sham,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2009-07,2010-10,2012-04,2009-07-21,2013-05-27,2013-05-27
NCT00940342,Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00940342,,COMPLETED,YES,Leukemia,DRUG: GM-CSF (Sargramostim)|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2004-10-12,2017-01-05,2017-01-05,2009-07-16,2018-09-19,2018-09-19
NCT00930605,The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT00930605,C+CHOP/ESHAP,COMPLETED,NO,Peripheral T-cell Lymphoma,DRUG: CHOP regimen alternate with ESHAP regimen|DRUG: Alemtuzumab,King Chulalongkorn Memorial Hospital,Bayer,INTERVENTIONAL,2005-01,2006-11,2008-07,2009-06-30,,2011-10-06
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,https://clinicaltrials.gov/study/NCT00930553,,COMPLETED,YES,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: alemtuzumab,"Genzyme, a Sanofi Company",Bayer,INTERVENTIONAL,2009-08,2016-02,2016-02,2009-06-30,2017-05-15,2017-05-15
NCT00919061,Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy,https://clinicaltrials.gov/study/NCT00919061,,COMPLETED,YES,Extrahepatic Bile Duct Cancer|Gallbladder Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Sorafenib,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2009-08,2014-03,2014-03,2009-06-12,2016-02-03,2016-02-03
NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,https://clinicaltrials.gov/study/NCT00917462,,COMPLETED,YES,Esophageal Cancer|Gastroesophageal Junction Cancer,"DRUG: Sorafenib, administered orally|PROCEDURE: CT/MRI",Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2009-06,2018-08,2018-08,2009-06-10,2019-03-13,2019-03-27
NCT00893373,Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age,https://clinicaltrials.gov/study/NCT00893373,SORAML,COMPLETED,NO,Acute Myeloid Leukemia (AML),DRUG: sorafenib|DRUG: placebo,Technische Universität Dresden,Bayer,INTERVENTIONAL,2009-03,2011-11,2014-09,2009-05-06,,2016-02-05
NCT00884416,Sorafenib in Newly Diagnosed High Grade Glioma,https://clinicaltrials.gov/study/NCT00884416,,COMPLETED,NO,Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma,DRUG: Sorafenib dose escalation,"University Hospital, Geneva",Bayer,INTERVENTIONAL,2009-03,2011-12,2012-03,2009-04-20,,2014-11-04
NCT00875745,Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS),https://clinicaltrials.gov/study/NCT00875745,,COMPLETED,NO,"Leukemia, Myeloid, Acute|Leukemia, Promyelocytic, Acute|Myelodysplastic Syndromes",DRUG: Sorafenib-Vorinostat,Indiana University School of Medicine,Bayer,INTERVENTIONAL,2009-04,2010-05,2013-10,2009-04-03,,2014-09-18
NCT00864032,Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall,https://clinicaltrials.gov/study/NCT00864032,,COMPLETED,YES,Soft Tissue Sarcoma,DRUG: Sorafenib,"University of California, Davis",Bayer,INTERVENTIONAL,2009-03,2011-08,2011-08,2009-03-18,2013-04-10,2013-04-10
NCT00858117,A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL,https://clinicaltrials.gov/study/NCT00858117,,COMPLETED,YES,Leukemia,BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Rituximab,Northwestern University,Bayer,INTERVENTIONAL,2005-09-26,2010-03-17,2013-01-24,2009-03-09,2020-10-19,2020-11-06
NCT00837148,Sorafenib and Dacarbazine in Soft Tissue Sarcoma,https://clinicaltrials.gov/study/NCT00837148,,COMPLETED,YES,Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor,DRUG: Sorafenib and Dacarbazine,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,2009-02,2013-11,2013-11,2009-02-05,2015-11-20,2015-11-20
NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00815295,,COMPLETED,YES,Squamous Cell Cancer,DRUG: Sorafenib|DRUG: Cetuximab,Duke University,Bayer,INTERVENTIONAL,2008-01,2013-07,2013-07,2008-12-30,2014-12-08,2014-12-08
NCT00810394,Sorafenib in Treating Patients With Advanced Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT00810394,,COMPLETED,YES,"Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Sorafenib,"University of California, Davis",Bayer,INTERVENTIONAL,2008-12,2011-10,2012-03,2008-12-18,2017-03-10,2018-01-10
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT00809965,,COMPLETED,YES,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,DRUG: Rivaroxaban 2.5 mg|DRUG: Rivaroxaban 5 mg|DRUG: Placebo|DRUG: Standard of care,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,INTERVENTIONAL,2008-11,2011-09,2011-09,2008-12-17,2014-06-02,2014-09-17
NCT00789477,DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact,https://clinicaltrials.gov/study/NCT00789477,DA VINCI,COMPLETED,YES,Diabetic Macular Edema,PROCEDURE: Laser Photocoagulation|DRUG: Intravitreal Aflibercept Injection,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2008-12,2009-12,2010-09,2008-11-11,2014-09-09,2014-09-09
NCT00780169,Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT00780169,,COMPLETED,NO,Metastatic Colorectal Cancer,DRUG: sorafenib + FOLFIRI,Ottawa Hospital Research Institute,Bayer,INTERVENTIONAL,2008-10,2011-05,2012-12,2008-10-27,,2013-05-13
NCT00775632,Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants,https://clinicaltrials.gov/study/NCT00775632,,COMPLETED,NO,Graft Versus Host Disease|Bone Marrow Transplantation,DRUG: Alemtuzumab|DRUG: mycophenolate or cyclosporine and methotrexate,"University Health Network, Toronto",Bayer,INTERVENTIONAL,2008-10,2010-09,2010-09,2008-10-20,,2016-06-23
NCT00761384,"High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma",https://clinicaltrials.gov/study/NCT00761384,HITT,COMPLETED,NO,B-cell Lymphoma,DRUG: 90Y-ibritumomab,Lund University Hospital,Bayer,INTERVENTIONAL,2008-04,2016-01,2016-01,2008-09-29,,2016-02-19
NCT00759928,PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors,https://clinicaltrials.gov/study/NCT00759928,,COMPLETED,NO,Refractory Solid Tumors,DRUG: Erlotinib|DRUG: Sorafenib,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2008-10,2013-09,2014-06,2008-09-25,,2014-07-02
NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,https://clinicaltrials.gov/study/NCT00722761,,COMPLETED,YES,Acne Vulgaris,DRUG: drospirenone and ethinyl estradiol|DRUG: Placebo tablet,Massachusetts General Hospital,Bayer,INTERVENTIONAL,2009-04,2012-04,2012-04,2008-07-28,2013-03-05,2013-03-05
NCT00718705,Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin),https://clinicaltrials.gov/study/NCT00718705,PREMYC,COMPLETED,NO,Prematurity,DRUG: Josamycin|DRUG: Placebo,Assistance Publique - Hôpitaux de Paris,Bayer,INTERVENTIONAL,2008-07,2011-09,2011-09,2008-07-21,,2011-12-29
NCT00689169,Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00689169,ZBEAM2,COMPLETED,NO,"Lymphoma, Large Cell, Diffuse","DRUG: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|PROCEDURE: ASCT|DRUG: Rituximab",Lymphoma Study Association,Bayer,INTERVENTIONAL,2007-08,2011-01,2014-01,2008-06-03,,2018-03-07
NCT00639262,Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors,https://clinicaltrials.gov/study/NCT00639262,,COMPLETED,NO,Brain Metastases|Primary Brain Tumors,DRUG: Sorafenib|DRUG: Temozolomide|RADIATION: Radiotherapy,Sidney Kimmel Cancer Center at Thomas Jefferson University,Bayer,INTERVENTIONAL,2008-03,2012-09,2012-09,2008-03-20,,2016-10-21
NCT00629135,Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses,https://clinicaltrials.gov/study/NCT00629135,MEMO,COMPLETED,NO,"Abscess, Intra-Abdominal",DRUG: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam,Hannover Medical School,Bayer,INTERVENTIONAL,2005-11-15,2011-08-15,2011-08-15,2008-03-05,,2018-07-24
NCT00617903,Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea,https://clinicaltrials.gov/study/NCT00617903,,COMPLETED,YES,Papulopustular Rosacea,DRUG: Azelaic acid|DRUG: Vehicle foam,LEO Pharma,Bayer,INTERVENTIONAL,2008-01,2008-06,2008-06,2008-02-18,2013-07-04,2020-04-07
NCT00613145,Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT00613145,,COMPLETED,NO,Refractory Malignancy,DRUG: Capecitabine and Sorafenib|DRUG: Capecitabine and Sorafenib,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2008-02,2009-05,2010-05,2008-02-12,,2013-02-04
NCT00607854,Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007),https://clinicaltrials.gov/study/NCT00607854,ZEVALLO,COMPLETED,NO,Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma,DRUG: Ibritumomab Tiuxetan (Zevalin),"University Hospital, Bordeaux",Bayer,INTERVENTIONAL,2008-02,2011-02,2011-11,2008-02-06,,2016-10-05
NCT00606866,MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00606866,MRI,COMPLETED,NO,Metastatic Renal Cell Carcinoma,DRUG: placebo|DRUG: Sorafenib|DRUG: Sorafenib,University of Chicago,Bayer,INTERVENTIONAL,2004-07,2007-01,2008-06,2008-02-05,,2023-11-29
NCT00601003,Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma,https://clinicaltrials.gov/study/NCT00601003,,COMPLETED,YES,Neuroblastoma|Medulloblastoma,DRUG: Nifurtimox|DRUG: Cyclophosphamide|DRUG: Topotecan,Giselle Sholler,Bayer,INTERVENTIONAL,2008-01-14,2020-04-28,2022-10-28,2008-01-25,2022-12-29,2024-08-06
NCT00600015,Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00600015,,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib + Sorafenib|DRUG: Erlotinib + Placebo,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2008-02,2009-02,2009-02,2008-01-24,2012-09-21,2022-03-10
NCT00598507,Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00598507,,COMPLETED,YES,Melanoma,DRUG: ZK-EPO,H. Lee Moffitt Cancer Center and Research Institute,Bayer,INTERVENTIONAL,2007-05,2013-01,2013-01,2008-01-22,2013-11-15,2013-12-11
NCT00560430,Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,https://clinicaltrials.gov/study/NCT00560430,METATEL,COMPLETED,NO,Hypertension|Metabolic Syndrome|Hypertriglyceridemia,DRUG: telmisartan|DRUG: telmisartan|DRUG: placebo,Ludwig-Maximilians - University of Munich,Bayer,INTERVENTIONAL,2007-11,2009-09,2009-10,2007-11-19,,2010-07-15
NCT00548899,Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer,https://clinicaltrials.gov/study/NCT00548899,SOFIA,COMPLETED,NO,Breast Cancer,DRUG: Nexavar (Sorafenib),German Breast Group,Bayer,INTERVENTIONAL,2007-11,2011-09,2011-12,2007-10-24,,2015-03-09
NCT00548847,"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",https://clinicaltrials.gov/study/NCT00548847,,COMPLETED,YES,Leukemia,BIOLOGICAL: GM-CSF|BIOLOGICAL: Interferon-α-2b,Emory University,Bayer,INTERVENTIONAL,2007-01,2015-03,2015-03,2007-10-24,2016-08-18,2016-10-26
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",https://clinicaltrials.gov/study/NCT00548405,CARE-MS II,COMPLETED,YES,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Alemtuzumab 12 mg|BIOLOGICAL: Alemtuzumab 24 mg|BIOLOGICAL: Interferon beta-1a,"Genzyme, a Sanofi Company",Bayer,INTERVENTIONAL,2007-10,2011-09,2011-09,2007-10-24,2015-01-08,2017-04-17
NCT00544817,Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme,https://clinicaltrials.gov/study/NCT00544817,,COMPLETED,YES,Glioblastoma Multiforme,RADIATION: Radiation Therapy|DRUG: Temozolomide|DRUG: Sorafenib,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2007-04,2008-06,2010-08,2007-10-16,2012-12-13,2016-09-01
NCT00542971,"Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)",https://clinicaltrials.gov/study/NCT00542971,,COMPLETED,YES,AML|Acute Myeloid Leukemia|Myelodysplastic Disorders,DRUG: Idarubicin|DRUG: Sorafenib|DRUG: Ara-C,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2007-10,2011-05,2011-05,2007-10-12,2012-07-13,2018-08-23
NCT00536575,Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients,https://clinicaltrials.gov/study/NCT00536575,,COMPLETED,YES,Multiple Myeloma,DRUG: Bortezomib|DRUG: Sorafenib,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2007-11,2010-02,2010-08,2007-09-28,2013-02-27,2013-02-27
NCT00533923,Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders,https://clinicaltrials.gov/study/NCT00533923,,COMPLETED,NO,AML|ALL|CLL|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma|Aplastic Anemia|Myeloproliferative Disorder,DRUG: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF,Beth Israel Deaconess Medical Center,Bayer,INTERVENTIONAL,2002-12,2007-01,2007-01,2007-09-24,,2016-07-18
NCT00533585,BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00533585,,COMPLETED,NO,Lung Cancer,DRUG: BAY 43-9006|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Bevacizumab,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2006-05,2016-01,2016-01,2007-09-21,,2016-02-10
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",https://clinicaltrials.gov/study/NCT00530348,CARE-MS I,COMPLETED,YES,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Interferon beta-1a,"Genzyme, a Sanofi Company",Bayer,INTERVENTIONAL,2007-08,2011-04,2011-04,2007-09-17,2014-11-24,2014-11-24
NCT00527423,"Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD",https://clinicaltrials.gov/study/NCT00527423,,COMPLETED,YES,Macular Degeneration,DRUG: VEGF Trap Eye,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2007-08,2011-10,2011-10,2007-09-10,2013-06-12,2013-06-12
NCT00525603,CFAR Study in Patients With Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00525603,,COMPLETED,YES,Leukemia|Chronic Lymphocytic Leukemia,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Alemtuzumab|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2005-06,2011-07,2011-07,2007-09-06,2013-03-04,2013-03-04
NCT00516828,Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT00516828,,COMPLETED,NO,Leukemia|Myelodysplastic Syndromes,DRUG: cytarabine,NCIC Clinical Trials Group,Bayer,INTERVENTIONAL,2007-11-27,2010-03-18,2013-01-10,2007-08-15,,2023-08-04
NCT00510250,A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer,https://clinicaltrials.gov/study/NCT00510250,,COMPLETED,NO,Cancer of the Cervix,DRUG: Sorafenib|DRUG: Cisplatin|PROCEDURE: Radiation,"University Health Network, Toronto",Bayer,INTERVENTIONAL,2007-06,2010-09,2015-07,2007-08-01,,2015-07-27
NCT00509795,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),https://clinicaltrials.gov/study/NCT00509795,VIEW1,COMPLETED,YES,Macular Degeneration,"BIOLOGICAL: ranibizumab|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2007-08,2010-09,2011-07,2007-08-01,2012-04-16,2012-12-28
NCT00509613,Phase 1 Study With Sorafenib and Sirolimus,https://clinicaltrials.gov/study/NCT00509613,,COMPLETED,NO,Advanced Solid Tumor|Refractory to Standard Therapies,DRUG: Sorafenib|DRUG: Sirolimus,Radboud University Medical Center,Bayer,INTERVENTIONAL,2007-06,2009-05,,2007-07-31,,2009-09-18
NCT00499343,G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients,https://clinicaltrials.gov/study/NCT00499343,,COMPLETED,YES,Lymphoma,DRUG: Etoposide|DRUG: G-CSF|DRUG: GM-CSF|DRUG: Isophosphamide|DRUG: Rituximab|PROCEDURE: Apheresis,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2004-01,2008-10,2008-10,2007-07-11,2009-07-07,2013-08-02
NCT00480389,Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal,https://clinicaltrials.gov/study/NCT00480389,,COMPLETED,NO,Renal Cell Carcinoma|Metastatic Disease,DRUG: Sorafenib,"University Health Network, Toronto",Bayer,INTERVENTIONAL,2007-05,2012-10,2013-03,2007-05-30,,2015-12-09
NCT00478114,Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC),https://clinicaltrials.gov/study/NCT00478114,,COMPLETED,NO,Renal Cell Carcinoma,DRUG: sorafenib,Mahidol University,Bayer,INTERVENTIONAL,2007-05,2009-08,2010-03,2007-05-24,,2011-08-29
NCT00461851,"Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma",https://clinicaltrials.gov/study/NCT00461851,,COMPLETED,YES,Bladder Cancer,DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Sorafenib,Yale University,Bayer,INTERVENTIONAL,2007-03,2013-08,2013-08,2007-04-18,2016-11-01,2017-12-14
NCT00452218,Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH),https://clinicaltrials.gov/study/NCT00452218,,COMPLETED,NO,Pulmonary Arterial Hypertension,DRUG: Sorafenib,University of Chicago,Bayer,INTERVENTIONAL,2007-03,2012-05,2012-05,2007-03-27,,2016-08-24
NCT00449280,Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies,https://clinicaltrials.gov/study/NCT00449280,,COMPLETED,NO,Advanced Solid Tumor,DRUG: Sorafenib|DRUG: Rapamycin|DRUG: Rapamycin,University of Chicago,Bayer,INTERVENTIONAL,2006-11,2009-06,2009-09,2007-03-20,,2013-06-12
NCT00447304,Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy,https://clinicaltrials.gov/study/NCT00447304,ACDC,COMPLETED,NO,Acute Cholecystitis,DRUG: moxifloxacin|PROCEDURE: cholecystectomy,Heidelberg University,Bayer,INTERVENTIONAL,2006-10,2010-11,2010-12,2007-03-14,,2012-07-23
NCT00440583,The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP,https://clinicaltrials.gov/study/NCT00440583,,COMPLETED,NO,Diffuse Large B-cell Lymphoma,DRUG: chemotherapy followed by Zevalin,Mahidol University,Bayer,INTERVENTIONAL,2006-09,2011-09,2012-05,2007-02-27,,2015-01-30
NCT00429104,Herceptin and GM-CSF for Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00429104,,COMPLETED,YES,Breast Cancer,DRUG: Herceptin|DRUG: GM-CSF,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2002-08,2009-11,2009-11,2007-01-31,2011-04-15,2012-12-06
NCT00426452,A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers,https://clinicaltrials.gov/study/NCT00426452,,COMPLETED,NO,Healthy,DRUG: Vatalinib,Novartis,Bayer,INTERVENTIONAL,2006-07,,,2007-01-24,,2009-11-19
NCT00408330,A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face,https://clinicaltrials.gov/study/NCT00408330,,COMPLETED,NO,Seborrheic Dermatitis on the Face,DRUG: Azelaic Acid 15% Gel|DRUG: Inactive 15% gel base,LEO Pharma,Bayer,INTERVENTIONAL,2006-12,2007-03,2007-03,2006-12-06,,2023-06-09
NCT00403949,A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis,https://clinicaltrials.gov/study/NCT00403949,,COMPLETED,NO,Perioral Dermatitis,DRUG: Azelaic acid 15% gel|DRUG: Non-active base from azelaic acid 15% gel,LEO Pharma,Bayer,INTERVENTIONAL,2006-11,2007-03,2007-03,2006-11-27,,2023-06-09
NCT00403793,Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057),https://clinicaltrials.gov/study/NCT00403793,,COMPLETED,NO,Contraception,DRUG: etonogestrel with testosterone undecanoate|DRUG: Placebo,Organon and Co,Bayer,INTERVENTIONAL,2003-10,2006-12,2006-12,2006-11-27,,2022-02-04
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,https://clinicaltrials.gov/study/NCT00403767,,COMPLETED,YES,Atrial Fibrillation|Stroke|Embolism,DRUG: Rivaroxaban|DRUG: Warfarin|DRUG: Matching placebo for Rivaroxaban arm (Warfarin placebo)|DRUG: Matching placebo for Warfarin arm (Rivaroxaban placebo),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,INTERVENTIONAL,2006-12,2010-09,2010-09,2006-11-27,2012-07-17,2014-04-29
NCT00402597,Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial),https://clinicaltrials.gov/study/NCT00402597,,COMPLETED,YES,Acute Coronary Syndrome,DRUG: Rivaroxaban/Placebo|DRUG: Placebo|DRUG: Rivaroxaban,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,INTERVENTIONAL,2006-11,2008-10,2008-10,2006-11-22,2012-08-29,2012-10-04
NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,https://clinicaltrials.gov/study/NCT00390611,,COMPLETED,YES,Ovarian Cancer,DRUG: Sorafenib|DRUG: Paclitaxel|DRUG: Carboplatin,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2006-10,2012-07,2014-04,2006-10-20,2014-12-22,2014-12-22
NCT00381004,FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00381004,,COMPLETED,YES,Chronic Lymphocytic Leukemia,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Sargramostim|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2006-09,2014-12,2014-12,2006-09-27,2015-08-14,2016-01-14
NCT00376077,A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.,https://clinicaltrials.gov/study/NCT00376077,,COMPLETED,NO,Immune Thrombocytopenic Purpura,DRUG: Methylprednisolone and IVIG|DRUG: Placebo and IVIG,The Hospital for Sick Children,Bayer,INTERVENTIONAL,2005-08,2016-03,2016-04,2006-09-14,,2016-05-09
NCT00373373,Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML,https://clinicaltrials.gov/study/NCT00373373,,COMPLETED,NO,Acute Myeloid Leukemia,DRUG: Sorafenib|DRUG: Placebo,University Hospital Muenster,Bayer,INTERVENTIONAL,2006-09,2009-07,2009-07,2006-09-08,,2009-08-19
NCT00323557,Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients,https://clinicaltrials.gov/study/NCT00323557,,COMPLETED,YES,Leukemia,DRUG: Sargramostim (GM-CSF)|BIOLOGICAL: Pneumococcal Vaccine,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2004-06,2011-05,2011-05,2006-05-09,2012-05-02,2012-12-05
NCT00323323,CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00323323,,COMPLETED,NO,Non-Hodgkin's Lymphoma,DRUG: CHOP|DRUG: Alemtuzumab|PROCEDURE: Plasma Samples,Ohio State University Comprehensive Cancer Center,Bayer,INTERVENTIONAL,2004-03,2012-08,2016-10,2006-05-09,,2017-01-20
NCT00320775,Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,https://clinicaltrials.gov/study/NCT00320775,,COMPLETED,NO,Macular Degeneration,DRUG: VEGF Trap,Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2005-06,2008-06,2008-08,2006-05-03,,2015-03-18
NCT00320788,Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),https://clinicaltrials.gov/study/NCT00320788,,COMPLETED,YES,Macular Degeneration,"BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals,Bayer,INTERVENTIONAL,2006-04,2008-06,2008-08,2006-05-03,2012-03-01,2012-03-01
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,https://clinicaltrials.gov/study/NCT00256282,,COMPLETED,YES,Metastatic Melanoma,DRUG: Vinorelbine|DRUG: Docetaxel|DRUG: Sargramostim,John P. Fruehauf,Bayer,INTERVENTIONAL,2003-04,2012-08,2012-08,2005-11-21,2018-05-03,2018-05-03
NCT00244023,Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone,https://clinicaltrials.gov/study/NCT00244023,,COMPLETED,NO,Erectile Dysfunction|Hypogonadism,DRUG: Testosterone gel|DRUG: testosterone|OTHER: placebo gel,SELARL du Dr Jacques BUVAT,Bayer,INTERVENTIONAL,2005-10,2007-07,2007-07,2005-10-25,,2008-08-25
NCT00230282,"Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00230282,,COMPLETED,YES,Leukemia|B-cell Leukemia|Chronic Leukemia|Chronic Lymphocytic Leukemia (CLL),DRUG: Alemtuzumab|DRUG: Fludarabine|DRUG: Cytoxan,Steven E. Coutre,Bayer,INTERVENTIONAL,2004-07,2010-12,2011-10,2005-09-30,2014-09-08,2014-10-06
NCT00193466,Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,https://clinicaltrials.gov/study/NCT00193466,,COMPLETED,NO,Non-Hodgkins Lymphoma,DRUG: Rituximab|DRUG: Fludarabine|DRUG: CAMPTH-1H,"SCRI Development Innovations, LLC",Bayer,INTERVENTIONAL,2002-01,2007-01,2008-04,2005-09-19,,2010-12-30
NCT00171587,"Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00171587,,COMPLETED,NO,Tumors|Neoplasm Metastasis,DRUG: PTK787/ZK 222584 (vatalanib),Novartis,Bayer,INTERVENTIONAL,2002-05,2007-03,2007-03,2005-09-15,,2009-11-19
NCT00161590,"Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00161590,,COMPLETED,NO,"T-Cell Lymphoma|Lymphoma, Non-Hodgkin's",DRUG: CHOP and alemtuzumab,Weill Medical College of Cornell University,Bayer,INTERVENTIONAL,2004-07,,,2005-09-12,,2008-10-22
NCT00137787,Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases,https://clinicaltrials.gov/study/NCT00137787,,COMPLETED,NO,Febrile Neutropenia,DRUG: ciprofloxacin|DRUG: cefepime,Center for Supporting Hematology-Oncology Trials,Bayer,INTERVENTIONAL,2005-04,2009-12,2010-05,2005-08-30,,2018-06-26
NCT00117299,PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib,https://clinicaltrials.gov/study/NCT00117299,,COMPLETED,NO,Sarcoma,DRUG: PTK787/ZK222584,University of Helsinki,Bayer,INTERVENTIONAL,2004-09,2007-09,2009-01,2005-07-06,,2010-05-27
NCT00071396,Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders,https://clinicaltrials.gov/study/NCT00071396,,COMPLETED,YES,Chronic Lymphocytic Leukemia,DRUG: Campath-1H|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL,2002-10,2006-09,2007-08,2003-10-22,2011-02-25,2012-08-07
NCT00056459,Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.,https://clinicaltrials.gov/study/NCT00056459,,COMPLETED,NO,Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms,DRUG: Vatalanib,Novartis,Bayer,INTERVENTIONAL,2003-02,2007-01,,2003-03-14,,2020-02-10
NCT00056446,Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT00056446,,COMPLETED,NO,Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms,DRUG: Vatalanib,Novartis Pharmaceuticals,Bayer,INTERVENTIONAL,2003-01,2007-01,2007-01,2003-03-14,,2017-03-06
NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",https://clinicaltrials.gov/study/NCT00050778,,COMPLETED,YES,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Interferon beta-1a|BIOLOGICAL: Alemtuzumab 12 mg|BIOLOGICAL: Alemtuzumab 24 mg,"Genzyme, a Sanofi Company",Bayer,INTERVENTIONAL,2002-12,2007-09,2010-01,2002-12-23,2009-08-25,2015-01-08
NCT00031096,Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne,https://clinicaltrials.gov/study/NCT00031096,,COMPLETED,NO,Acne Vulgaris,"DRUG: Azelaic Acid Gel 15% (Finacea, BAY39-6251)|DRUG: Vehicle gel (SH H 655 PBA)",LEO Pharma,Bayer,INTERVENTIONAL,2002-01,2002-07,2002-07,2002-02-22,,2023-06-09
NCT02903160,"Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",https://clinicaltrials.gov/study/NCT02903160,,COMPLETED,YES,Prostate Cancer,DRUG: Abiraterone acetate|DRUG: Prednisone|DRUG: Radium-223 dichloride|DRUG: cabazitaxel|DRUG: Carboplatin|DRUG: Enzalutamide,Icahn School of Medicine at Mount Sinai,Sanofi|Bayer,INTERVENTIONAL,2017-01-13,2021-11-15,2021-11-15,2016-09-16,2024-02-07,2024-02-07
NCT02463799,Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,https://clinicaltrials.gov/study/NCT02463799,,COMPLETED,YES,Prostate Cancer,DRUG: Radium-223|BIOLOGICAL: Sipuleucel-T,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Dendreon|Bayer,INTERVENTIONAL,2016-02-22,2019-12-12,2019-12-12,2015-06-04,2021-07-08,2021-07-08
NCT02164240,Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,https://clinicaltrials.gov/study/NCT02164240,SURE,COMPLETED,YES,Gastrointestinal Stromal Tumor,DRUG: Sunitinib|DRUG: Regorafenib,Dana-Farber Cancer Institute,Bayer|Pfizer,INTERVENTIONAL,2014-07,2016-12,2021-05,2014-06-16,2019-09-12,2021-06-14
NCT00997022,Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients,https://clinicaltrials.gov/study/NCT00997022,,COMPLETED,NO,Hepatocellular Cancer,DRUG: Sorafenib,Columbia University,Bayer|Amgen,INTERVENTIONAL,2009-05,2015-05,2015-05,2009-10-16,,2015-08-10
NCT00942682,Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors,https://clinicaltrials.gov/study/NCT00942682,,COMPLETED,NO,Neuroendocrine Tumor|Carcinoid Tumor|Pancreatic Neuroendocrine Tumor,DRUG: Sorafenib|DRUG: RAD001,Dana-Farber Cancer Institute,Novartis|Bayer,INTERVENTIONAL,2009-07,2013-03,2013-03,2009-07-21,,2014-04-29
NCT02459119,Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),https://clinicaltrials.gov/study/NCT02459119,,COMPLETED,YES,"Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",DRUG: Regorafenib,University of Alabama at Birmingham,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",INTERVENTIONAL,2015-05,2019-02,2020-04,2015-06-01,2020-04-15,2020-08-06
NCT00634751,"CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma",https://clinicaltrials.gov/study/NCT00634751,,COMPLETED,YES,Pancreatic Neoplasms|Bile Duct Neoplasms,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Sorafenib,"University of Wisconsin, Madison",Bayer|Sanofi,INTERVENTIONAL,2008-02,2010-07,2010-07,2008-03-13,2017-08-08,2019-11-26
NCT00589420,Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy,https://clinicaltrials.gov/study/NCT00589420,,COMPLETED,YES,Prostate Cancer,DRUG: docetaxel|DRUG: sorafenib tosylate,Abramson Cancer Center at Penn Medicine,Sanofi|Bayer,INTERVENTIONAL,2007-07-27,2010-02-02,2011-02-02,2008-01-09,2022-02-17,2022-02-17
NCT00534287,Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock,https://clinicaltrials.gov/study/NCT00534287,MaxSep,COMPLETED,NO,Severe Sepsis|Septic Shock,"DRUG: meropenem|DRUG: meropenem, moxifloxacin",Kompetenznetz Sepsis,AstraZeneca|Bayer,INTERVENTIONAL,2007-10,2010-04,2010-06,2007-09-24,,2012-06-29
NCT00456716,Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT00456716,,COMPLETED,NO,Lung Cancer,DRUG: sorafenib,Swedish Medical Center,Bayer|Amgen,INTERVENTIONAL,2007-03,2008-12,2008-12,2007-04-05,,2010-03-04
NCT00445042,Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer,https://clinicaltrials.gov/study/NCT00445042,,COMPLETED,NO,"Carcinoma, Renal Cell",DRUG: Sorafenib,The Methodist Hospital Research Institute,Bayer|Amgen,INTERVENTIONAL,2005-11,2008-09,2008-10,2007-03-08,,2016-03-17
NCT00418496,Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00418496,,COMPLETED,NO,Renal Cancer|Melanoma,DRUG: Aldesleukin|DRUG: Sorafenib,Ohio State University Comprehensive Cancer Center,Bayer|Novartis,INTERVENTIONAL,2006-11-08,2013-02-28,2013-10,2007-01-04,,2017-02-20
NCT00392821,Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer,https://clinicaltrials.gov/study/NCT00392821,,COMPLETED,YES,Kidney Cancer,DRUG: Sorafenib|DRUG: RAD001,"SCRI Development Innovations, LLC",Novartis|Bayer,INTERVENTIONAL,2006-12,2013-10,2013-10,2006-10-26,2014-03-26,2022-06-06
NCT00142272,Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial,https://clinicaltrials.gov/study/NCT00142272,,COMPLETED,NO,Cholera,DRUG: Ciprofloxacin,"International Centre for Diarrhoeal Disease Research, Bangladesh",Bayer|NEMC,INTERVENTIONAL,2001-05,,2002-07,2005-09-02,,2022-02-11
NCT00383994,"Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation",https://clinicaltrials.gov/study/NCT00383994,,COMPLETED,NO,"Lymphoma|Leukemia|Transplantation, Stem Cell|Lymphoid Malignancies|Disorder Related to Transplantation",DRUG: GM-CSF|DRUG: Rituximab|BIOLOGICAL: NK Cell Infusion,M.D. Anderson Cancer Center,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",INTERVENTIONAL,2006-09,2019-07-22,2019-07-22,2006-10-04,,2019-07-31
NCT00328198,"Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00328198,,COMPLETED,YES,B-Cell Chronic Lymphocytic Leukemia (B-CLL),BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Alemtuzumab,"Genzyme, a Sanofi Company","Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",INTERVENTIONAL,2006-05,2011-08,2011-08,2006-05-19,2012-08-10,2014-03-13
NCT03522259,Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery,https://clinicaltrials.gov/study/NCT03522259,BARIVA,COMPLETED,NO,Bariatric Surgery,DRUG: Rivaroxaban 10 MG Oral Tablet [Xarelto],"Insel Gruppe AG, University Hospital Bern",Bayer|Janssen Pharmaceuticals,INTERVENTIONAL,2018-07-19,2023-12-31,2023-12-31,2018-05-11,,2024-11-13
NCT02926222,Regorafenib in Relapsed Glioblastoma,https://clinicaltrials.gov/study/NCT02926222,REGOMA,COMPLETED,NO,Glioblastoma Multiforme,DRUG: Regorafenib|DRUG: Lomustine,Istituto Oncologico Veneto IRCCS,BAYER S.p.A. - Italia,INTERVENTIONAL,2015-11,2017-07,2021-06,2016-10-06,,2022-09-09
NCT01126645,Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer,https://clinicaltrials.gov/study/NCT01126645,SORAMIC,COMPLETED,NO,Hepatocellular Carcinoma,PROCEDURE: RFA|PROCEDURE: Radioembolization (SIRT),University of Magdeburg,Bayer|Sirtex Medical,INTERVENTIONAL,2010-12,2018-01-25,2018-12-31,2010-05-20,,2019-05-31
NCT00696696,Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT00696696,,COMPLETED,YES,Pancreatic Cancer,DRUG: Gemcitabine|DRUG: Erlotinib|DRUG: Sorafenib,NYU Langone Health,Bayer|OSI Pharmaceuticals,INTERVENTIONAL,2007-09,2010-11,2013-06,2008-06-13,2011-12-21,2016-06-30
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT00616564,,COMPLETED,NO,Malignant Melanoma,DRUG: GM-CSF,"Mt. Sinai Medical Center, Miami",Bayer|Chiron Corporation,INTERVENTIONAL,2006-02,2009-09,2009-09,2008-02-15,,2012-05-03
NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,https://clinicaltrials.gov/study/NCT00609804,,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Sorafenib|DRUG: Erlotinib,"SCRI Development Innovations, LLC",Bayer|OSI Pharmaceuticals,INTERVENTIONAL,2008-03,2012-05,2014-11,2008-02-07,2015-06-02,2016-04-08
NCT00597493,Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM,https://clinicaltrials.gov/study/NCT00597493,,COMPLETED,YES,Recurrent Glioblastoma Multiforme,DRUG: Sorafenib and Temozolomide,Duke University,Bayer|Schering-Plough,INTERVENTIONAL,2007-09,2009-02,2010-12,2008-01-18,2013-06-24,2013-06-24
NCT00572078,Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT00572078,,COMPLETED,NO,SOLID TUMORS,DRUG: Sorafenib,Safi Shahda,"Genentech, Inc.|Bayer",INTERVENTIONAL,2008-01-23,2011-01-04,2014-09-14,2007-12-12,,2017-09-25
NCT00483301,"A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",https://clinicaltrials.gov/study/NCT00483301,,COMPLETED,NO,Malignant Melanoma,DRUG: Sorafenib (BAY 43-9006)|DRUG: ABI-007(Abraxane),"Mt. Sinai Medical Center, Miami",Celgene Corporation|Bayer,INTERVENTIONAL,2007-05,2009-08,2009-08,2007-06-07,,2012-05-03
NCT03273322,Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure,https://clinicaltrials.gov/study/NCT03273322,ADRIFT,COMPLETED,NO,Atrial Fibrillation|Atrial Appendage|Hemorrhage,DRUG: Rivaroxaban 10 mg qd|DRUG: Rivaroxaban 15 mg qd|DRUG: DAPT,Assistance Publique - Hôpitaux de Paris,Action Research Group|Bayer,INTERVENTIONAL,2017-09-13,2018-11-20,2019-09-30,2017-09-06,,2021-12-21
NCT01683149,Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,https://clinicaltrials.gov/study/NCT01683149,,COMPLETED,NO,Solid Tumor,DRUG: Topotecan|DRUG: Sorafenib,H. Lee Moffitt Cancer Center and Research Institute,Pediatric Cancer Foundation|Bayer,INTERVENTIONAL,2013-01,2016-01,2016-01,2012-09-11,,2016-03-04
NCT01529320,Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers,https://clinicaltrials.gov/study/NCT01529320,,COMPLETED,NO,Allergic Contact Eczema,"DRUG: Adventan® (methylprednisolone aceponate 0,1%)",Fundacion IMIM,Adknoma Health Research|Bayer,INTERVENTIONAL,2012-02,2012-05,2012-05,2012-02-08,,2016-05-12
NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00844883,,COMPLETED,YES,Hepatocellular Carcinoma|Hepatoma,DRUG: sorafenib|PROCEDURE: LC Bead-TACE,Yale University,Bayer|Biocompatibles UK Ltd,INTERVENTIONAL,2009-02,2015-03,2015-03,2009-02-16,2017-08-28,2021-11-11
NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00825734,,COMPLETED,YES,Metastatic Breast Cancer,DRUG: Sorafenib|DRUG: Ixabepilone,"SCRI Development Innovations, LLC",Bayer|Bristol-Myers Squibb,INTERVENTIONAL,2009-03,2013-06,2014-08,2009-01-21,2014-12-22,2014-12-22
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,https://clinicaltrials.gov/study/NCT00350597,,COMPLETED,NO,Malignant Melanoma,DRUG: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF),Northern California Melanoma Center,Bayer|Melanoma Research Institute,INTERVENTIONAL,2004-09,,2010-07,2006-07-11,,2006-07-11
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,https://clinicaltrials.gov/study/NCT01234870,,COMPLETED,YES,"Heart Disease, Ischemic|Atherosclerosis, Coronary",DRUG: Gadolinium|DRUG: Adenosine,Northwestern University,"Astellas Pharma US, Inc.|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",INTERVENTIONAL,2010-06,2012-01,2012-01,2010-11-04,2014-09-26,2014-09-26
NCT00501644,Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer,https://clinicaltrials.gov/study/NCT00501644,,COMPLETED,YES,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,DRUG: Carboplatin|DRUG: GM-CSF (Sargramostim)|DRUG: Interferon Gamma,M.D. Anderson Cancer Center,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Bristol-Myers Squibb|InterMune",INTERVENTIONAL,2003-01,2009-01,2009-01,2007-07-16,2011-01-10,2012-08-07
NCT04483505,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",https://clinicaltrials.gov/study/NCT04483505,ROGABREAST,COMPLETED,NO,Breast Cancer Metastatic|Hormone Receptor Positive Malignant Neoplasm of Breast,"DRUG: Combination, Rogaratinib + palbociclib + fulvestrant",Fundacion CRIS de Investigación para Vencer el Cáncer,Bayer|Pfizer|Apices Soluciones S.L.,INTERVENTIONAL,2020-11-25,2023-04-04,2023-04-04,2020-07-23,,2023-12-28
NCT02833948,"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)",https://clinicaltrials.gov/study/NCT02833948,GALILEO-4D,COMPLETED,YES,Aortic Valve Stenosis|Cardiovascular Diseases|Heart Valve Diseases|Ventricular Outflow Obstruction|Thrombosis,DRUG: Acetylsalicylic acid|DRUG: Clopidogrel|DRUG: Rivaroxaban,ECRI bv,"Rigshospitalet, Denmark|Bayer|Cardialysis BV",INTERVENTIONAL,2016-05,2018-12,2019-03-06,2016-07-14,2020-01-18,2020-01-18
NCT02832544,"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority",https://clinicaltrials.gov/study/NCT02832544,INVICTUS-VKA,COMPLETED,NO,Rheumatic Heart Disease,DRUG: Rivaroxaban (20 mg)|DRUG: Vitamin K antagonists (VKA),Population Health Research Institute,University of Cape Town|Bayer,INTERVENTIONAL,2016-08-22,2022-08-18,2022-08-18,2016-07-14,,2022-10-05
NCT02728050,"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",https://clinicaltrials.gov/study/NCT02728050,,COMPLETED,YES,Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Myeloproliferative Neoplasm,DRUG: Cladribine|DRUG: Cytarabine|BIOLOGICAL: Filgrastim|OTHER: Laboratory Biomarker Analysis|OTHER: Quality-of-Life Assessment|DRUG: Mitoxantrone|DRUG: Sorafenib,University of Washington,National Cancer Institute (NCI)|Bayer,INTERVENTIONAL,2016-12-01,2022-02-03,2023-04-04,2016-04-05,2023-06-29,2023-07-05
NCT02438098,Rivaroxaban in Bariatric Surgery,https://clinicaltrials.gov/study/NCT02438098,,COMPLETED,NO,Prophylaxis of Venous Thromboembolism,DRUG: Rivaroxaban 10 mg,"Insel Gruppe AG, University Hospital Bern",Centre Hospitalier Universitaire Vaudois|Bayer,INTERVENTIONAL,2015-06,2015-11,2015-11,2015-05-08,,2016-01-08
NCT02048722,"Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",https://clinicaltrials.gov/study/NCT02048722,,COMPLETED,YES,Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,DRUG: regorafenib,Northwestern University,Bayer|National Cancer Institute (NCI),INTERVENTIONAL,2014-06-13,2019-10-14,2021-10-12,2014-01-29,2020-07-29,2022-04-25
NCT01254890,Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT01254890,,COMPLETED,YES,Leukemia,DRUG: Azacitidine|DRUG: Sorafenib,M.D. Anderson Cancer Center,"Bayer|Onyx Therapeutics, Inc.|Celgene",INTERVENTIONAL,2011-01,2015-03,2015-03,2010-12-07,2016-05-06,2016-05-06
NCT00635791,Phase I Study of Vorinostat and Sorafenib in Advanced Cancer,https://clinicaltrials.gov/study/NCT00635791,,COMPLETED,NO,Malignant Solid Tumour|Renal Cell Carcinoma|Non Small Cell Lung Carcinoma,DRUG: Sorafenib|DRUG: Vorinostat,"University of Colorado, Denver",Merck Sharp & Dohme LLC|Bayer,INTERVENTIONAL,2008-03,2011-10,2012-03,2008-03-14,,2013-06-20
NCT00495755,Campath in Chronic GVHD,https://clinicaltrials.gov/study/NCT00495755,,COMPLETED,YES,Chronic Graft-vs.-Host Disease,DRUG: Alemtuzumab (Campath),Dana-Farber Cancer Institute,"Genzyme, a Sanofi Company|Bayer",INTERVENTIONAL,2007-07,2011-10,2012-10,2007-07-03,2013-08-09,2013-08-09
NCT00411086,Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00411086,,COMPLETED,YES,Lymphoma,BIOLOGICAL: Rituximab|BIOLOGICAL: Sargramostim (GM-CSF),M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Bayer,INTERVENTIONAL,2006-11,2016-11,2016-11,2006-12-13,2017-12-05,2017-12-05
NCT00157573,"GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer",https://clinicaltrials.gov/study/NCT00157573,,COMPLETED,YES,Ovarian Cancer|Fallopian Tube Cancer,"DRUG: GM-CSF, sargramostim",Massachusetts General Hospital,Dana-Farber Cancer Institute|Bayer,INTERVENTIONAL,2004-12,2008-10,2010-04,2005-09-12,2017-05-08,2017-05-08
NCT03383614,"Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside",https://clinicaltrials.gov/study/NCT03383614,,COMPLETED,YES,Filariasis,DRUG: LSF emodepside (BAY 44-4400) or matching placebo,Drugs for Neglected Diseases,Bayer|Bill and Melinda Gates Foundation,INTERVENTIONAL,2017-11-14,2018-10-15,2018-10-15,2017-12-26,2020-04-15,2020-04-15
NCT03383523,Relative Bioavailability Study of Emodepside IR-tablets and Solution,https://clinicaltrials.gov/study/NCT03383523,,COMPLETED,YES,Filariasis,DRUG: Emodepside (BAY 44-4400),Drugs for Neglected Diseases,Bayer|Bill and Melinda Gates Foundation,INTERVENTIONAL,2017-10-26,2018-03-26,2018-03-26,2017-12-26,2020-03-09,2020-03-09
NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,https://clinicaltrials.gov/study/NCT02795156,,COMPLETED,YES,"Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma",DRUG: Afatinib|DRUG: Regorafenib|DRUG: Cabozantinib,"SCRI Development Innovations, LLC",Foundation Medicine|Boehringer Ingelheim|Bayer|Exelixis,INTERVENTIONAL,2016-09-28,2022-08-17,2022-08-17,2016-06-09,2023-09-15,2023-12-05
NCT02661178,First in Man Clinical Trial of Emodepside (BAY 44-4400),https://clinicaltrials.gov/study/NCT02661178,,COMPLETED,YES,Healthy Volunteers,DRUG: emodepside (BAY 44-4400)|DRUG: placebo,Drugs for Neglected Diseases,Bayer|Bill and Melinda Gates Foundation,INTERVENTIONAL,2015-12,2017-03-27,2017-03-27,2016-01-22,2020-04-13,2020-04-13
NCT02050919,"Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",https://clinicaltrials.gov/study/NCT02050919,,COMPLETED,YES,Pleomorphic Rhabdomyosarcoma|Stage IIB Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7|Stage IV Adult Soft Tissue Sarcoma AJCC v7,DRUG: Epirubicin Hydrochloride|RADIATION: External Beam Radiation Therapy|DRUG: Ifosfamide|OTHER: Laboratory Biomarker Analysis|DRUG: Sorafenib Tosylate|PROCEDURE: Therapeutic Conventional Surgery,OHSU Knight Cancer Institute,Bayer|Oregon Health and Science University,INTERVENTIONAL,2013-12-03,2018-05-07,2020-12-31,2014-01-31,2020-06-11,2022-03-21
NCT00948987,Mechanism Based Resistance to Aspirin,https://clinicaltrials.gov/study/NCT00948987,,COMPLETED,NO,Aspirin Resistance|Pharmacological Aspirin Non-responsiveness,DRUG: Aspirin,University of Pennsylvania,National Institutes of Health (NIH)|Bayer,INTERVENTIONAL,2004-09,2009-10,2009-10,2009-07-30,,2009-10-15
NCT00908167,Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00908167,,COMPLETED,NO,Acute Myeloid Leukemia|Infantile Leukemia (Both AML and ALL)|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasms|Biphenotypic Leukemia,DRUG: Sorafenib|DRUG: Cytarabine|DRUG: Clofarabine,St. Jude Children's Research Hospital,National Cancer Institute (NCI)|Bayer/Onyx,INTERVENTIONAL,2009-09,2015-06,2015-06,2009-05-25,,2018-01-12
NCT00703365,Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT00703365,,COMPLETED,NO,"Carcinoma, Hepatocellular",DRUG: Sorafenib and Gemcitabine,Mahidol University,Bayer|Chulalongkorn University|Bumrungrad International Hospital,INTERVENTIONAL,2008-02,2010-01,2011-08,2008-06-23,,2011-08-29
NCT00411671,BATTLE Program: Sorafenib in Patients With NSCLC,https://clinicaltrials.gov/study/NCT00411671,,COMPLETED,YES,Lung Cancer,DRUG: Sorafenib,M.D. Anderson Cancer Center,United States Department of Defense|Bayer,INTERVENTIONAL,2006-11,2012-11,2012-11,2006-12-14,2016-02-11,2016-02-11
NCT00712790,Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT00712790,,COMPLETED,NO,Hepatocellular Carcinoma,DRUG: Sorafenib|RADIATION: SIR-Spheres,Singapore Clinical Research Institute,"National Medical Research Council (NMRC), Singapore|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sirtex Medical",INTERVENTIONAL,2008-06,2009-06,2014-04,2008-07-10,,2016-01-06
NCT03585504,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,https://clinicaltrials.gov/study/NCT03585504,Implanon,COMPLETED,YES,Contraceptive Usage,DRUG: Etonogestrel contraceptive implant,Medical University of South Carolina,American College of Obstetricians and Gynecologists|Bayer,INTERVENTIONAL,2010-01,2013-01,2013-01,2018-07-13,2018-10-04,2018-10-04
NCT03406871,Regorafenib and Nivolumab Simultaneous Combination Therapy,https://clinicaltrials.gov/study/NCT03406871,REGONIVO,COMPLETED,NO,Advanced and Metastatic Solid Tumor,DRUG: Regorafenib|DRUG: Nivolumab,Kohei Shitara,"Ono Pharmaceutical Co. Ltd|Bayer Yakuhin, Ltd.",INTERVENTIONAL,2018-01-25,2019-10-23,2020-11-26,2018-01-23,,2021-04-26
NCT03052933,Copanlisib and Gemcitabine in Relapsed/Refractory PTCL,https://clinicaltrials.gov/study/NCT03052933,,COMPLETED,NO,Mature T-Cell and NK-Cell Neoplasm,DRUG: Copanlisib|DRUG: Gemcitabine,Chonnam National University Hospital,Bayer|Consortium for Improving Survival of Lymphoma,INTERVENTIONAL,2018-02-01,2021-07-01,2021-07-01,2017-02-14,,2022-06-10
NCT02283749,BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases,https://clinicaltrials.gov/study/NCT02283749,,COMPLETED,YES,Non Small Cell Lung Cancer With Bone Metastatses,BIOLOGICAL: Xofigo,Angela Taber MD,Rhode Island Hospital|The Miriam Hospital|Bayer,INTERVENTIONAL,2015-09,2018-07-05,2018-11-13,2014-11-05,2018-06-08,2021-02-02
NCT00144417,TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment,https://clinicaltrials.gov/study/NCT00144417,,COMPLETED,NO,Tuberculosis,"DRUG: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|DRUG: isoniazid",Centers for Disease Control and Prevention,Global Alliance for TB Drug Development|Bayer,INTERVENTIONAL,2006-02,2007-06,2007-12,2005-09-05,,2011-08-03
NCT03076203,Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad),https://clinicaltrials.gov/study/NCT03076203,,COMPLETED,NO,Prostate Carcinoma Metastatic to the Bone|Stage IV Prostate Adenocarcinoma|Hormone-refractory Prostate Cancer,DRUG: Niraparib|RADIATION: Radium Ra 223 Dichloride,Sidney Kimmel Cancer Center at Thomas Jefferson University,"Janssen, LP|Prostate Cancer Clinical Trials Consortium|Bayer",INTERVENTIONAL,2017-09-22,2020-01-13,2022-11-07,2017-03-10,,2023-10-10
NCT02861534,A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001),https://clinicaltrials.gov/study/NCT02861534,VICTORIA,COMPLETED,YES,Heart Failure|Chronic Heart Failure With Reduced Ejection Fraction,DRUG: Vericiguat|DRUG: Placebo for vericiguat,Merck Sharp & Dohme LLC,Bayer|Canadian VIGOUR Centre|Duke Clinical Research Institute,INTERVENTIONAL,2016-09-20,2019-06-18,2019-09-02,2016-08-10,2020-06-29,2021-11-15
NCT02695810,"The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes",https://clinicaltrials.gov/study/NCT02695810,,COMPLETED,NO,Prediabetic State|Obesity,DRUG: Dapagliflozin|DRUG: Metformin|BEHAVIORAL: Exercise,Steno Diabetes Center Copenhagen,"The Novo Nordic Foundation|Rigshospitalet, Denmark|AstraZeneca|Bayer",INTERVENTIONAL,2016-02-24,2018-09-20,2019-01-13,2016-03-01,,2019-10-07
NCT01534260,"Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",https://clinicaltrials.gov/study/NCT01534260,,COMPLETED,YES,Acute Myeloid Leukemia,"DRUG: sorafenib, vorinostat and bortezomib",Hamid Sayar,"Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme LLC",INTERVENTIONAL,2012-02-10,2016-08-29,2017-02-13,2012-02-16,2018-08-17,2018-08-17
NCT00864383,Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis,https://clinicaltrials.gov/study/NCT00864383,REMoxTB,COMPLETED,YES,Pulmonary Tuberculosis,"DRUG: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin",Global Alliance for TB Drug Development,"European and Developing Countries Clinical Trials Partnership (EDCTP)|University College, London|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi",INTERVENTIONAL,2008-01,2013-10,2014-02,2009-03-18,2015-05-25,2017-03-21
NCT01844947,Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,https://clinicaltrials.gov/study/NCT01844947,VINSOR,COMPLETED,NO,Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer,DRUG: Vinflunine|DRUG: Sorafenib,Dr Anders Ullén,Bayer|Pierre Fabre Laboratories|Nordic Urothelial Cancer Oncology Group,INTERVENTIONAL,2012-05,2017-10-18,2018-06-05,2013-05-03,,2019-04-26
NCT03305913,Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy,https://clinicaltrials.gov/study/NCT03305913,REMETY,COMPLETED,NO,Pretreated Metastatic Colorectal Cancer,DRUG: TAS 102|DRUG: Regorafenib,AIO-Studien-gGmbH,Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH|Bayer,INTERVENTIONAL,2017-07-31,2018-10-31,2019-04-26,2017-10-10,,2021-03-26
NCT02293395,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT02293395,GEMINI ACS 1,COMPLETED,YES,Acute Coronary Syndrome,DRUG: Acetylsalicylic acid|DRUG: Rivaroxaban|DRUG: Clopidogrel|DRUG: Ticagrelor,"Janssen Research & Development, LLC",Bayer|Duke Clinical Research Institute|Harvard Medical School (HMS and HSDM),INTERVENTIONAL,2015-04-20,2016-10-14,2016-10-14,2014-11-18,2017-11-13,2017-12-26
NCT00608946,Treatment With Copper in Patients With Mild Alzheimer´s Dementia,https://clinicaltrials.gov/study/NCT00608946,,COMPLETED,NO,Alzheimer´s Disease,DIETARY_SUPPLEMENT: copper|DIETARY_SUPPLEMENT: placebo,"University Hospital, Saarland","University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany",INTERVENTIONAL,2004-03,2007-08,,2008-02-06,,2008-02-06
NCT00164463,TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment,https://clinicaltrials.gov/study/NCT00164463,,COMPLETED,NO,Tuberculosis,DRUG: Moxifloxacin|DRUG: Isoniazid,Centers for Disease Control and Prevention,US Department of Veterans Affairs|Bayer|National Institutes of Health (NIH),INTERVENTIONAL,2004-07,2007-08,2007-08,2005-09-14,,2011-06-08
NCT01675076,Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events,https://clinicaltrials.gov/study/NCT01675076,BRUISECONTROL2,COMPLETED,NO,Hematoma,DRUG: Dabigatran|DRUG: Rivaroxaban|DRUG: Apixaban,Ottawa Heart Institute Research Corporation,Boehringer Ingelheim|Heart and Stroke Foundation of Canada|Bayer|Bristol-Myers Squibb,INTERVENTIONAL,2013-01,2017-10,2018-05,2012-08-29,,2019-10-07
NCT00178464,Aspirin Prophylaxis in Sickle Cell Disease,https://clinicaltrials.gov/study/NCT00178464,START,COMPLETED,YES,Sickle Cell Disease,DRUG: aspirin,University of Rochester,University of Miami|Bayer|National Institute of Neurological Disorders and Stroke (NINDS),INTERVENTIONAL,2005-03,2009-04,2009-11,2005-09-15,2012-01-04,2017-11-06
NCT01136005,Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI),https://clinicaltrials.gov/study/NCT01136005,BeCet,COMPLETED,NO,Cancer|Skin Rash,OTHER: dexpanthenol 5% cream|OTHER: Cetomacrogol cream,Impaqtt Foundation,CB Boers ORG|Memorial Sloan Kettering Cancer Center|Leiden University Medical Center|Bayer,INTERVENTIONAL,2010-09,2016-12,2017-03,2010-06-03,,2017-11-13
NCT00634634,Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer,https://clinicaltrials.gov/study/NCT00634634,,COMPLETED,YES,Metastatic Breast Cancer,DRUG: Sorafenib|DRUG: Letrozole,"Rutgers, The State University of New Jersey",Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Bayer|Novartis Pharmaceuticals,INTERVENTIONAL,2008-08-11,2019-04-20,2023-04-28,2008-03-13,2023-05-06,2023-11-09
NCT00943943,Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations,https://clinicaltrials.gov/study/NCT00943943,,COMPLETED,NO,Acute Myelogenous Leukemia|Leukemia,DRUG: G-CSF|DRUG: Plerixafor|DRUG: Sorafenib,M.D. Anderson Cancer Center,"Bayer|Genzyme, a Sanofi Company|Amgen|National Cancer Institute (NCI)|Georgia Institute of Technology",INTERVENTIONAL,2010-10-29,2017-03-23,2017-03-23,2009-07-22,,2017-03-29
NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,https://clinicaltrials.gov/study/NCT00813293,,COMPLETED,YES,Hepatocellular Cancer,DRUG: Sorafenib|PROCEDURE: radiofrequency ablation,Beth Israel Deaconess Medical Center,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Bayer|Onyx Therapeutics, Inc.|National Cancer Institute (NCI)",INTERVENTIONAL,2009-06,2013-11,2013-11,2008-12-23,2020-06-22,2023-06-13
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT01078961,,COMPLETED,NO,Melanoma,DRUG: bortezomib|DRUG: sorafenib,Massachusetts General Hospital,"Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bayer|Millennium Pharmaceuticals, Inc.",INTERVENTIONAL,2010-09,2013-02,2016-06,2010-03-02,,2016-06-08
NCT01068769,Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,https://clinicaltrials.gov/study/NCT01068769,,COMPLETED,YES,Gastrointestinal Stromal Tumor,DRUG: regorafenib,"Suzanne George, MD",Brigham and Women's Hospital|Massachusetts General Hospital|Fox Chase Cancer Center|Oregon Health and Science University|Bayer,INTERVENTIONAL,2010-02,2012-06,2020-08,2010-02-15,2014-02-24,2020-08-24
NCT00142181,Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia,https://clinicaltrials.gov/study/NCT00142181,,COMPLETED,NO,Lymphoplasmacytic Lymphoma|Waldenstrom's Macroglobulinemia,DRUG: Campath-1H,Dana-Farber Cancer Institute,"Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Bayer|University of California, Los Angeles|Northwestern University|Arizona Oncology Associates",INTERVENTIONAL,2003-03,2005-10,2008-06,2005-09-02,,2012-12-21
